| Drug |
carboplatin |
379 |
2010 |
| Drug |
cisplatin |
278 |
2010 |
| Drug |
paclitaxel |
249 |
2010 |
| Drug |
docetaxel |
190 |
2011 |
| placebo |
placebo |
188 |
2020 |
| Drug |
pemetrexed |
187 |
2010 |
| Radiation |
radiotherapy |
140 |
2010 |
| Other |
laboratory biomarker analysis |
133 |
2014 |
| Drug |
gemcitabine |
120 |
2014 |
| Drug |
pembrolizumab |
115 |
2014 |
| Drug |
bevacizumab |
107 |
2011 |
| Drug |
nivolumab |
97 |
2014 |
| Drug |
erlotinib |
96 |
2011 |
| Drug |
etoposide |
92 |
2009 |
| Drug |
gemcitabine hydrochloride |
57 |
2017 |
| Drug |
gefitinib |
53 |
2011 |
| Drug |
durvalumab |
51 |
2018 |
| Other |
quality-of-life assessment |
51 |
2014 |
| Drug |
cetuximab |
42 |
2009 |
| Drug |
erlotinib hydrochloride |
40 |
2010 |
| Other |
pharmacological study |
39 |
2017 |
| Drug |
ipilimumab |
37 |
2014 |
| Drug |
osimertinib |
37 |
2016 |
| Other |
questionnaire administration |
36 |
2014 |
| Drug |
vinorelbine |
35 |
2010 |
| Drug |
chemotherapy |
34 |
2017 |
| Drug |
atezolizumab |
33 |
2018 |
| Drug |
pemetrexed disodium |
32 |
2020 |
| Drug |
topotecan |
32 |
2016 |
| Drug |
irinotecan hydrochloride |
24 |
2007 |
| Drug |
nab-paclitaxel |
22 |
2014 |
| Radiation |
stereotactic body radiation therapy |
22 |
2018 |
| Procedure |
conventional surgery |
21 |
2018 |
| Drug |
topotecan hydrochloride |
20 |
2009 |
| Drug |
crizotinib |
19 |
2016 |
| Drug |
erlotinib [tarceva] |
19 |
2010 |
| Drug |
tremelimumab |
19 |
2018 |
| Drug |
bortezomib |
18 |
2008 |
| Drug |
celecoxib |
18 |
2008 |
| Drug |
cyclophosphamide |
18 |
2009 |
| Drug |
irinotecan |
18 |
2019 |
| Procedure |
surgery |
18 |
2009 |
| Other |
standard care |
17 |
2015 |
| Drug |
anlotinib |
16 |
2013 |
| Other |
educational intervention |
16 |
2014 |
| Radiation |
radiation |
16 |
2018 |
| Drug |
ramucirumab |
15 |
2010 |
| Drug |
temozolomide |
14 |
2018 |
| Drug |
olaparib |
13 |
2013 |
| Procedure |
therapeutic conventional surgery |
13 |
2018 |
| Drug |
vinorelbine tartrate |
13 |
2011 |
| Biological |
filgrastim |
12 |
2007 |
| Other |
questionnaire |
12 |
2017 |
| Drug |
sunitinib |
12 |
2011 |
| Radiation |
3-dimensional conformal radiation therapy |
11 |
2010 |
| Drug |
alectinib |
11 |
2015 |
| Drug |
avelumab |
11 |
2017 |
| Drug |
cediranib maleate |
11 |
2010 |
| Drug |
vorinostat |
11 |
2009 |
| Procedure |
adjuvant therapy |
10 |
2006 |
| Other |
best supportive care |
10 |
2011 |
| Drug |
dexamethasone |
10 |
2010 |
| Drug |
everolimus |
10 |
2012 |
| Other |
immunohistochemistry staining method |
10 |
2008 |
| Procedure |
neoadjuvant therapy |
10 |
2019 |
| Biological |
sargramostim |
10 |
2007 |
| Radiation |
sbrt |
10 |
2018 |
| Drug |
selumetinib |
10 |
2018 |
| Drug |
sintilimab |
10 |
2018 |
| Drug |
sorafenib |
10 |
2009 |
| Drug |
trametinib |
10 |
2011 |
| Drug |
veliparib |
10 |
2016 |
| Drug |
bevacizumab [avastin] |
9 |
2009 |
| Procedure |
biopsy |
9 |
2018 |
| Other |
ct-scan |
9 |
2009 |
| Drug |
icotinib |
9 |
2017 |
| Other |
immunoenzyme technique |
9 |
2008 |
| Drug |
palbociclib |
9 |
2016 |
| Procedure |
positron emission tomography |
9 |
2009 |
| Radiation |
stereotactic body radiation therapy (sbrt) |
9 |
2018 |
| Drug |
afatinib |
8 |
2011 |
| Drug |
ceritinib |
8 |
2015 |
| Procedure |
computed tomography |
8 |
2013 |
| Drug |
dasatinib |
8 |
2015 |
| Drug |
necitumumab |
8 |
2019 |
| Device |
pet |
8 |
2016 |
| Biological |
trastuzumab |
8 |
2015 |
| Drug |
azd6244 |
7 |
2010 |
| Drug |
binimetinib |
7 |
2016 |
| Drug |
brigatinib |
7 |
2018 |
| Drug |
enzastaurin |
7 |
2007 |
| Behavioral |
exercise |
7 |
2013 |
| Other |
flow cytometry |
7 |
2009 |
| Drug |
imatinib mesylate |
7 |
2010 |
| Radiation |
intensity-modulated radiation therapy |
7 |
2014 |
| Drug |
ldk378 |
7 |
2012 |
| Drug |
pazopanib |
7 |
2009 |
| Drug |
pemetrexed/cisplatin |
7 |
2010 |
| Drug |
vandetanib |
7 |
2014 |
| Drug |
amifostine trihydrate |
6 |
1999 |
| Drug |
amrubicin |
6 |
2015 |
| Drug |
anlotinib hydrochloride |
6 |
2019 |
| Drug |
apatinib |
6 |
2018 |
| Drug |
azd9291 |
6 |
2014 |
| Other |
best available therapy |
6 |
2014 |
| Procedure |
care |
6 |
2009 |
| Drug |
concurrent chemotherapy |
6 |
2019 |
| Other |
counseling intervention |
6 |
2011 |
| Procedure |
ebus-tbna |
6 |
2009 |
| Drug |
entinostat |
6 |
2016 |
| Radiation |
fludeoxyglucose f 18 |
6 |
2009 |
| Drug |
gemcitabine/carboplatin |
6 |
2010 |
| Genetic |
gene expression analysis |
6 |
2007 |
| Drug |
kg |
6 |
2010 |
| Drug |
m2 |
6 |
2015 |
| Procedure |
management |
6 |
2009 |
| Other |
medical chart review |
6 |
2009 |
| Drug |
oxaliplatin |
6 |
2010 |
| Genetic |
protein expression analysis |
6 |
2008 |
| Procedure |
psychosocial assessment |
6 |
2009 |
| Procedure |
psychosocial assessment/care |
6 |
2009 |
| Drug |
temsirolimus |
6 |
2010 |
| Radiation |
thoracic radiotherapy |
6 |
2020 |
| Drug |
NA |
5 |
2018 |
| Biological |
aldesleukin |
5 |
2014 |
| Drug |
alimta |
5 |
2007 |
| Drug |
arq 197 |
5 |
2012 |
| Drug |
bavituximab |
5 |
2010 |
| Drug |
bkm120 |
5 |
2014 |
| Biological |
cixutumumab |
5 |
2010 |
| Other |
control |
5 |
2019 |
| Drug |
dacomitinib |
5 |
2011 |
| Drug |
darbepoetin alfa |
5 |
2018 |
| Drug |
docetaxel/cisplatin |
5 |
2010 |
| Drug |
doxorubicin |
5 |
2019 |
| Drug |
doxorubicin hydrochloride |
5 |
1999 |
| Drug |
endostar |
5 |
2018 |
| Drug |
erlotinib (tarceva) |
5 |
2007 |
| Behavioral |
exercise intervention |
5 |
2013 |
| Drug |
gemcitabine/cisplatin |
5 |
2011 |
| Radiation |
hypofractionated radiation therapy |
5 |
2009 |
| Drug |
ifosfamide |
5 |
2000 |
| Drug |
inc280 |
5 |
2014 |
| Drug |
lenvatinib |
5 |
2012 |
| Drug |
m^2 |
5 |
2013 |
| Drug |
medi4736 |
5 |
2013 |
| Drug |
mk-3475 |
5 |
2014 |
| Drug |
paclitaxel albumin-stabilized nanoparticle formulation |
5 |
2008 |
| Drug |
pertuzumab |
5 |
2009 |
| Other |
pet/ct |
5 |
2018 |
| Drug |
platinum |
5 |
2013 |
| Drug |
porfimer sodium |
5 |
2017 |
| Procedure |
radiofrequency ablation |
5 |
2016 |
| Behavioral |
smoking cessation intervention |
5 |
2017 |
| Procedure |
standard follow-up care |
5 |
2014 |
| Radiation |
stereotactic body radiotherapy (sbrt) |
5 |
2019 |
| Drug |
talazoparib |
5 |
2017 |
| Drug |
tipifarnib |
5 |
2018 |
| Drug |
tirapazamine |
5 |
2000 |
| Drug |
vinorelbine ditartrate |
5 |
2010 |
| Drug |
zoledronic acid |
5 |
2013 |
| Drug |
abemaciclib |
4 |
2014 |
| Drug |
anamorelin hcl |
4 |
2018 |
| Drug |
auy922 |
4 |
2012 |
| Drug |
azd6738 |
4 |
2016 |
| Drug |
bexarotene |
4 |
2006 |
| Other |
blood sample |
4 |
2018 |
| Procedure |
bronchoscopy |
4 |
2007 |
| Drug |
budesonide |
4 |
2019 |
| Drug |
cabozantinib |
4 |
2019 |
| Drug |
canakinumab |
4 |
2019 |
| Procedure |
cryosurgery |
4 |
2016 |
| Other |
cytology specimen collection procedure |
4 |
2015 |
| Drug |
erlotinib hcl |
4 |
2009 |
| Drug |
etoposide/cisplatin |
4 |
2015 |
| Drug |
lorlatinib |
4 |
2016 |
| Device |
low dose computed tomography |
4 |
2016 |
| Drug |
m7824 |
4 |
2018 |
| Drug |
metformin hydrochloride |
4 |
2014 |
| Drug |
motexafin gadolinium |
4 |
2005 |
| Drug |
nicotine |
4 |
2001 |
| Drug |
nimotuzumab |
4 |
2016 |
| Drug |
nintedanib |
4 |
2014 |
| Biological |
oblimersen sodium |
4 |
2000 |
| Other |
observation |
4 |
2020 |
| Drug |
oleclumab |
4 |
2017 |
| Biological |
pegfilgrastim |
4 |
2012 |
| Biological |
pembrolizumab 200 mg |
4 |
2019 |
| Drug |
pemetrexed/carboplatin |
4 |
2019 |
| Radiation |
prophylactic cranial irradiation |
4 |
2018 |
| Other |
pulmonary rehabilitation |
4 |
2016 |
| Drug |
rad001 |
4 |
2011 |
| Biological |
ras peptide cancer vaccine |
4 |
2007 |
| Drug |
rovalpituzumab tesirine |
4 |
2017 |
| Drug |
s-1 |
4 |
2016 |
| Other |
screening questionnaire administration |
4 |
2009 |
| Drug |
single low dose cyclophosphamide |
4 |
2009 |
| Drug |
sirolimus |
4 |
2014 |
| Drug |
sorafenib tosylate |
4 |
2007 |
| Radiation |
split-course radiotherapy |
4 |
2019 |
| Radiation |
stereotactic body radiotherapy |
4 |
2017 |
| Radiation |
stereotactic radiosurgery |
4 |
2016 |
| Radiation |
stereotactic radiotherapy |
4 |
2009 |
| Drug |
sunitinib malate |
4 |
2015 |
| Other |
supportive care |
4 |
2019 |
| Drug |
tarceva |
4 |
2009 |
| Biological |
tecemotide (l-blp25) |
4 |
2009 |
| Drug |
thalidomide |
4 |
2005 |
| Dietary Supplement |
vitamin b12 |
4 |
2010 |
| Drug |
40 mg |
3 |
2018 |
| Procedure |
acupuncture |
3 |
2014 |
| Drug |
afatinib dimaleate |
3 |
2015 |
| Drug |
albumin-bound paclitaxel |
3 |
2015 |
| Drug |
amifostine |
3 |
2004 |
| Drug |
anlotinib/docetaxel |
3 |
2018 |
| Drug |
apg-1252 |
3 |
2019 |
| Drug |
arq 197/erlotinib |
3 |
2011 |
| Drug |
azacitidine |
3 |
2013 |
| Drug |
azd1775 |
3 |
2015 |
| Drug |
azd4547 |
3 |
2016 |
| Other |
blood |
3 |
2016 |
| Procedure |
bronchoscopic |
3 |
2000 |
| Procedure |
bronchoscopic/lung imaging studies |
3 |
2000 |
| Drug |
bupropion hydrochloride |
3 |
2007 |
| Drug |
camrelizumab |
3 |
2019 |
| Drug |
capecitabine |
3 |
2005 |
| Drug |
capmatinib |
3 |
2018 |
| Drug |
carboplatin/paclitaxel |
3 |
2010 |
| Drug |
cc-486 |
3 |
2014 |
| Other |
clinical observation |
3 |
2014 |
| Procedure |
comparison of screening methods |
3 |
2009 |
| Other |
ct scan |
3 |
2007 |
| Drug |
dabrafenib |
3 |
2011 |
| Drug |
danvatirsen |
3 |
2018 |
| Drug |
decitabine |
3 |
2004 |
| Drug |
denosumab |
3 |
2014 |
| Drug |
docetaxel/carboplatin |
3 |
2008 |
| Behavioral |
education |
3 |
2013 |
| Drug |
egf816 |
3 |
2014 |
| Procedure |
end-of-life treatment |
3 |
2009 |
| Procedure |
end-of-life treatment/management |
3 |
2009 |
| Drug |
ensartinib |
3 |
2016 |
| Drug |
erdafitinib |
3 |
2016 |
| Drug |
exemestane |
3 |
2016 |
| Drug |
exisulind |
3 |
2004 |
| Procedure |
fatigue assessment |
3 |
2009 |
| Procedure |
fatigue assessment/management |
3 |
2009 |
| Drug |
fgfr inhibitor azd4547 |
3 |
2015 |
| Device |
flt-pet |
3 |
2016 |
| Drug |
fludarabine |
3 |
2019 |
| Dietary Supplement |
folic acid |
3 |
2010 |
| Drug |
gefitinib 250 mg |
3 |
2018 |
| Drug |
hpph |
3 |
2012 |
| Drug |
ibi308 |
3 |
2019 |
| Drug |
indocyanine green |
3 |
2015 |
| Other |
informational intervention |
3 |
2009 |
| Drug |
iressa |
3 |
2005 |
| Drug |
itraconazole |
3 |
2015 |
| Drug |
lapatinib |
3 |
2011 |
| Procedure |
lobectomy |
3 |
2013 |
| Diagnostic Test |
low dose ct |
3 |
2016 |
| Procedure |
lung imaging studies |
3 |
2000 |
| Drug |
metformin |
3 |
2017 |
| Drug |
methylprednisolone |
3 |
2018 |
| Drug |
midazolam |
3 |
2014 |
| Drug |
minocycline |
3 |
2011 |
| Device |
mri |
3 |
2016 |
| Genetic |
mutation analysis |
3 |
2010 |
| Drug |
nicotine replacement therapy |
3 |
2017 |
| Drug |
niraparib |
3 |
2017 |
| Drug |
panitumumab |
3 |
2009 |
| Drug |
pemetrexed 500 mg |
3 |
2013 |
| Diagnostic Test |
pet imaging |
3 |
2018 |
| Drug |
pf-00299804 |
3 |
2010 |
| Drug |
pf-02341066 |
3 |
2007 |
| Other |
pharmacogenomic studies |
3 |
2012 |
| Drug |
platinum-based chemotherapy |
3 |
2017 |
| Radiation |
proton beam radiation therapy |
3 |
2013 |
| Biological |
recombinant interferon alfa |
3 |
1999 |
| Drug |
romidepsin |
3 |
2012 |
| Other |
saline |
3 |
2009 |
| Drug |
saline solution |
3 |
2019 |
| Drug |
simvastatin |
3 |
2010 |
| Behavioral |
smoking cessation counseling |
3 |
2019 |
| Drug |
sorafenib (nexavar, bay43-9006) |
3 |
2009 |
| Other |
sputum cytology |
3 |
2001 |
| Procedure |
study of high risk factors |
3 |
2000 |
| Procedure |
surgical procedure |
3 |
1999 |
| Procedure |
surgical resection |
3 |
2014 |
| Drug |
tak-788 |
3 |
2019 |
| Drug |
tarceva (erlotinib hcl) |
3 |
2004 |
| Drug |
taselisib |
3 |
2015 |
| Drug |
taxol |
3 |
2005 |
| Drug |
taxotere |
3 |
2007 |
| Behavioral |
telephone-based intervention |
3 |
2009 |
| Drug |
tepotinib |
3 |
2019 |
| Procedure |
therapeutic thoracoscopy |
3 |
2009 |
| Drug |
triapine |
3 |
2004 |
| Drug |
trilaciclib |
3 |
2015 |
| Drug |
valacyclovir |
3 |
2016 |
| Drug |
varenicline |
3 |
2016 |
| Procedure |
vats |
3 |
2015 |
| Drug |
vitamin c |
3 |
2016 |
| Drug |
zd1839 |
3 |
2005 |
| Drug |
zd6474 |
3 |
2008 |
| Radiation |
18 f fluorodeoxyglucose |
2 |
2009 |
| Drug |
18f-fdg |
2 |
2015 |
| Procedure |
4-dimensional computed tomography |
2 |
2009 |
| Drug |
7-hydroxystaurosporine |
2 |
2004 |
| Drug |
ab928 |
2 |
2020 |
| Biological |
abi-007 |
2 |
2003 |
| Device |
ablation |
2 |
2019 |
| Drug |
abraxane |
2 |
2014 |
| Drug |
abt-751 |
2 |
2006 |
| Drug |
abx-egf |
2 |
2005 |
| Biological |
ad5cmv-p53 gene |
2 |
1999 |
| Other |
adjuvant |
2 |
2017 |
| Biological |
adv |
2 |
2016 |
| Biological |
adv/hsv-tk |
2 |
2016 |
| Drug |
aflibercept (ziv-aflibercept, ave0005, vegf trap, zaltrapâ®) |
2 |
2007 |
| Biological |
ak105 |
2 |
2019 |
| Drug |
alisertib |
2 |
2019 |
| Biological |
alt-803 |
2 |
2015 |
| Procedure |
alternative medicine procedure |
2 |
2006 |
| Drug |
amrubicin hydrochloride |
2 |
2008 |
| Drug |
anamorelin hydrochloride |
2 |
2018 |
| Biological |
antigen-specific dth |
2 |
2019 |
| Drug |
ap |
2 |
2018 |
| Drug |
aprepitant |
2 |
2014 |
| Drug |
apricoxib |
2 |
2008 |
| Drug |
apx005m |
2 |
2018 |
| Drug |
arsenic trioxide |
2 |
2011 |
| Procedure |
assessment of therapy complications |
2 |
2009 |
| Drug |
at-101 |
2 |
2006 |
| Drug |
atezolizumab (mpdl3280a) [tecentriq], an engineered anti-pdl1 antibody |
2 |
2013 |
| Drug |
atezolizumab (mpdl3280a), an engineered anti-pd-l1 antibody |
2 |
2017 |
| Procedure |
autofluorescence bronchoscopy |
2 |
2007 |
| Biological |
autologous tumor cell vaccine |
2 |
2001 |
| Biological |
avastin |
2 |
2008 |
| Drug |
axitinib |
2 |
2017 |
| Procedure |
az7550 |
2 |
2014 |
| Drug |
azd2014 |
2 |
2015 |
| Drug |
azd3759 |
2 |
2014 |
| Drug |
azd5363 |
2 |
2016 |
| Drug |
azd9291 80 mg |
2 |
2015 |
| Biological |
bcg |
2 |
1999 |
| Drug |
belinostat |
2 |
2009 |
| Drug |
bibf 1120 |
2 |
2012 |
| Other |
blood draw |
2 |
2019 |
| Drug |
bms-986012 |
2 |
2016 |
| Radiation |
brachytherapy |
2 |
2005 |
| Other |
bronchoalveolar lavage |
2 |
2007 |
| Drug |
cabozantinib s-malate |
2 |
2020 |
| Drug |
calcitriol |
2 |
2008 |
| Biological |
cancer stem cell vaccine |
2 |
2014 |
| Drug |
carboplatin) |
2 |
2009 |
| Drug |
carboplatin/etoposide |
2 |
2019 |
| Drug |
carboxyamidotriazole |
2 |
2001 |
| Drug |
carfilzomib |
2 |
2013 |
| Biological |
cemiplimab |
2 |
2020 |
| Drug |
chemo |
2 |
2018 |
| Procedure |
chemoradiotherapy |
2 |
2016 |
| Biological |
cik cell |
2 |
2012 |
| Drug |
cisplatin 75 mg |
2 |
2013 |
| Drug |
cisplatin 75 mg/m^2 |
2 |
2013 |
| Drug |
cisplatin injection |
2 |
2020 |
| Drug |
cisplatin/carboplatin |
2 |
2011 |
| Drug |
cobimetinib |
2 |
2017 |
| Other |
cognitive assessment |
2 |
2016 |
| Procedure |
complementary |
2 |
2006 |
| Procedure |
complementary/alternative medicine procedure |
2 |
2006 |
| Device |
computed tomography perfusion imaging |
2 |
2016 |
| Procedure |
cone-beam computed tomography |
2 |
2018 |
| Biological |
control dth |
2 |
2019 |
| Other |
counseling |
2 |
2019 |
| Drug |
cp-751,871 |
2 |
2005 |
| Drug |
crlx101 |
2 |
2016 |
| Device |
cryoablation |
2 |
2013 |
| Procedure |
cryotherapy |
2 |
2018 |
| Biological |
cs1001 monoclonal antibody |
2 |
2018 |
| placebo |
cs1001 placebo |
2 |
2018 |
| Diagnostic Test |
ct scans |
2 |
2007 |
| Genetic |
ctdna analysis |
2 |
2019 |
| Drug |
custirsen sodium |
2 |
2007 |
| Drug |
day |
2 |
2012 |
| Behavioral |
decision aid |
2 |
2019 |
| Drug |
demcizumab |
2 |
2014 |
| Other |
demographic variables |
2 |
2009 |
| Biological |
dendritic cell immunotherapy |
2 |
2019 |
| Biological |
denileukin diftitox |
2 |
2005 |
| Drug |
detoxpc |
2 |
1999 |
| Drug |
dexamethasone 4 mg |
2 |
2019 |
| Drug |
dnib0600a |
2 |
2013 |
| Drug |
docetaxel (taxotereâ®) |
2 |
2007 |
| Drug |
docetaxel/gemcitabine |
2 |
2007 |
| Drug |
docetaxel/pemetrexed |
2 |
2008 |
| Biological |
dribble vaccine |
2 |
2009 |
| Drug |
ds-1205c |
2 |
2018 |
| Drug |
durvalumab (medi4736) |
2 |
2019 |
| Combination Product |
durvalumab / monalizumab |
2 |
2018 |
| Combination Product |
durvalumab / oleclumab |
2 |
2018 |
| Other |
early palliative care |
2 |
2015 |
| Drug |
ef5 |
2 |
2014 |
| Procedure |
endobronchial ultrasound (ebus) |
2 |
2009 |
| Biological |
enoblituzumab |
2 |
2015 |
| Drug |
enoxaparin |
2 |
2008 |
| Drug |
epacadostat |
2 |
2017 |
| Drug |
epirubicin |
2 |
2005 |
| Drug |
eribulin mesylate |
2 |
2006 |
| Behavioral |
exercise training |
2 |
2010 |
| Radiation |
fdg-pet |
2 |
2010 |
| Device |
fiber optic |
2 |
2017 |
| Drug |
fluorouracil |
2 |
2001 |
| Dietary Supplement |
folate |
2 |
2005 |
| Dietary Supplement |
folic acid 350-1000 î¼g |
2 |
2019 |
| Drug |
fulvestrant |
2 |
2012 |
| Behavioral |
gain-framed messaging |
2 |
2017 |
| Drug |
gemcitabine, cisplatin |
2 |
2005 |
| Drug |
gleevec |
2 |
2005 |
| Biological |
gm-csf |
2 |
2013 |
| Drug |
gtx-024 |
2 |
2011 |
| Drug |
guadecitabine |
2 |
2019 |
| Biological |
her-2 |
2 |
1999 |
| Biological |
her-2/neu peptide vaccine |
2 |
1999 |
| Other |
high performance liquid chromatography |
2 |
2007 |
| Biological |
hla-a*2402restricted urlc10, cdca1, |
2 |
2013 |
| Drug |
hlx10 |
2 |
2019 |
| Drug |
hsp90 inhibitor auy922 |
2 |
2010 |
| Biological |
hsv-tk |
2 |
2016 |
| Drug |
hydroxychloroquine |
2 |
2016 |
| Radiation |
hypofractionated radiotherapy |
2 |
2019 |
| Biological |
î³î´ t cell |
2 |
2017 |
| Drug |
ibrutinib |
2 |
2014 |
| Device |
ima_detect |
2 |
2017 |
| Radiation |
image-guided radiation therapy |
2 |
2018 |
| Radiation |
image guided radiation therapy |
2 |
2012 |
| Drug |
imiquimod |
2 |
2013 |
| Biological |
immune killer cells (ikc) |
2 |
2018 |
| Other |
immunologic technique |
2 |
2007 |
| Device |
indocyanine green (icg) |
2 |
2014 |
| Drug |
iniparib |
2 |
2010 |
| Dietary Supplement |
inositol |
2 |
2003 |
| Device |
inspiratory muscle training |
2 |
2019 |
| Other |
internet-based intervention |
2 |
2009 |
| Procedure |
interventional therapy |
2 |
2015 |
| Radiation |
iodine i 131 monoclonal antibody 3f8 |
2 |
2007 |
| Drug |
ipi |
2 |
2018 |
| Drug |
ipi-504 |
2 |
2011 |
| Procedure |
irreversible electroporation (ire) |
2 |
2015 |
| Biological |
isis 3521 |
2 |
2001 |
| Drug |
itacitinib |
2 |
2018 |
| Drug |
ixabepilone |
2 |
2009 |
| Drug |
ixabepilone, 32 mg |
2 |
2008 |
| Biological |
kif20a peptides |
2 |
2010 |
| Biological |
kn046 |
2 |
2019 |
| Drug |
l-dos47 |
2 |
2015 |
| Drug |
leucovorin calcium |
2 |
2001 |
| Drug |
lidocaine |
2 |
2007 |
| Biological |
lmb-9 immunotoxin |
2 |
2001 |
| Drug |
lobaplatin |
2 |
2018 |
| Procedure |
local consolidation therapy |
2 |
2018 |
| Drug |
lomustine |
2 |
2018 |
| Other |
low dose ct scan |
2 |
2019 |
| Procedure |
lung surgery |
2 |
2013 |
| Drug |
lurbinectedin (pm01183) |
2 |
2013 |
| Drug |
ly2603618 |
2 |
2009 |
| Drug |
ly900003 |
2 |
2002 |
| Diagnostic Test |
magnetic resonance imaging (mri) |
2 |
2016 |
| Drug |
marimastat |
2 |
1999 |
| Other |
mass spectrometry |
2 |
2007 |
| placebo |
matching placebo |
2 |
2020 |
| Procedure |
mediastinoscopy |
2 |
2010 |
| Drug |
mek162 |
2 |
2013 |
| Genetic |
microarray analysis |
2 |
2007 |
| Procedure |
microwave ablation |
2 |
2016 |
| Drug |
min |
2 |
2013 |
| Drug |
mk-2206 |
2 |
2010 |
| Drug |
mm-121 |
2 |
2009 |
| Combination Product |
monalizumab |
2 |
2018 |
| Biological |
monoclonal antibody bec2 |
2 |
1999 |
| Drug |
motexafin gadolinium injection |
2 |
2005 |
| Drug |
mpdl3280a |
2 |
2015 |
| Biological |
mutant p53 peptide pulsed dendritic cell vaccine |
2 |
2001 |
| Drug |
nab paclitaxel |
2 |
2020 |
| Device |
nanoknife |
2 |
2015 |
| Device |
near infrared camera imaging system |
2 |
2020 |
| Procedure |
needle biopsy |
2 |
2010 |
| Biological |
neo-pv-01 |
2 |
2017 |
| Biological |
neu peptide vaccine |
2 |
1999 |
| Drug |
ngr-htnf |
2 |
2009 |
| Drug |
nicotine patch |
2 |
2006 |
| Drug |
nivolumab 10 mg |
2 |
2019 |
| Biological |
nk immunotherapy |
2 |
2016 |
| Device |
novottf-100l |
2 |
2008 |
| Drug |
onartuzumab |
2 |
2011 |
| Drug |
ono-4538 |
2 |
2015 |
| Procedure |
open surgery |
2 |
2019 |
| Drug |
otl38 for injection |
2 |
2020 |
| Drug |
paclitaxel 200 mg |
2 |
2013 |
| Drug |
paclitaxel 200 mg/m^2 |
2 |
2013 |
| Drug |
paclitaxel/carboplatin |
2 |
2010 |
| Behavioral |
palliative care |
2 |
2016 |
| Drug |
patupilone |
2 |
2005 |
| Drug |
pd-1 inhibitor |
2 |
2019 |
| Drug |
pdr001 |
2 |
2018 |
| Drug |
pe |
2 |
2011 |
| Drug |
pemetrexed (alimta) |
2 |
2009 |
| Drug |
pemetrexed 500 mg/m^2 |
2 |
2013 |
| Procedure |
peripheral blood stem cell transplantation |
2 |
1999 |
| Device |
pet scan imaging |
2 |
2015 |
| Drug |
pf-06463922 |
2 |
2013 |
| Procedure |
pharmacokinetic sampling - az5140 |
2 |
2014 |
| Procedure |
pharmacokinetic sampling - az5140/az7550 |
2 |
2014 |
| Procedure |
pharmacokinetic sampling - azd9291 |
2 |
2014 |
| Other |
pharmacokinetic study |
2 |
2018 |
| Drug |
phenethyl isothiocyanate |
2 |
2008 |
| Drug |
photodynamic therapy |
2 |
2013 |
| Radiation |
photon beam radiation therapy |
2 |
2013 |
| Radiation |
photon therapy |
2 |
2009 |
| Procedure |
physical therapy |
2 |
2019 |
| placebo |
placebo azd9291 80 mg |
2 |
2015 |
| placebo |
placebo for olaparib |
2 |
2020 |
| placebo |
placebo gefitinib 250 mg |
2 |
2018 |
| Drug |
placebo/docetaxel |
2 |
2011 |
| Drug |
plb1001 |
2 |
2016 |
| Drug |
plinabulin |
2 |
2018 |
| Genetic |
polymerase chain reaction |
2 |
2008 |
| Drug |
ponatinib |
2 |
2013 |
| Procedure |
positron emission tomography (pet) |
2 |
2018 |
| Drug |
pralatrexate |
2 |
2000 |
| Drug |
propofol |
2 |
2019 |
| Radiation |
proton radiotherapy |
2 |
2007 |
| Radiation |
proton therapy |
2 |
2009 |
| Drug |
ptk787 |
2 |
2005 |
| Drug |
r-(-)-gossypol acetic acid |
2 |
2008 |
| Radiation |
radiolabeled (99tc) ec-dg (ethylenedicysteine-deoxyglucose) |
2 |
2009 |
| Procedure |
radionuclide imaging |
2 |
2008 |
| Drug |
raltitrexed |
2 |
2000 |
| Biological |
recombinant ephb4-hsa fusion protein |
2 |
2017 |
| Biological |
recombinant fowlpox-cea(6d) |
2 |
2005 |
| Biological |
recombinant fowlpox-cea(6d)/tricom vaccine |
2 |
2005 |
| Drug |
recombinant human endostatin |
2 |
2010 |
| Biological |
recombinant interleukin-12 |
2 |
1999 |
| Drug |
regn2810 |
2 |
2018 |
| Drug |
regn2810/chemo/ipi |
2 |
2018 |
| Other |
rehabilitation education |
2 |
2017 |
| Behavioral |
rehabilitation training |
2 |
2017 |
| Biological |
reolysin |
2 |
2009 |
| Procedure |
resection |
2 |
2007 |
| Drug |
ribociclib |
2 |
2014 |
| Biological |
romiplostim |
2 |
2019 |
| Drug |
rubitecan |
2 |
2000 |
| Combination Product |
rucaparib |
2 |
2019 |
| Radiation |
sabr |
2 |
2018 |
| Drug |
sagopilone (bay86-5302, zk 219477) |
2 |
2006 |
| placebo |
saline placebo for pembrolizumab |
2 |
2016 |
| Drug |
sar408701 |
2 |
2019 |
| Drug |
saracatinib |
2 |
2008 |
| Drug |
savolitinib |
2 |
2019 |
| Diagnostic Test |
screening |
2 |
2014 |
| Procedure |
segmentectomy |
2 |
2015 |
| Drug |
selinexor |
2 |
2017 |
| Drug |
selpercatinib |
2 |
2020 |
| Biological |
shr-1210 |
2 |
2017 |
| Procedure |
single photon emission computed tomography |
2 |
2011 |
| Biological |
sintilimab injection |
2 |
2020 |
| Drug |
sitravatinib |
2 |
2016 |
| Biological |
ss1(dsfv)-pe38 immunotoxin |
2 |
2003 |
| Radiation |
stereotactic body radiation |
2 |
2009 |
| Radiation |
stereotactic radiation |
2 |
2017 |
| Radiation |
stereotactic radiosurgery (srs) |
2 |
2018 |
| Other |
study of socioeconomic |
2 |
2009 |
| Other |
study of socioeconomic/demographic variables |
2 |
2009 |
| Drug |
suramin |
2 |
2003 |
| Drug |
talactoferrin |
2 |
2009 |
| Drug |
tarceva (trademark) (erlotinib hcl, osi-774) |
2 |
2004 |
| Drug |
tcm |
2 |
2017 |
| Other |
telehealth |
2 |
2017 |
| Behavioral |
telephone counseling |
2 |
2014 |
| Drug |
tetrahydrouridine (thu) |
2 |
2017 |
| Biological |
therapeutic autologous dendritic cells |
2 |
2005 |
| Radiation |
thoracic irradiation |
2 |
2020 |
| Radiation |
thoracic radiation therapy |
2 |
2017 |
| Radiation |
thoracic radiation therapy (trt) |
2 |
2018 |
| Procedure |
thoracic surgical procedure |
2 |
2017 |
| Procedure |
thoracotomy |
2 |
2015 |
| Drug |
tiragolumab |
2 |
2020 |
| Drug |
tislelizumab |
2 |
2020 |
| Drug |
tki |
2 |
2018 |
| Drug |
tqb2450 |
2 |
2019 |
| Biological |
trastuzumab emtansine |
2 |
2015 |
| Drug |
trc105 |
2 |
2015 |
| Biological |
tricom vaccine |
2 |
2005 |
| Biological |
vegfr2 |
2 |
2009 |
| Drug |
velcade |
2 |
2006 |
| Drug |
vidaza |
2 |
2014 |
| Procedure |
video-assisted surgery |
2 |
1999 |
| Procedure |
video-assisted thoracic surgery |
2 |
2018 |
| Drug |
vinblastine sulfate |
2 |
1999 |
| Drug |
vincristine sulfate |
2 |
1999 |
| Drug |
vindesine |
2 |
1999 |
| Drug |
vinflunine |
2 |
2006 |
| Drug |
vinorelbine (navelbine) |
2 |
2008 |
| Drug |
vinorelbine/cisplatin |
2 |
2011 |
| Drug |
vismodegib |
2 |
2009 |
| Drug |
vistusertib |
2 |
2016 |
| Dietary Supplement |
vitamin b12 1000 î¼g |
2 |
2019 |
| Dietary Supplement |
vitamin d |
2 |
2012 |
| Drug |
wbrt |
2 |
2013 |
| Procedure |
wedge resection |
2 |
2015 |
| Drug |
x-396 (ensartinib) |
2 |
2012 |
| Drug |
ym155 |
2 |
2010 |
| Radiation |
yttrium y 90-edotreotide |
2 |
2000 |
| Drug |
zileuton |
2 |
2003 |
| Drug |
zimberelimab |
2 |
2020 |
| Drug |
zk 222584 |
2 |
2005 |
| Drug |
- bevacizumab |
1 |
2013 |
| Drug |
- disulfiram |
1 |
2006 |
| Drug |
(99m tc) ecdg (ethylenedicysteine-deoxyglucose) |
1 |
2011 |
| Other |
[18f]hx4 diagnostic pet |
1 |
2016 |
| Other |
[18f]hx4 diagnostic pet/ct scan |
1 |
2016 |
| Drug |
[68ga]cbp8 |
1 |
2018 |
| Drug |
[f-18] vm4-037 |
1 |
2009 |
| Drug |
0.5% ropivacaine |
1 |
2012 |
| Drug |
01 |
1 |
2002 |
| Drug |
100 mg |
1 |
2014 |
| Drug |
100mg |
1 |
2014 |
| Drug |
12-month icotinib |
1 |
2013 |
| Drug |
13-cis-retinoic acid |
1 |
2003 |
| Drug |
13-cis retinoic acid |
1 |
1999 |
| Radiation |
131i-3f8 |
1 |
2007 |
| Drug |
160 mg |
1 |
2020 |
| Drug |
1650-g vaccine |
1 |
2008 |
| Radiation |
177lu-dota0-tyr3-octreotate |
1 |
2017 |
| Biological |
18-f-faza |
1 |
2014 |
| Drug |
18 f fdg followed by pet |
1 |
2011 |
| Drug |
18 f fdg followed by pet/ct imaging |
1 |
2011 |
| Radiation |
18f-(2s,4r)4-fluoroglutamine |
1 |
2017 |
| Drug |
18f-arag |
1 |
2019 |
| Drug |
18f-fludeoxyglucose (18f-fdg) |
1 |
2013 |
| Drug |
18f-fmiso |
1 |
2013 |
| Drug |
18f-fpprgd2 |
1 |
2013 |
| Drug |
18f-fspg |
1 |
2015 |
| Drug |
18f-peg6-ipqa |
1 |
2011 |
| Drug |
1st line chemotherapy |
1 |
2006 |
| Other |
2-deoxy-2-[18f]fluoro-d-glucose (fdg) |
1 |
2007 |
| Radiation |
2 gy targeted radiotherapy |
1 |
2016 |
| Radiation |
2.5 gy |
1 |
2018 |
| Radiation |
2.5 gy/fraction |
1 |
2018 |
| Procedure |
2d vats lobectomy |
1 |
2019 |
| Other |
3’-deoxy-3’-[18f]fluorothymidine (flt) |
1 |
2007 |
| Radiation |
3-d crt) |
1 |
2014 |
| Radiation |
3-dimensional conformal radiation therapy (3d-crt) |
1 |
2017 |
| Diagnostic Test |
3d-ex |
1 |
2017 |
| Radiation |
3d conform radiotherapy |
1 |
2009 |
| Procedure |
3d vats lobectomy |
1 |
2019 |
| Diagnostic Test |
4-d ct scan |
1 |
2017 |
| Radiation |
4 gy targeted radiotherapy |
1 |
2016 |
| Behavioral |
4 week assessment |
1 |
2015 |
| Drug |
40mg |
1 |
2018 |
| Radiation |
45 gray (gy) regimen |
1 |
2019 |
| Radiation |
4d-ct pre-treatment scan |
1 |
2011 |
| Other |
4d-ct scan |
1 |
2012 |
| Device |
4d pet-ct |
1 |
2011 |
| Drug |
5-fluoro-2’-deoxycytidine (fdcyd) |
1 |
2009 |
| Drug |
5-fluoro-2’-deoxycytidine (fdcyd) / tetrahydrouridine (thu) |
1 |
2009 |
| Drug |
5-fluorouracil |
1 |
2012 |
| Drug |
5-fluorouracil/interferon |
1 |
2012 |
| Drug |
6-hydroxymethylacylfulvene |
1 |
1999 |
| Drug |
6-month icotinib |
1 |
2013 |
| Drug |
6,8-bis(benzylthio)octanoic acid |
1 |
2013 |
| Radiation |
60 gy rt |
1 |
2007 |
| Procedure |
64-mdct scanning |
1 |
2015 |
| Radiation |
68ga-labeled peptides of dimer rgd (alfatide ii) |
1 |
2015 |
| Radiation |
68ga-labeled peptides of dimer rgd (alfatide ii)/18f-fdg |
1 |
2015 |
| Drug |
68ga-nota-3p-tate-rgd |
1 |
2016 |
| Other |
68ga-nota-ae105 pet |
1 |
2016 |
| Other |
68ga-nota-ae105 pet/ct |
1 |
2016 |
| Radiation |
70 gy in 20 fractions over 4 weeks |
1 |
2015 |
| Radiation |
74 gy rt |
1 |
2007 |
| Behavioral |
8 week assessment |
1 |
2015 |
| Biological |
86 |
1 |
2017 |
| Diagnostic Test |
89zr-avelumab pet |
1 |
2018 |
| Drug |
89zr-pembrolizumab |
1 |
2016 |
| Device |
89zr-pembrolizumab pet |
1 |
2016 |
| Drug |
9-ing-41 |
1 |
2018 |
| Drug |
99mtc-3prgd2 |
1 |
2020 |
| Other |
99mtc-sestamibi imaging |
1 |
2003 |
| Other |
a cryosurgery |
1 |
2017 |
| Procedure |
a: radiotherapy alone |
1 |
2005 |
| Drug |
ab154 |
1 |
2020 |
| Drug |
abbv-011 |
1 |
2018 |
| Drug |
abbv-075 |
1 |
2015 |
| Drug |
abbv-181 |
1 |
2018 |
| Drug |
abbv-399 |
1 |
2018 |
| Device |
abdominal compression belt system |
1 |
2020 |
| Drug |
abemaciclib, |
1 |
2019 |
| Drug |
abexinostat |
1 |
2018 |
| Drug |
abi-007 (abraxane) |
1 |
2006 |
| Drug |
abi-007 (abraxane)/carboplatin |
1 |
2006 |
| Biological |
abi-007/carboplatin/trastuzumab |
1 |
1999 |
| Drug |
abi-009 |
1 |
2018 |
| Drug |
abp 215 |
1 |
2013 |
| Drug |
abraxane (induction) |
1 |
2014 |
| Drug |
abraxane (maintenance) |
1 |
2014 |
| Drug |
abraxane / carboplatin |
1 |
2017 |
| Drug |
abt-263 |
1 |
2007 |
| Drug |
abt-869 |
1 |
2008 |
| Drug |
abt-869 .25 mg |
1 |
2007 |
| Drug |
abt-869 .25 mg/kg |
1 |
2007 |
| Drug |
abt-869 0.10 mg |
1 |
2007 |
| Drug |
abt-869 0.10 mg/kg |
1 |
2007 |
| Drug |
abx |
1 |
2013 |
| Drug |
abx/with cisplatin |
1 |
2013 |
| Drug |
ac |
1 |
2017 |
| Drug |
ac0010 |
1 |
2014 |
| Radiation |
accelerated conformational radiotherapy |
1 |
2001 |
| Radiation |
accelerated fraction |
1 |
2014 |
| Other |
accure navigator |
1 |
2013 |
| Drug |
acetazolamide in combination with platinum |
1 |
2018 |
| Drug |
acetazolamide in combination with platinum/etoposide-based radiochemotherapy |
1 |
2018 |
| Drug |
acetylcysteine inhalation |
1 |
2015 |
| Drug |
acridine carboxamide |
1 |
1999 |
| Diagnostic Test |
act-hla |
1 |
2017 |
| Behavioral |
act-lcs therapy |
1 |
2018 |
| Biological |
activated cik |
1 |
2018 |
| Biological |
activated cik/cd3-muc1 bispecific antibody in treating lung cancer |
1 |
2018 |
| Other |
active breathing control |
1 |
2015 |
| Drug |
active comparator (erlotinib) |
1 |
2011 |
| Behavioral |
active pain management |
1 |
2011 |
| Behavioral |
active smokers - control arm |
1 |
2015 |
| Behavioral |
active smokers - smoking cessation arm |
1 |
2015 |
| Other |
active surveillance |
1 |
2019 |
| Drug |
acupan 160mg |
1 |
2012 |
| Procedure |
acupuncture/questionnaires |
1 |
2005 |
| Drug |
acy-241 |
1 |
2015 |
| Drug |
acyclovir |
1 |
2013 |
| Biological |
ad-magea3 |
1 |
2016 |
| Biological |
ad100-gp96ig-hla a1 |
1 |
2007 |
| Drug |
adavosertib |
1 |
2015 |
| Drug |
adjuvant bevacizumab |
1 |
2005 |
| Drug |
adjuvant chemotherapy (taxol |
1 |
2009 |
| Drug |
adjuvant chemotherapy (taxol/carboplatin) |
1 |
2009 |
| Drug |
adriamycin, cyclophosphamide, vindesine, valproic acid |
1 |
2008 |
| Biological |
adv-tk (aglatimagene besadenovec) |
1 |
2017 |
| Biological |
adv-tk (aglatimagene besadenovec) / valacyclovir |
1 |
2017 |
| Drug |
adxs-503 |
1 |
2019 |
| Behavioral |
aerobic |
1 |
2013 |
| Behavioral |
aerobic exercise intervention |
1 |
2016 |
| Behavioral |
aerobic/muscle resistance training |
1 |
2013 |
| Drug |
afatinib - 1a |
1 |
2013 |
| Drug |
afatinib - 1b |
1 |
2013 |
| Drug |
afatinib (bibw 2992) |
1 |
2011 |
| Biological |
aflibercept |
1 |
2008 |
| Drug |
ag-013736 |
1 |
2008 |
| Behavioral |
ai-human interaction |
1 |
2018 |
| Drug |
akt inhibitor mk2206 |
1 |
2011 |
| Drug |
al3810 |
1 |
2020 |
| Drug |
al3818 |
1 |
2019 |
| Drug |
albumin-bound paclitaxel, carboplatin, toripalimab |
1 |
2020 |
| Drug |
albumin paclitaxel |
1 |
2010 |
| Drug |
albumin paclitaxel/carboplatin |
1 |
2010 |
| Drug |
alclometasone cream |
1 |
2011 |
| Biological |
ald518 |
1 |
2009 |
| Drug |
alfentanil |
1 |
2007 |
| Drug |
alflutinib mesylate (ast2818) 80mg |
1 |
2018 |
| Drug |
alflutinib mesylate (ast2818) 80mg//40 mg/ placebo |
1 |
2018 |
| Drug |
alimta (pemetrexed) |
1 |
2010 |
| Drug |
alimta injectable product |
1 |
2019 |
| Drug |
alimta/taxotere |
1 |
2007 |
| Drug |
alimtaâ® |
1 |
2006 |
| Other |
alk analysis on ctcs detected by iset |
1 |
2014 |
| Device |
alk qpcr assay |
1 |
2013 |
| Drug |
alkotinib |
1 |
2018 |
| Drug |
all-trans retinoic acid (atra) |
1 |
2008 |
| Drug |
all -trans retinoic acid (atra) |
1 |
2008 |
| Biological |
allogeneic tumor cell vaccine |
1 |
1999 |
| Biological |
allogeneic tumour lysate (melcancervac) |
1 |
2007 |
| Drug |
alrn-6924 |
1 |
2019 |
| Drug |
alt-803 / atezolizumab |
1 |
2017 |
| Drug |
alt-803 / avelumab |
1 |
2017 |
| Drug |
alt-803 / nivolumab |
1 |
2017 |
| Drug |
alt-803 / pembrolizumab |
1 |
2017 |
| Biological |
alvac-cea vaccine |
1 |
1999 |
| Drug |
amg 102 |
1 |
2008 |
| Biological |
amg 119 |
1 |
2018 |
| Drug |
amg 386 |
1 |
2012 |
| placebo |
amg 386 placebo |
1 |
2012 |
| Drug |
amg 479 |
1 |
2008 |
| Drug |
amg 655 |
1 |
2007 |
| placebo |
amg 655 placebo |
1 |
2007 |
| Drug |
amg 951 (rhapo2l |
1 |
2007 |
| Drug |
amg 951 (rhapo2l/trail) |
1 |
2007 |
| Drug |
aminocamptothecin colloidal dispersion |
1 |
1999 |
| Drug |
amrubicin hydrocloride |
1 |
2010 |
| Drug |
amurubicin |
1 |
2017 |
| Drug |
amuvatinib |
1 |
2011 |
| Drug |
anastrozole |
1 |
2016 |
| Procedure |
anatomic pulmonary resection |
1 |
2016 |
| Procedure |
anatomical segmentectomy, lobectomy |
1 |
2018 |
| Procedure |
anatomical segmentectomy, lobectomy/bilobectomy |
1 |
2018 |
| Drug |
anlotinib / ap/pc |
1 |
2018 |
| Drug |
anlotinib 10mg |
1 |
2018 |
| Drug |
anlotinib 10mg / ap/pc |
1 |
2018 |
| Drug |
anlotinib 12mg |
1 |
2018 |
| Drug |
anlotinib 12mg / ap/pc |
1 |
2018 |
| Drug |
anlotinib 8mg |
1 |
2018 |
| Drug |
anlotinib 8mg / ap/pc |
1 |
2018 |
| Drug |
anlotinib hydrochloride capsule |
1 |
2020 |
| Drug |
anlotinib/pemetrexed |
1 |
2018 |
| Drug |
anlotinib<erlotinib<ibi308<pemetrexed<gemcitabine<carboplatin |
1 |
2018 |
| Procedure |
annual screening |
1 |
2005 |
| Biological |
anti-igf-1r recombinant monoclonal antibody mk-0646 |
1 |
2009 |
| Drug |
anti-pd-l1 monoclonal antibody mpdl3280a |
1 |
2015 |
| Biological |
anti-pd1 |
1 |
2019 |
| Biological |
anti-pd1 antibody-activated tils |
1 |
2019 |
| Drug |
antibody tf2 |
1 |
2010 |
| Other |
antitumor drug screening assay |
1 |
2006 |
| Drug |
antroquinonol |
1 |
2010 |
| Drug |
ap/ac |
1 |
2017 |
| Drug |
apatinib 250mg |
1 |
2017 |
| Drug |
apatinib 500mg |
1 |
2017 |
| Drug |
apatinib 750mg |
1 |
2017 |
| Drug |
apatinib mesylate tablet |
1 |
2017 |
| Drug |
apatinib mesylate tablet/with s-1 capsules |
1 |
2017 |
| Drug |
apatinib s-1 |
1 |
2019 |
| Drug |
apatinib/with vinorelbine |
1 |
2018 |
| Drug |
apatinib(250mg |
1 |
2019 |
| Drug |
apatinib(250mg/d)/with egfr-tki |
1 |
2019 |
| Procedure |
apheresis |
1 |
2009 |
| Drug |
apl-101 oral capsules |
1 |
2017 |
| Drug |
approved anti-pd-1 inhibitor |
1 |
2017 |
| Drug |
apricoxib/erlotinib |
1 |
2008 |
| Drug |
arm a |
1 |
2018 |
| Drug |
arm a: pemetrexed cisplatin |
1 |
2008 |
| Drug |
arm b |
1 |
2018 |
| Drug |
arm b pemetrexed, cisplatin |
1 |
2008 |
| Drug |
arm b pemetrexed, cisplatin/mk-0646 |
1 |
2008 |
| Drug |
armodafinil |
1 |
2011 |
| Procedure |
artery ligation first |
1 |
2018 |
| Other |
as usual |
1 |
2011 |
| Drug |
asa404 |
1 |
2008 |
| Drug |
asn007 rd |
1 |
2018 |
| Drug |
asn007: ascending doses |
1 |
2018 |
| Other |
assessment of pdl1 expression |
1 |
2016 |
| Behavioral |
assisted relaxation therapy |
1 |
2020 |
| Biological |
ast-vac2 |
1 |
2017 |
| Drug |
at-101/docetaxel |
1 |
2007 |
| Drug |
at13387 |
1 |
2012 |
| Drug |
atezolizumab-bevacizumab |
1 |
2019 |
| Drug |
atezolizumab (mpdl3280a), an engineered anti-programmed death-ligand 1 (anti-pd-l1) antibody |
1 |
2015 |
| Drug |
atezolizumab 1200 mg in 20 ml injection |
1 |
2019 |
| Drug |
atezolizumab injection [tecentriq] |
1 |
2019 |
| Biological |
atl001 |
1 |
2019 |
| Drug |
atra |
1 |
2009 |
| Device |
atrium express dry seal chest drain |
1 |
2013 |
| Drug |
auranofin |
1 |
2012 |
| Procedure |
auscultation |
1 |
2014 |
| Biological |
autologous dendritic cell-adenovirus ccl21 vaccine |
1 |
2008 |
| Biological |
autologous dendritic cell-adenovirus p53 vaccine |
1 |
2002 |
| Biological |
autologous dendritic cell cancer vaccine |
1 |
2005 |
| Biological |
autologous genetically modified t cells, magea10á¶œâ·â¹â¶t |
1 |
2015 |
| Biological |
autologous wt1-tcrc4 gene-transduced cd8-positive tcm |
1 |
2015 |
| Biological |
autologous wt1-tcrc4 gene-transduced cd8-positive tcm/tn lymphocytes |
1 |
2015 |
| Biological |
av-299 |
1 |
2009 |
| Biological |
av-299 / gefitinib |
1 |
2009 |
| Drug |
avastin (bevacizumab) |
1 |
2004 |
| Drug |
avastinâ® |
1 |
2017 |
| Drug |
avelumab (msb0010718c) |
1 |
2018 |
| Drug |
axitinib (ag-013736) |
1 |
2018 |
| Drug |
axl1717 |
1 |
2011 |
| Drug |
azacitidine 30mg |
1 |
2006 |
| Drug |
azacitidine 30mg/m2 |
1 |
2006 |
| Drug |
azacitidine 40mg |
1 |
2006 |
| Drug |
azacitidine 40mg/m2 |
1 |
2006 |
| Drug |
azd1775/carboplatin (cbpt) |
1 |
2016 |
| Drug |
azd2171 |
1 |
2008 |
| Drug |
azd4205 |
1 |
2018 |
| Drug |
azd6244 / erlotinib |
1 |
2010 |
| Drug |
azd6738/olaparib |
1 |
2016 |
| Drug |
azd8931 |
1 |
2014 |
| Drug |
azd9150 |
1 |
2017 |
| Drug |
azd9291 80 mg/40 mg |
1 |
2015 |
| Drug |
azd9291 80 mg/40 mg / placebo |
1 |
2014 |
| Drug |
azd9291 dosing |
1 |
2015 |
| Drug |
azd9291 tablet dosing |
1 |
2014 |
| Drug |
azd9291 tablets |
1 |
2014 |
| Radiation |
b.i.d.rt |
1 |
2015 |
| Drug |
b: cbdca |
1 |
2005 |
| Drug |
b: cbdca/radiotherapy |
1 |
2005 |
| Dietary Supplement |
b12 |
1 |
2016 |
| Procedure |
baseline ecg |
1 |
2015 |
| Procedure |
baseline visit blood |
1 |
2015 |
| Procedure |
baseline visit blood/urine testing |
1 |
2015 |
| Drug |
bavituximab/paclitaxel/carboplatin |
1 |
2008 |
| Drug |
bay 43-9006 |
1 |
2007 |
| Drug |
bay 43-9006 (sorafenib) |
1 |
2004 |
| Drug |
bb-10901 |
1 |
2003 |
| Drug |
bca101 |
1 |
2020 |
| Drug |
bcd-100 |
1 |
2017 |
| Biological |
bec2 vaccine |
1 |
2002 |
| Drug |
becatecarin |
1 |
2000 |
| Behavioral |
behavioral intervention |
1 |
2018 |
| Other |
behavioral, psychological |
1 |
2019 |
| Other |
behavioral, psychological/informational intervention |
1 |
2019 |
| Drug |
belinostat, carboplatin, paclitaxel |
1 |
2011 |
| Drug |
belloxa |
1 |
2010 |
| Drug |
belotaxel |
1 |
2010 |
| Drug |
belotecan |
1 |
2011 |
| Drug |
belotecan hydrochloride |
1 |
2008 |
| Drug |
bendamustine hydrochloride |
1 |
2009 |
| Other |
best standard of care (bsc) |
1 |
2005 |
| Other |
best support treatment |
1 |
2010 |
| Other |
best supportive care (maintenance) |
1 |
2014 |
| Dietary Supplement |
beta-glucan |
1 |
2008 |
| Biological |
beta-glucan mm-10-001 |
1 |
2009 |
| Drug |
bevacizumab-eu |
1 |
2015 |
| Drug |
bevacizumab-pfizer |
1 |
2015 |
| Drug |
bevacizumab (avastin) |
1 |
2005 |
| Drug |
bevacizumab (avastin), taxotere (docetaxel), vinorelbine tartrate (navelbine) |
1 |
2008 |
| Drug |
bevacizumab / erlotinib hydrochloride |
1 |
2006 |
| Drug |
bevacizumab / pemetrexed |
1 |
2009 |
| Drug |
bevacizumab / pemetrexed / carboplatin |
1 |
2009 |
| Drug |
bevacizumab 15 mg |
1 |
2010 |
| Drug |
bevacizumab 15 mg/kg |
1 |
2010 |
| Drug |
bevacizumab 7.5 mg |
1 |
2010 |
| Drug |
bevacizumab 7.5 mg/kg |
1 |
2010 |
| Drug |
bevacizumab) |
1 |
2009 |
| Biological |
bevacizumab, erlotinib |
1 |
2010 |
| Drug |
bevacizumab, pemetrexed, cisplatin |
1 |
2010 |
| Drug |
bevacizumab,erlotinib |
1 |
2008 |
| Drug |
bevacizumab/pemetrexed/cisplatin |
1 |
2013 |
| Drug |
bexarotene (targretin) |
1 |
2005 |
| Drug |
bexarotene with carboplatin |
1 |
2002 |
| Drug |
bexarotene with carboplatin/paclitaxel |
1 |
2002 |
| Drug |
bgb-a317 |
1 |
2018 |
| Drug |
bgb-a317/etoposide/cisplatin (or carboplatin) |
1 |
2018 |
| Drug |
bgb-a317/gemcitabine/cisplatin (or carboplatin) |
1 |
2018 |
| Drug |
bgb-a317/paclitaxel/cisplatin (or carboplatin) |
1 |
2018 |
| Drug |
bgb-a317and pemetrexed |
1 |
2018 |
| Drug |
bgb-a317and pemetrexed/cisplatin (or carboplatin) |
1 |
2018 |
| Device |
bi-plane chest radiography |
1 |
2008 |
| Biological |
bi 1361849 |
1 |
2017 |
| Drug |
bi 754091 |
1 |
2018 |
| Drug |
bi 836880 |
1 |
2018 |
| Drug |
bibw 2992 |
1 |
2010 |
| Drug |
bibw 2992 ma2 20mg |
1 |
2008 |
| Drug |
bibw 2992 ma2 20mg/day |
1 |
2008 |
| Drug |
bibw 2992 ma2 40mg |
1 |
2008 |
| Drug |
bibw 2992 ma2 40mg/day |
1 |
2008 |
| Drug |
bibw 2992 ma2 50mg |
1 |
2008 |
| Drug |
bibw 2992 ma2 50mg/day |
1 |
2008 |
| Drug |
bibw 2992 qd |
1 |
2008 |
| Drug |
biib022 with paclitaxel |
1 |
2009 |
| Drug |
biib022 with paclitaxel/carboplatin |
1 |
2009 |
| Procedure |
bilobectomy |
1 |
2018 |
| Drug |
bind-014 |
1 |
2013 |
| Drug |
bind-014 (docetaxel nanoparticles for injectable suspension) |
1 |
2014 |
| Drug |
bio-11006 |
1 |
2018 |
| Drug |
bio-11006/standard of care |
1 |
2018 |
| Device |
bio-seal track plug |
1 |
2007 |
| Biological |
biological |
1 |
2011 |
| Other |
biological samples |
1 |
2016 |
| Biological |
biological/vaccine: vaccine comprised of klh conjugates of gd2l, gd3l, globo h, fucosyl gm1,/n-propionylated polysialic acid/opt-821 adjuvant |
1 |
2011 |
| Procedure |
biopsy samples |
1 |
2005 |
| Procedure |
biospecimen collection |
1 |
2017 |
| Drug |
bisphosphates |
1 |
2008 |
| Drug |
bkm120/erlotinib |
1 |
2011 |
| Diagnostic Test |
blood-sampled |
1 |
2018 |
| Biological |
blood-stage infection of p. vivax |
1 |
2016 |
| Other |
blood collection |
1 |
2019 |
| Procedure |
blood sample for methylation analysis |
1 |
2010 |
| Other |
blood sample, biopsy |
1 |
2014 |
| Diagnostic Test |
blood test |
1 |
2018 |
| Diagnostic Test |
blood tests/cardiac imaging |
1 |
2018 |
| Biological |
blood/respiratory fluids sampling |
1 |
2016 |
| Other |
blood/urine sample collection |
1 |
2015 |
| Drug |
bms-813160 |
1 |
2019 |
| Biological |
bms-986012 (anti-fucosyl-gm1) |
1 |
2014 |
| Drug |
bms-986253 |
1 |
2019 |
| Drug |
bnp7787 |
1 |
2004 |
| Procedure |
bone marrow aspiration from the iliac crest |
1 |
2015 |
| Radiation |
boost stereotactic body radiation therapy |
1 |
2012 |
| Drug |
bpi-15086 |
1 |
2016 |
| Drug |
bpi-7711 capsule |
1 |
2017 |
| Device |
breath actuated nebulizer |
1 |
2017 |
| Other |
breath collection |
1 |
2019 |
| Procedure |
breath test |
1 |
2013 |
| Combination Product |
breathe anew survivorship program |
1 |
2018 |
| Drug |
brentuximab vedotin |
1 |
2016 |
| Dietary Supplement |
broccoli sprout extract |
1 |
2005 |
| Device |
bronchoscopic thermal vapor ablation |
1 |
2017 |
| Drug |
bryostatin 1 |
1 |
2000 |
| Drug |
bsc |
1 |
2012 |
| Drug |
budesonide/formoterol fumarate dihydrate inhalation aerosol |
1 |
2007 |
| Drug |
bupivacaine-epinephrine |
1 |
2018 |
| Drug |
bupivacaine in epidural catheter |
1 |
2015 |
| Drug |
byl719 |
1 |
2014 |
| Drug |
ca |
1 |
2018 |
| Drug |
ca/nivolumab |
1 |
2018 |
| Drug |
cabazitaxel |
1 |
2011 |
| Drug |
cabazitaxel-xrp6258 (3-week cycle) |
1 |
2011 |
| Drug |
cabazitaxel-xrp6258 (5-week cycle) |
1 |
2011 |
| Drug |
cabiralizumab |
1 |
2018 |
| Drug |
cabozantinib 20 mg |
1 |
2019 |
| Drug |
cabozantinib 40 mg |
1 |
2019 |
| Drug |
cabozantinib 60 mg |
1 |
2019 |
| Drug |
calcitriol / docetaxel |
1 |
2003 |
| Dietary Supplement |
calcium |
1 |
2006 |
| Device |
calypso beacon implantation |
1 |
2014 |
| Device |
canady helios cold plasma scalpel |
1 |
2020 |
| placebo |
canakinumab matching placebo |
1 |
2018 |
| Behavioral |
cancer-related discussion program |
1 |
2015 |
| Device |
cancer ablation |
1 |
2017 |
| Behavioral |
cancer educational materials |
1 |
2019 |
| Drug |
canfosfamide hydrochloride |
1 |
2002 |
| Drug |
capivasertib |
1 |
2015 |
| Drug |
capmatinib (inc280) |
1 |
2016 |
| Device |
capp-seq |
1 |
2016 |
| Biological |
car-t cells |
1 |
2018 |
| Biological |
car-t cells targeting her2, mesothelin, psca, muc1, lewis-y, |
1 |
2017 |
| Biological |
car-t cells targeting her2, mesothelin, psca, muc1, lewis-y,/cd80/86 |
1 |
2017 |
| Biological |
car-t cells to treat advanced lung cancer |
1 |
2017 |
| Combination Product |
car-t combining pd-1 knockout |
1 |
2018 |
| Drug |
carboplatin-based |
1 |
2013 |
| Drug |
carboplatin-based chemotherapy |
1 |
2008 |
| Drug |
carboplatin-nab-paclitaxel |
1 |
2017 |
| Drug |
carboplatin-paclitaxel |
1 |
2017 |
| Drug |
carboplatin-taxol-radiotherapy |
1 |
2005 |
| Drug |
carboplatin (area under the concentration curve [auc] 6) |
1 |
2008 |
| Drug |
carboplatin (auc 5) |
1 |
2010 |
| Drug |
carboplatin (auc 6) |
1 |
2010 |
| Drug |
carboplatin (cbpt) |
1 |
2016 |
| Drug |
carboplatin (induction) |
1 |
2014 |
| Drug |
carboplatin (palaplatin) |
1 |
2008 |
| Drug |
carboplatin ,pemetrexed |
1 |
2018 |
| Drug |
carboplatin / cisplatin, etoposide |
1 |
2019 |
| Drug |
carboplatin / etoposide |
1 |
2020 |
| Drug |
carboplatin // gemcitabine // docetaxel //cisplatin |
1 |
2007 |
| Drug |
carboplatin auc |
1 |
2019 |
| Drug |
carboplatin auc 2 |
1 |
2012 |
| Drug |
carboplatin auc 5 mg |
1 |
2013 |
| Drug |
carboplatin auc 5 mg/ml/min |
1 |
2013 |
| Drug |
carboplatin auc 6 |
1 |
2017 |
| Drug |
carboplatin auc 6 mg |
1 |
2013 |
| Drug |
carboplatin auc 6 mg/ml/min |
1 |
2013 |
| Drug |
carboplatin auc2 |
1 |
2018 |
| Drug |
carboplatin auc6 |
1 |
2018 |
| Drug |
carboplatin injection |
1 |
2020 |
| Drug |
carboplatin paclitaxel |
1 |
2018 |
| Drug |
carboplatin pemetrexed |
1 |
2017 |
| Drug |
carboplatin, 5 mg |
1 |
2008 |
| Drug |
carboplatin, 6 mg |
1 |
2008 |
| Drug |
carboplatin, etoposide |
1 |
2003 |
| Drug |
carboplatin, etoposide/placebo |
1 |
2003 |
| Drug |
carboplatin, etoposide/thalidomide |
1 |
2003 |
| Drug |
carboplatin, gemcitabine , pametrexed |
1 |
2013 |
| Drug |
carboplatin, pemetrexed |
1 |
2008 |
| Drug |
carboplatin, pemetrexed/bevacizumab |
1 |
2008 |
| Drug |
carboplatin,pemetrexed |
1 |
2018 |
| Drug |
carboplatin. |
1 |
2018 |
| Drug |
carboplatin/ paclitaxel |
1 |
2018 |
| Drug |
carboplatin/gemcitabine |
1 |
2007 |
| Drug |
carboplatin/gemcitabine, carboplatin/taxol |
1 |
2005 |
| Drug |
carboplatin/nab paclitaxel |
1 |
2019 |
| Drug |
carboplatin/paclitaxel/medi-575 |
1 |
2010 |
| Diagnostic Test |
cardiac imaging |
1 |
2018 |
| Other |
care coordination tool |
1 |
2018 |
| Other |
caregiver-related intervention |
1 |
2014 |
| Other |
caregiver-related intervention/procedure |
1 |
2014 |
| Behavioral |
caresteps |
1 |
2015 |
| Other |
case management |
1 |
2012 |
| Drug |
cb-839 |
1 |
2016 |
| Drug |
cbp501 |
1 |
2009 |
| Drug |
cbp501 / cisplatin / pemetrexed |
1 |
2009 |
| Drug |
cc-223, erlotinib |
1 |
2012 |
| Drug |
cc-223, oral azacitidine |
1 |
2012 |
| Drug |
cc-5013 |
1 |
2005 |
| Drug |
cc-90011 |
1 |
2019 |
| Biological |
cccr-nk92 cells |
1 |
2018 |
| Biological |
cd3-muc1 bispecific antibody in treating lung cancer |
1 |
2018 |
| Biological |
cd80 |
1 |
2017 |
| Drug |
cdp791 10mg |
1 |
2005 |
| Drug |
cdp791 10mg/kg |
1 |
2005 |
| Drug |
cdp791 20mg |
1 |
2005 |
| Drug |
cdp791 20mg/kg |
1 |
2005 |
| Biological |
cea rna-pulsed dc cancer vaccine |
1 |
2000 |
| Drug |
cediranib |
1 |
2017 |
| Behavioral |
center for epidemiological studies depression scale |
1 |
2015 |
| Radiation |
centrally located lung tumor |
1 |
2009 |
| Drug |
centrum |
1 |
2012 |
| Procedure |
cervical mediastinoscopy |
1 |
2009 |
| Drug |
cetuximab / cisplatin / vinorelbine |
1 |
2005 |
| Drug |
cetuximab / platinum / gemcitabine |
1 |
2005 |
| Drug |
cetuximab 250 mg |
1 |
2009 |
| Drug |
cetuximab 250 mg/m^2 |
1 |
2009 |
| Drug |
cetuximab 500 mg |
1 |
2009 |
| Drug |
cetuximab 500 mg/m^2 |
1 |
2009 |
| Drug |
cetuximab in combination with carboplatin |
1 |
2009 |
| Drug |
cetuximab in combination with carboplatin/gemcitabine |
1 |
2009 |
| Drug |
cetuximab/platinum-based doublet chemotherapy |
1 |
2009 |
| Biological |
cg8123 |
1 |
2004 |
| Other |
chemo-irradiation |
1 |
2004 |
| Other |
chemoradiotherapy regimen between pc |
1 |
2011 |
| Other |
chemoradiotherapy regimen between pc/pe |
1 |
2011 |
| Radiation |
chemoradiotherapy with integrated boost dose |
1 |
2016 |
| Drug |
chemotherapy //- disulfiram |
1 |
2006 |
| Other |
chemotherapy concurrent with radiotherapy |
1 |
2019 |
| Other |
chemotherapy/radiotherapy |
1 |
2009 |
| Procedure |
chemotherapy/surgery |
1 |
2006 |
| Other |
chess website for lung cancer patient |
1 |
2009 |
| Other |
chess website for lung cancer patient / internet access if needed |
1 |
2009 |
| Procedure |
chest computed tomography scan |
1 |
2008 |
| Radiation |
chest irradiation |
1 |
2009 |
| Radiation |
chest radiation |
1 |
2018 |
| Procedure |
chest radiograph imaging |
1 |
2014 |
| Device |
chest radiography |
1 |
2002 |
| Procedure |
chest radiotherapy |
1 |
1999 |
| Other |
chest x ray |
1 |
2007 |
| Diagnostic Test |
chest xray |
1 |
2018 |
| Drug |
chiauranib |
1 |
2017 |
| Drug |
chidamide |
1 |
2013 |
| Dietary Supplement |
chinese herbs formula: shu yu wan |
1 |
2015 |
| Drug |
chinese traditional medicine xh1 |
1 |
2018 |
| Drug |
chlorogenic acid |
1 |
2018 |
| Drug |
chloroquinoxaline sulfonamide |
1 |
2001 |
| Behavioral |
chw navigation |
1 |
2019 |
| Drug |
ci-1040 |
1 |
2002 |
| Drug |
ci 1033 |
1 |
2002 |
| Other |
cicaplast balm b5 |
1 |
2018 |
| Drug |
cilengitide, radiochemotherapy |
1 |
2010 |
| Drug |
cis |
1 |
2015 |
| Drug |
cis-platinum |
1 |
2013 |
| Drug |
cis/carboplatin/etoposide |
1 |
2015 |
| Drug |
cisplatin-gemzar |
1 |
2005 |
| Drug |
cisplatin-navelbine-radiotherapy |
1 |
2005 |
| Drug |
cisplatin (or carboplatin) |
1 |
2018 |
| Drug |
cisplatin / docetaxel |
1 |
2008 |
| Drug |
cisplatin / docetaxel / enoxaparin |
1 |
2008 |
| Drug |
cisplatin / etoposide |
1 |
2008 |
| Drug |
cisplatin / pemetrexed |
1 |
2009 |
| Drug |
cisplatin / vinorelbine |
1 |
2005 |
| Drug |
cisplatin after chemoradiotherapy |
1 |
2005 |
| Drug |
cisplatin followed by concurrent chemoradiotherapy with docetaxel |
1 |
2005 |
| Drug |
cisplatin iv |
1 |
2009 |
| Drug |
cisplatin phase 1 |
1 |
2007 |
| Drug |
cisplatin phase 2 |
1 |
2007 |
| Drug |
cisplatin) |
1 |
2007 |
| Drug |
cisplatin, dexamethasone,vitamin b12, folic acid |
1 |
2010 |
| Drug |
cisplatin, etoposide |
1 |
2019 |
| Drug |
cisplatin, gemcitabine |
1 |
2010 |
| Drug |
cisplatin, thiosulfate |
1 |
2010 |
| Drug |
cisplatin/ etoposide |
1 |
2018 |
| Drug |
cisplatin/carboplatin-based |
1 |
2013 |
| Drug |
cisplatin/carboplatin,pemetrexed |
1 |
2018 |
| Drug |
cisplatin/carboplatin/etoposide |
1 |
2018 |
| Drug |
cisplatin/docetaxel |
1 |
2007 |
| Drug |
cisplatin/gemcitabine |
1 |
2018 |
| Drug |
cisplatin/pemetrexed |
1 |
2017 |
| Procedure |
cisplatin/radiation therapy |
1 |
2007 |
| Drug |
cisplatin/vindesine/mmc/ concurrent radiation |
1 |
2005 |
| Drug |
cisplatin/vinorelbine |
1 |
2007 |
| Drug |
cisplatinum |
1 |
2008 |
| Drug |
cisplatinum (50mg |
1 |
2012 |
| Drug |
cisplatinum (50mg/m2) iv (in the vein) on day 1/day 8 of a 28-day cycle for 2 cycles |
1 |
2012 |
| Drug |
cisplatinum/carboplatin/e.g.etoposide. |
1 |
2008 |
| Drug |
cisplatinum/carboplatin/e.g.etoposide/enoxaparin |
1 |
2008 |
| Device |
civasheet |
1 |
2017 |
| Device |
ck |
1 |
2009 |
| Drug |
ck-101 |
1 |
2016 |
| Drug |
ck-301 (cosibelimab) |
1 |
2017 |
| Drug |
clarithromycin |
1 |
2016 |
| Drug |
clindamycin 2% in hydrocortisone 1% lotion |
1 |
2007 |
| Drug |
cln-081 |
1 |
2019 |
| Drug |
cmp-001 |
1 |
2018 |
| Device |
cmpe optical sensor device |
1 |
2014 |
| Drug |
cnto 328; anti-interleukin-6 monoclonal antibody |
1 |
2009 |
| Drug |
cofetuzumab pelidotin |
1 |
2019 |
| Behavioral |
cognitive behavior therapy |
1 |
2017 |
| Behavioral |
cognitive behavioral intervention for breathlessness |
1 |
2013 |
| Behavioral |
cognitive behavioral therapy for insomnia |
1 |
2013 |
| Other |
cohort |
1 |
2016 |
| Procedure |
collection of biospecimen |
1 |
2010 |
| Device |
collection of volatile organic compounds during exhalation |
1 |
2017 |
| Drug |
com701 |
1 |
2018 |
| Drug |
com701 with opdivo (nivolumab). |
1 |
2018 |
| Drug |
combination carboplatin |
1 |
2004 |
| Drug |
combination carboplatin/paclitaxel |
1 |
2004 |
| Drug |
combination chemotherapy (pemetrexed |
1 |
2007 |
| Drug |
combination chemotherapy (pemetrexed / cisplatin) |
1 |
2007 |
| Drug |
combination of arixtra with chemotherapy |
1 |
2007 |
| Drug |
combined epidural-general anesthesia |
1 |
2016 |
| Procedure |
combined general |
1 |
2016 |
| Procedure |
combined general/epidural anesthesia |
1 |
2016 |
| Drug |
combo pbf-509 (160 mg) |
1 |
2015 |
| Drug |
combo pbf-509 (160 mg) / pdr001 |
1 |
2015 |
| Drug |
combo pbf-509 (320 mg) |
1 |
2015 |
| Drug |
combo pbf-509 (320 mg) / pdr001 |
1 |
2015 |
| Drug |
combo pbf-509 (640 mg) |
1 |
2015 |
| Drug |
combo pbf-509 (640 mg) / pdr001 |
1 |
2015 |
| Behavioral |
communication feedback form for patients with serious illness |
1 |
2013 |
| Other |
communication intervention |
1 |
2012 |
| Behavioral |
community health worker phone call |
1 |
2019 |
| Genetic |
comparative genomic hybridization |
1 |
2007 |
| Radiation |
comparator: ct |
1 |
2008 |
| Radiation |
comparator: ct/mri/fdg-pet |
1 |
2008 |
| Behavioral |
comparison group) |
1 |
2013 |
| Drug |
compound 121564 |
1 |
2018 |
| Device |
comprehensive health enhancement support system |
1 |
2006 |
| Behavioral |
comprehensive intervention |
1 |
2017 |
| Procedure |
computed tomography-guided optical sensor-guided radiofrequency ablation |
1 |
2005 |
| Drug |
concomitant docetaxel 20mg |
1 |
2012 |
| Radiation |
concomitant radiotherapy |
1 |
2017 |
| Drug |
concomitant rdt 2gy |
1 |
2012 |
| Other |
concurrent chemo-therapy |
1 |
2010 |
| Radiation |
concurrent chemoradiotherapy |
1 |
2014 |
| Drug |
concurrent chemoradiotherapy (paclitaxel |
1 |
2008 |
| Drug |
concurrent chemoradiotherapy (paclitaxel/cisplatin/radiotherapy) |
1 |
2008 |
| Drug |
concurrent radiation |
1 |
2005 |
| Radiation |
concurrent thoracic radiation therapy |
1 |
2006 |
| Radiation |
conformal thoracic radiotherapy (ctrt) |
1 |
2008 |
| Behavioral |
connect intervention |
1 |
2019 |
| Drug |
consolidation carboplatin |
1 |
2004 |
| Drug |
consolidation paclitaxel |
1 |
2004 |
| Drug |
consolidative durvalumab |
1 |
2019 |
| Behavioral |
consultation with survivorship navigator |
1 |
2010 |
| Radiation |
contralateral esophageal sparing technique (cest) |
1 |
2015 |
| Procedure |
contrast-enhanced dynamic ct perfusion study |
1 |
2005 |
| Other |
control / |
1 |
2017 |
| Drug |
control arm (seq): |
1 |
2006 |
| Behavioral |
control intervention |
1 |
2016 |
| Behavioral |
control invitation materials |
1 |
2015 |
| Procedure |
conventional |
1 |
2014 |
| Radiation |
conventional fractionation |
1 |
2014 |
| Radiation |
conventional radiation |
1 |
2011 |
| Radiation |
conventional radiotherapy (crt) |
1 |
2013 |
| Procedure |
conventional surgical technique |
1 |
2005 |
| Radiation |
conventionally fractionated radiotherapy (conrt) |
1 |
2009 |
| Drug |
copanlisib |
1 |
2015 |
| Drug |
copanlisib hydrochloride |
1 |
2015 |
| Other |
copd assessment test |
1 |
2020 |
| Other |
copd assessment test/modified medical research council dyspnea patient reported outcomes |
1 |
2020 |
| Biological |
cord blood-derived expanded allogeneic natural killer cells |
1 |
2018 |
| Device |
coredx pulmonary mini-forceps |
1 |
2019 |
| Behavioral |
counseling alone |
1 |
2017 |
| Drug |
cp-547,632 |
1 |
2003 |
| Drug |
cp-751,871 / carboplatin / paclitaxel |
1 |
2008 |
| Procedure |
cpap (continuous airway pressure) |
1 |
2011 |
| Drug |
cpg 7909 |
1 |
2003 |
| Drug |
cpt-11 |
1 |
2006 |
| Drug |
cross-over to osimertinib |
1 |
2014 |
| Device |
cryospray ablation system |
1 |
2008 |
| Procedure |
cryosurgery/ire surgery |
1 |
2017 |
| Drug |
cs-1008 |
1 |
2009 |
| Drug |
cs-7017 |
1 |
2010 |
| Drug |
cs7017 tablets |
1 |
2008 |
| Other |
ct-guided localization |
1 |
2016 |
| Device |
ct-guided transthoracic needle aspiration |
1 |
2019 |
| Device |
ct-simulation |
1 |
2011 |
| Device |
ct-simulation/4d pet-ct |
1 |
2011 |
| Other |
ct for the diagnosis |
1 |
2016 |
| Drug |
ct imaging |
1 |
2011 |
| Other |
ct perfusion imaging |
1 |
2012 |
| Radiation |
ct scan before chest physician |
1 |
2013 |
| Radiation |
ct scan/education |
1 |
2012 |
| Biological |
ctl |
1 |
2019 |
| Drug |
cudc-101 |
1 |
2010 |
| Biological |
cv301 |
1 |
2016 |
| Biological |
cv9201 |
1 |
2009 |
| Biological |
cxcr5 modified egfr chimeric antigen receptor autologous t cells |
1 |
2019 |
| Radiation |
cyberknife stereotactic radiosurgery |
1 |
2008 |
| Radiation |
cyclical hypofractionated palliative radiation (quad shot) |
1 |
2020 |
| Drug |
cyclophosphamide (ctx) |
1 |
2015 |
| Device |
cypath |
1 |
2009 |
| Device |
cypathâ® |
1 |
2015 |
| Genetic |
cytogenetic analysis |
1 |
2003 |
| Other |
cytology |
1 |
2007 |
| Other |
cytology/cytometry specimen collection procedure |
1 |
2007 |
| Other |
cytometry specimen collection procedure |
1 |
2007 |
| Procedure |
cytoreductive surgery |
1 |
2019 |
| Drug |
d |
1 |
2012 |
| Drug |
d-0316 |
1 |
2018 |
| Drug |
daborafenib |
1 |
2018 |
| Drug |
daborafenib/trametinib |
1 |
2018 |
| Drug |
dabrafenib mesylate |
1 |
2015 |
| Drug |
dacarbazine |
1 |
2007 |
| Drug |
dacarbazine/bortezomib |
1 |
2007 |
| Drug |
dacomitinib (pf-00299804) |
1 |
2011 |
| Radiation |
daily rt to the chest |
1 |
2015 |
| Radiation |
daily stereotactic body radiotherapy |
1 |
2018 |
| Drug |
dalteparin |
1 |
1999 |
| Drug |
dalteparin (fragminâ®) |
1 |
2012 |
| Drug |
dasatinib - 1a |
1 |
2013 |
| Drug |
dasatinib - 1b |
1 |
2013 |
| Drug |
dasatinib / placebo |
1 |
2008 |
| Other |
data feedback only |
1 |
2012 |
| Drug |
day 1: carboplatin auc=5 |
1 |
2015 |
| Drug |
day 1: cisplatin 75 mg |
1 |
2015 |
| Drug |
day 1: cisplatin 75 mg/m2 |
1 |
2015 |
| Drug |
day 1: vinorelbine 25 mg |
1 |
2015 |
| Drug |
day 1: vinorelbine 25 mg/m2 |
1 |
2015 |
| Drug |
day 1: vinorelbine 30 mg |
1 |
2015 |
| Drug |
day 1: vinorelbine 30 mg/m2 |
1 |
2015 |
| Drug |
day 8 of a 28-day cycle for 2 cycles |
1 |
2012 |
| Drug |
day 8: capsule vinorelbine 50 mg |
1 |
2015 |
| Drug |
day 8: capsule vinorelbine 50 mg/m2 |
1 |
2015 |
| Drug |
day 8: capsule vinorelbine 60 mg |
1 |
2015 |
| Drug |
day 8: capsule vinorelbine 60 mg/m2 |
1 |
2015 |
| Biological |
dc-cik |
1 |
2015 |
| Biological |
dc-cik cells |
1 |
2015 |
| Biological |
dc vaccine |
1 |
2016 |
| Other |
dcam levels in blood |
1 |
2012 |
| Other |
dce-mri scan |
1 |
2012 |
| Biological |
dcvac |
1 |
2015 |
| Biological |
dcvac add on to soc |
1 |
2015 |
| Biological |
dcvac/immune enhancers add on to soc |
1 |
2015 |
| Drug |
ddp |
1 |
2005 |
| Biological |
dec-205 |
1 |
2012 |
| Biological |
dec-205/ny-eso-1 fusion protein cdx-1401 |
1 |
2012 |
| Behavioral |
decision aid invitation |
1 |
2016 |
| Behavioral |
decision support tool |
1 |
2019 |
| Drug |
decitabine (dac) |
1 |
2017 |
| Drug |
decitabine in combination with genistein |
1 |
2012 |
| Drug |
defactinib |
1 |
2015 |
| Drug |
defactinib (vs-6063) |
1 |
2013 |
| Drug |
defactinib hydrochloride |
1 |
2015 |
| Drug |
defined green tea catechin extract |
1 |
2007 |
| Drug |
delayed metformin |
1 |
2014 |
| Biological |
dendritic cell based p53 vaccine |
1 |
2018 |
| Biological |
dendritic vaccine, allogeneic hematopoietic stem cells, cytotoxic lymphocytes |
1 |
2013 |
| Biological |
dendritic vaccine, autologous hematopoietic stem cells, cytotoxic lymphocytes |
1 |
2013 |
| Biological |
depsipeptide |
1 |
2002 |
| Drug |
desflurane |
1 |
2019 |
| Drug |
desloratadine |
1 |
2015 |
| Behavioral |
detached mindfulness components) |
1 |
2018 |
| Drug |
detox-b adjuvant |
1 |
2007 |
| Device |
device for pet |
1 |
2016 |
| Biological |
dex2 |
1 |
2010 |
| Drug |
dexamethasone (pre- |
1 |
2007 |
| Drug |
dexamethasone (pre-/post-medication for docetaxel) |
1 |
2007 |
| Other |
dexeryl |
1 |
2018 |
| Drug |
d) |
1 |
2019 |
| Diagnostic Test |
diagnosis with tomosynthesis |
1 |
2018 |
| Other |
diagnostic laboratory biomarker analysis |
1 |
2002 |
| Procedure |
diagnostic thoracoscopy |
1 |
1999 |
| Radiation |
dibh vmat |
1 |
2015 |
| Other |
dietary fasted |
1 |
2014 |
| Other |
dietary high fat |
1 |
2014 |
| Procedure |
different types of ultrasound technique |
1 |
2019 |
| Drug |
diflomotecan (bn80915) |
1 |
2004 |
| Behavioral |
dignity therapy |
1 |
2014 |
| Biological |
dinutuximab |
1 |
2017 |
| Drug |
diphenhydramine |
1 |
2011 |
| Drug |
diprosone |
1 |
2009 |
| Behavioral |
discussion sessions |
1 |
2015 |
| Drug |
dkn-01 |
1 |
2011 |
| Drug |
dmxaa in combination with carboplatin |
1 |
2009 |
| Drug |
dmxaa in combination with carboplatin/paclitaxel |
1 |
2009 |
| Genetic |
dna analysis |
1 |
2007 |
| Genetic |
dna methylation analysis |
1 |
2007 |
| Drug |
docetaxel-carboplatin |
1 |
2009 |
| Drug |
docetaxel (d) |
1 |
2015 |
| Drug |
docetaxel (taxane) |
1 |
2005 |
| Drug |
docetaxel / carboplatin / radiotherapy / docetaxel / gemcitabine |
1 |
2005 |
| Other |
docetaxel / gemcitabine / carboplatin / radiotherapy |
1 |
2005 |
| Drug |
docetaxel / plinabulin (dp) |
1 |
2015 |
| Drug |
docetaxel 20mg |
1 |
2012 |
| Drug |
docetaxel 20mg/m2/week / carboplatin auc 2/weekly - concomitant chemoradiation 2gy/day |
1 |
2012 |
| Drug |
docetaxel 40mg<7m2 d1,8, 21, 28 |
1 |
2012 |
| Drug |
docetaxel 40mg<7m2 d1,8, 21, 28/ gemcitabine 1200mg/m2 d1,8, 21, 28 / concomitant docetaxel 20mg/m2/w/carboplatin auc 2/w/ concomitant rdt 2gy/d |
1 |
2012 |
| Drug |
docetaxel 60 mg |
1 |
2012 |
| Drug |
docetaxel 60 mg/m2 |
1 |
2012 |
| Drug |
docetaxel 75 mg |
1 |
2012 |
| Drug |
docetaxel 75 mg/m2 |
1 |
2012 |
| Procedure |
docetaxel alone |
1 |
2010 |
| Drug |
docetaxel combination |
1 |
2003 |
| Drug |
docetaxel, cisplatin |
1 |
2005 |
| Drug |
docetaxel/bavituximab/placebo |
1 |
2010 |
| Drug |
docetaxel/carboplatin/bevacizumab/erlotinib |
1 |
2007 |
| Drug |
docetaxel/cisplatin / radiotherapy followed by docetaxel/cisplatin |
1 |
2005 |
| Drug |
docetaxel/cisplatin followed by concurrent chemoradiotherapy with docetaxel/cisplatin / radiotherapy |
1 |
2005 |
| Drug |
docetaxel/ddp |
1 |
2005 |
| Drug |
docetaxel/oxaliplatin |
1 |
2016 |
| Drug |
docetaxel/reolysin |
1 |
2012 |
| Drug |
docetaxelâ® |
1 |
2016 |
| Drug |
donafenib tablets |
1 |
2019 |
| Drug |
donepezil hydrochloride |
1 |
2000 |
| Biological |
donor-derived nk cell infusion |
1 |
2017 |
| Genetic |
dotap:chol-fus1 |
1 |
2003 |
| Drug |
dotap:chol-tusc2 |
1 |
2011 |
| Drug |
dovitinib |
1 |
2012 |
| Drug |
doxorubicin (dox) |
1 |
2015 |
| Drug |
doxorubicin. |
1 |
2018 |
| Drug |
doxycline |
1 |
2007 |
| Drug |
doxycycline |
1 |
2011 |
| Biological |
drug: ad.p53-dc vaccines |
1 |
2008 |
| Biological |
drug: hyperacute lung cancer cell vaccine |
1 |
2003 |
| Drug |
ds-3201b |
1 |
2019 |
| Procedure |
dual-agent therapy |
1 |
2010 |
| Procedure |
dual-agent therapy/docetaxel alone/best supportive care |
1 |
2010 |
| Drug |
duravalumab |
1 |
2014 |
| Combination Product |
durvalumab / danvatirsen |
1 |
2018 |
| Drug |
durvalumab/tremelimumab |
1 |
2016 |
| Drug |
dv281 |
1 |
2017 |
| Drug |
dv281 (rp2d) |
1 |
2017 |
| Procedure |
dynamic contrast-enhanced magnetic resonance imaging |
1 |
2008 |
| Behavioral |
dyspnea intervention |
1 |
2017 |
| Other |
dyspnoea counseling |
1 |
2010 |
| Drug |
dzd9008 |
1 |
2019 |
| Drug |
e.g.etoposide |
1 |
2008 |
| Drug |
e.g.etoposide. |
1 |
2008 |
| Drug |
e7080 |
1 |
2009 |
| Dietary Supplement |
eaa |
1 |
2010 |
| Dietary Supplement |
eaa/leu vs total aa |
1 |
2010 |
| Behavioral |
early allocation to palliative care |
1 |
2012 |
| Radiation |
early ccrt |
1 |
2010 |
| Biological |
early cdt lung blood test |
1 |
2013 |
| Other |
early integrated pc |
1 |
2017 |
| Procedure |
early paravertebral block |
1 |
2012 |
| Procedure |
ebna with rose |
1 |
2011 |
| Radiation |
ebr |
1 |
2011 |
| Radiation |
ebr/hdrib |
1 |
2011 |
| Procedure |
ebus-tbna followed by eus-b-fna |
1 |
2011 |
| Procedure |
ebus-tbna, eus-b-fna (eus-fna with bronchoscope) |
1 |
2008 |
| Procedure |
ebus-tbna, eus-na |
1 |
2017 |
| Drug |
ec145 |
1 |
2012 |
| Drug |
ec145 / docetaxel |
1 |
2012 |
| Drug |
ec20 |
1 |
2012 |
| Device |
echopulse |
1 |
2019 |
| Drug |
efaproxiral |
1 |
2000 |
| Drug |
egcg |
1 |
2015 |
| Drug |
egfr-tki |
1 |
2015 |
| Genetic |
egfr mutation test |
1 |
2009 |
| Behavioral |
ehr-based clinician jumpstart |
1 |
2020 |
| Drug |
ekb-569 |
1 |
2003 |
| Device |
electromagnetic navigation bronchoscopy |
1 |
2019 |
| Device |
electromagnetic navigation guided transthoracic needle aspiration |
1 |
2019 |
| Combination Product |
eloop device |
1 |
2018 |
| Drug |
emd 273066 |
1 |
2005 |
| Biological |
emd 521873 |
1 |
2009 |
| Device |
enb |
1 |
2019 |
| Drug |
encorafenib |
1 |
2019 |
| Device |
endo giaâ„¢ stapler with tri-stapleâ„¢ technology |
1 |
2010 |
| Procedure |
endobronchial forceps biopsy |
1 |
2017 |
| Procedure |
endobronchial ultrasound |
1 |
2007 |
| Procedure |
endobronchial ultrasound-guided transbronchial needle aspiration |
1 |
2016 |
| Procedure |
endobronchial ultrasound-guided transbronchial needle aspiration (ebus-tbna) |
1 |
2016 |
| Procedure |
endobronchial ultrasound guided transthoracic needle biopsy |
1 |
2006 |
| Device |
endobronchial ultrasound miniprobe |
1 |
2006 |
| Device |
endobronchial valve |
1 |
2011 |
| Procedure |
endoscopic biopsy |
1 |
2001 |
| Procedure |
endoscopic ultrasound (eus) |
1 |
2009 |
| Procedure |
endoscopic ultrasound staging |
1 |
2007 |
| Drug |
endostar -continued pumping into |
1 |
2012 |
| Drug |
endostar -continued pumping into/gp |
1 |
2012 |
| Drug |
endostar -injecting into |
1 |
2012 |
| Drug |
endostar -injecting into /gp |
1 |
2012 |
| Drug |
endostar(recombinant human endostatin injection) |
1 |
2008 |
| Drug |
endostar/pd-1 inhibitor |
1 |
2019 |
| Drug |
endostatin |
1 |
2015 |
| Dietary Supplement |
energy goal-based ons |
1 |
2018 |
| Behavioral |
enhance care |
1 |
2007 |
| Behavioral |
enhanced care (intervention group |
1 |
2013 |
| Behavioral |
enhanced care (intervention group/comparison group) |
1 |
2013 |
| Other |
enhanced supportive care - referrals |
1 |
2017 |
| Other |
enhanced supportive care - status checks |
1 |
2017 |
| Behavioral |
enhanced usual care |
1 |
2016 |
| Biological |
enoblituzumab/ipilimumab |
1 |
2015 |
| Drug |
entrectinib |
1 |
2017 |
| Biological |
enumeration of endothelial cell progenitor in peripheral blood by flow cytometry, endothelial cell progenitor characterization by primary cell cultures |
1 |
2009 |
| Drug |
enzyme inhibitor therapy |
1 |
2017 |
| Behavioral |
eortc qlq-c30 |
1 |
2016 |
| Behavioral |
eortc qlq-c30 questionnaire |
1 |
2020 |
| Behavioral |
eortc qlq-lc13 |
1 |
2016 |
| Biological |
ep2101 |
1 |
2003 |
| Behavioral |
epa |
1 |
2018 |
| Behavioral |
epac |
1 |
2016 |
| Procedure |
epidural anesthesia |
1 |
2016 |
| Drug |
epirubicin / ifosfamide / etoposide |
1 |
2008 |
| Drug |
epirubicin hydrochloride |
1 |
2001 |
| Biological |
epoetin alfa |
1 |
2002 |
| Drug |
epothilone d |
1 |
2004 |
| Behavioral |
eq-5d |
1 |
2015 |
| Other |
equip |
1 |
2016 |
| Drug |
erbitux |
1 |
2010 |
| Procedure |
erector spinae plane block (espb) |
1 |
2017 |
| Drug |
eribulin |
1 |
2011 |
| Drug |
eribulin mesylate / erlotinib |
1 |
2010 |
| Drug |
erlotinib (tarceva)/bexarotene (targretin) |
1 |
2005 |
| Drug |
erlotinib / docetaxel |
1 |
2011 |
| Drug |
erlotinib / placebo |
1 |
2007 |
| Drug |
erlotinib / sorafenib |
1 |
2007 |
| Drug |
erlotinib 150 |
1 |
2014 |
| Drug |
erlotinib 150/100 mg |
1 |
2014 |
| Drug |
erlotinib in combination with capecitabine |
1 |
2009 |
| Drug |
erlotinib, sunitinib |
1 |
2007 |
| Drug |
erlotinib/bevacizumab |
1 |
2017 |
| Drug |
erlotinib/bexarotene |
1 |
2005 |
| Drug |
erlotinib/dasatinib |
1 |
2008 |
| Drug |
erlotinib/placebo |
1 |
2008 |
| Drug |
erythromycin [eritex] |
1 |
2008 |
| Procedure |
escalation of dose (radiotherapy treatment) |
1 |
2005 |
| Radiation |
esophageal sparing imrt |
1 |
2009 |
| Drug |
ethaselen |
1 |
2014 |
| Drug |
etirinotecan pegol (nktr-102) |
1 |
2013 |
| Drug |
etoposide-based radiochemotherapy |
1 |
2018 |
| Drug |
etoposide-carboplatin |
1 |
2009 |
| Drug |
etoposide-cisplatin |
1 |
2008 |
| Drug |
etoposide-cisplatin/chemotherapy |
1 |
2008 |
| Drug |
etoposide - study |
1 |
2010 |
| Drug |
etoposide - usual |
1 |
2010 |
| Drug |
etoposide (50mg |
1 |
2012 |
| Drug |
etoposide (50mg/m2) iv (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles |
1 |
2012 |
| Drug |
etoposide 100 mg |
1 |
2013 |
| Drug |
etoposide 100 mg/m^2 |
1 |
2013 |
| Drug |
etoposide capsule |
1 |
2017 |
| Drug |
etoposide capsule / methotrexate tablet / everolimus tablet |
1 |
2017 |
| Drug |
etoposide capsule / methotrexate tablet / topotecan capsule |
1 |
2017 |
| Drug |
etoposide phosphate |
1 |
2007 |
| Drug |
etoposide/cisplatin after chemoradiotherapy |
1 |
2005 |
| Drug |
etoposide/lobaplatin |
1 |
2018 |
| Drug |
eu-approved avastinâ® |
1 |
2017 |
| Behavioral |
european organization for research |
1 |
2015 |
| Behavioral |
european organization for research/treatment of cancer quality of life questionnaire c30 |
1 |
2015 |
| Behavioral |
european organization for research/treatment of cancer quality of life questionnaire lc-13 |
1 |
2015 |
| Procedure |
eus-b-fna followed by ebus-tbna |
1 |
2011 |
| Procedure |
eus-fna |
1 |
2005 |
| Other |
evaluation of response by recist |
1 |
2017 |
| Drug |
everolimus tablet |
1 |
2017 |
| Other |
evozac calming skin spray |
1 |
2012 |
| Drug |
ex vivo-expanded her2-specific t cells |
1 |
2005 |
| Drug |
exatecan mesylate |
1 |
2000 |
| Device |
exatherm-tbh system |
1 |
2015 |
| Procedure |
excised tissues |
1 |
2016 |
| Behavioral |
exercise-based intervention |
1 |
2018 |
| Other |
exercise / |
1 |
2017 |
| Procedure |
exhalation analysis of breath sample |
1 |
2010 |
| Other |
exhaled breath collection |
1 |
2019 |
| Drug |
experimental arm (con): |
1 |
2006 |
| Drug |
experimental treatment (pcde |
1 |
2009 |
| Drug |
experimental treatment (pcde/pe / bevacizumab) |
1 |
2009 |
| Drug |
experimental: rp2d (pbf-509 |
1 |
2015 |
| Drug |
experimental: rp2d (pbf-509/pdr001)_immuno treated |
1 |
2015 |
| Radiation |
external beam radiation therapy |
1 |
2012 |
| Procedure |
extrapleural pneumonectomy |
1 |
2017 |
| Behavioral |
facilitator-based intervention |
1 |
2018 |
| Other |
faecal sample collection |
1 |
2019 |
| Drug |
famitinib h |
1 |
2015 |
| Drug |
famitinib h / docetaxel |
1 |
2015 |
| Drug |
famitinib l |
1 |
2015 |
| Drug |
famitinib l / docetaxel |
1 |
2015 |
| Drug |
famitinib m |
1 |
2015 |
| Drug |
famitinib m / docetaxel |
1 |
2015 |
| Other |
fasting-mimicking diet |
1 |
2018 |
| Device |
faza pet scan |
1 |
2015 |
| Drug |
fdg |
1 |
2009 |
| Radiation |
fdg pet |
1 |
2016 |
| Radiation |
fdg pet/ct |
1 |
2016 |
| Other |
feces samples |
1 |
2018 |
| Drug |
fenretinide |
1 |
2001 |
| Drug |
fentanyl 500mcg |
1 |
2012 |
| Drug |
fentanyl 500mcg / acupan 160mg / nasea 0.6mg |
1 |
2012 |
| Drug |
fentanyl i epidural catheter) |
1 |
2015 |
| Drug |
fentanyl in epidural catheter |
1 |
2015 |
| Drug |
fentanyl matrix |
1 |
2010 |
| Drug |
ferumoxytol |
1 |
2017 |
| Drug |
filgrastim-sd |
1 |
2002 |
| Drug |
filgrastim-sd/01 |
1 |
2002 |
| Drug |
first-line chemotherapy agents |
1 |
2006 |
| Other |
first session |
1 |
2015 |
| Drug |
fisiogel |
1 |
2008 |
| Drug |
flt |
1 |
2009 |
| Drug |
flt3 ligand therapy (cdx-301) |
1 |
2016 |
| Drug |
fludeoxyglucose f-18 |
1 |
2018 |
| Procedure |
fluorescence bronchoscopy |
1 |
2008 |
| Genetic |
fluorescence in situ hybridization |
1 |
2007 |
| Drug |
fluorine f 18 ara-g |
1 |
2019 |
| Radiation |
fluorine f 18 ef5 |
1 |
2009 |
| Other |
fluorine f 18 fluorothymidine |
1 |
2007 |
| Drug |
fluoxetine |
1 |
2000 |
| Drug |
fluzoparib |
1 |
2020 |
| Dietary Supplement |
folate/b12 |
1 |
2016 |
| Behavioral |
follow-up assessments: questionnaires |
1 |
2014 |
| Drug |
fondaparinux |
1 |
2010 |
| Device |
foreseal |
1 |
2009 |
| Drug |
formoterol fumarate dihydrate inhalation aerosol |
1 |
2007 |
| Drug |
fosbretabulin |
1 |
2008 |
| Drug |
fr901228 |
1 |
2007 |
| Radiation |
fraction |
1 |
2018 |
| Procedure |
fractionated stereotactic radiotherapy |
1 |
2006 |
| Other |
fresh tissue biopsy |
1 |
2015 |
| Biological |
fresolimumab |
1 |
2015 |
| Drug |
fruquintinib |
1 |
2015 |
| Combination Product |
fsrt |
1 |
2020 |
| Combination Product |
fsrt/with bevacizumab |
1 |
2020 |
| Procedure |
functional imaging of treatment effects |
1 |
2005 |
| Radiation |
functional lung avoidance thoracic radiotherapy |
1 |
2016 |
| Drug |
fusidic acid [verutex] |
1 |
2008 |
| Biological |
g-csf |
1 |
2003 |
| Drug |
g-csf (pegfilgrastim) 3.6 mg |
1 |
2013 |
| Drug |
g1t38 |
1 |
2018 |
| Combination Product |
gain-framed messaging/nrt |
1 |
2017 |
| Drug |
galunisertib |
1 |
2015 |
| Drug |
gamma-secretase inhibitor ro4929097 |
1 |
2010 |
| Drug |
ganetespib |
1 |
2012 |
| Drug |
ganetespib (sta-9090) |
1 |
2012 |
| Drug |
ganetespib (sta-9090)/crizotinib |
1 |
2012 |
| Drug |
gdc-0032 |
1 |
2013 |
| Drug |
gdc-0941 |
1 |
2009 |
| placebo |
gefitinib-matching placebo 250 mg |
1 |
2020 |
| Procedure |
gefitinib-surgery-gefitinib |
1 |
2015 |
| Drug |
gefitinib (iressa) |
1 |
2009 |
| Drug |
gefitinib 250mg |
1 |
2012 |
| Drug |
gefitinib only |
1 |
2007 |
| Drug |
gefitinib/bkm120 |
1 |
2012 |
| Drug |
gefitinib/docetaxel |
1 |
2005 |
| Drug |
gefitinib/nimotuzumab |
1 |
2011 |
| Drug |
gefitinib/olaparib |
1 |
2011 |
| Drug |
gemcitabine - 21 day cycle |
1 |
2018 |
| Drug |
gemcitabine - 28 day cycle |
1 |
2018 |
| Drug |
gemcitabine / carboplatin |
1 |
2017 |
| Drug |
gemcitabine / cisplatin |
1 |
2017 |
| Drug |
gemcitabine /carboplatin |
1 |
2011 |
| Drug |
gemcitabine 1200mg |
1 |
2012 |
| Drug |
gemcitabine cisplatin followed by docetaxel |
1 |
2007 |
| Drug |
gemcitabine hcl |
1 |
2006 |
| Drug |
gemcitabine hydrochloride / cisplatin/carboplatin |
1 |
2006 |
| Drug |
gemcitabine injection |
1 |
2012 |
| Drug |
gemcitabine prolonged continuous infusion |
1 |
2006 |
| Drug |
gemcitabine, carboplatin |
1 |
2005 |
| Drug |
gemcitabine, cisplatin/bevacizumab |
1 |
2014 |
| Drug |
gemcitabine/carboplatin/iniparib |
1 |
2010 |
| Drug |
gemcitabine/cisplatin/gemcitabine/carboplatin |
1 |
2008 |
| Drug |
gemcitabine/pemetrexed, paclitaxel/gemcitabine |
1 |
2007 |
| Drug |
gemcitabine/with cisplatin |
1 |
2013 |
| Drug |
gemcitabineâ® |
1 |
2016 |
| Drug |
general anesthesia alone |
1 |
2016 |
| Procedure |
general anesthesia with opioid analgesia |
1 |
2016 |
| Genetic |
genetic linkage analysis |
1 |
2012 |
| Drug |
genexol-pm |
1 |
2013 |
| Drug |
genexol-pm/gemcitabine |
1 |
2013 |
| Genetic |
genome analysis of tissue samples. |
1 |
2014 |
| Other |
geriatric follow up |
1 |
2016 |
| Drug |
gilotrif |
1 |
2013 |
| Drug |
ginseng compound |
1 |
2015 |
| Drug |
gleevec/taxotere |
1 |
2005 |
| Drug |
gleevecâ„¢ |
1 |
2005 |
| Drug |
glse compound |
1 |
2015 |
| Drug |
glufosfamide |
1 |
2000 |
| Drug |
gold sodium thiomalate |
1 |
2007 |
| Drug |
gp |
1 |
2012 |
| Drug |
gr-md-02 |
1 |
2015 |
| Drug |
granulocyte colony-stimulating factor (g-csf) |
1 |
2009 |
| Drug |
grapiprant |
1 |
2018 |
| Drug |
grapiprant/pembrolizumab |
1 |
2018 |
| Dietary Supplement |
green tea |
1 |
2006 |
| Radiation |
group 1: peripherally located tumors |
1 |
2016 |
| Radiation |
group 2: peripherally located chest wall adjacent tumors |
1 |
2016 |
| Radiation |
group 3: centrally located tumors |
1 |
2016 |
| Device |
group a - device guided breathing low dose |
1 |
2014 |
| Device |
group b - device guided breathing high dose |
1 |
2014 |
| Device |
group c - usual breathing control group |
1 |
2014 |
| Biological |
gsk 249553 vaccine |
1 |
2006 |
| Drug |
gsk1120212 |
1 |
2011 |
| Drug |
gt103 |
1 |
2020 |
| Biological |
gti-2040 |
1 |
2003 |
| Device |
guide sheath |
1 |
2009 |
| Behavioral |
hatha yoga |
1 |
2014 |
| Drug |
hbi-8000 in combination with nivolumab |
1 |
2016 |
| Drug |
hd204 |
1 |
2017 |
| Radiation |
hdrib |
1 |
2011 |
| Behavioral |
health coaching |
1 |
2015 |
| Behavioral |
healthy eating control |
1 |
2013 |
| Behavioral |
healthy living information |
1 |
2019 |
| Biological |
hekt cell |
1 |
2017 |
| Drug |
hematoporphyrin derivative |
1 |
2001 |
| Radiation |
heterogeneously hypofractionated radiotherapy |
1 |
2017 |
| Biological |
high-activity natural killer |
1 |
2016 |
| Radiation |
high-dose trt |
1 |
2016 |
| Other |
high dairy |
1 |
2018 |
| Radiation |
high dose chemoradiotherapy |
1 |
2018 |
| Other |
high intensity interval training exercise programme |
1 |
2016 |
| Other |
high protein |
1 |
2018 |
| Other |
high protein/high dairy |
1 |
2018 |
| Radiation |
high radiation dose therapy |
1 |
2008 |
| Behavioral |
hipec orientation |
1 |
2010 |
| Radiation |
hippocampal-sparing prophylactic cranial irradiation |
1 |
2012 |
| Radiation |
hippocampal-sparing wbrt |
1 |
2015 |
| Radiation |
hippocampus avoidance |
1 |
2016 |
| Drug |
hki-272 |
1 |
2005 |
| Biological |
hla-a*0201 |
1 |
2010 |
| Biological |
hla-a0201/hla-a0206-restricted urlc10 peptides |
1 |
2010 |
| Biological |
hla-a*0201restricted urlc10 peptides with adjuvant |
1 |
2013 |
| Biological |
hla-a*0206-restricted urlc10 peptides |
1 |
2010 |
| Biological |
hla-a*2402-restricted cdca1 |
1 |
2010 |
| Biological |
hla-a*2402-restricted cdca1/kif20a peptides |
1 |
2010 |
| Biological |
hla-a*2402restricted urlc10, cdca1, vegfr1 |
1 |
2009 |
| Biological |
hla-a*2402restricted urlc10, cdca1, vegfr1/vegfr2 |
1 |
2009 |
| Biological |
hla-a*2402restricted urlc10, cdca1,/kif20a peptides |
1 |
2010 |
| Biological |
hla-a*2402restricted urlc10, cdca1,/kif20a peptides with adjuvant |
1 |
2013 |
| Biological |
hla-a*2402restricted urlc10, ttk, vegfr1 |
1 |
2008 |
| Biological |
hla-a*2402restricted urlc10, ttk, vegfr1/vegfr2 |
1 |
2008 |
| Drug |
hmpl-453 |
1 |
2020 |
| Behavioral |
home-based pulmonary rehabilitation program |
1 |
2010 |
| Behavioral |
home nurse |
1 |
2016 |
| Behavioral |
home rehabilitation exercise program |
1 |
2019 |
| Other |
home training |
1 |
2010 |
| Device |
hook wire |
1 |
2019 |
| Biological |
hpv vaccine |
1 |
2013 |
| Behavioral |
hrha |
1 |
2019 |
| Behavioral |
hrla |
1 |
2019 |
| Biological |
hsppc-96 |
1 |
2004 |
| Other |
human breath samples |
1 |
2016 |
| Procedure |
hybrid apc |
1 |
2018 |
| Procedure |
hybrid dyna-ct guided localization |
1 |
2017 |
| Drug |
hycamtin, oral capsules |
1 |
2006 |
| Drug |
hydralazine |
1 |
2009 |
| Drug |
hydralazine/valproic acid: cohort -1 |
1 |
2009 |
| Drug |
hydralazine/valproic acid: cohort 0 |
1 |
2009 |
| Drug |
hydralazine/valproic acid: cohort 1 |
1 |
2009 |
| Drug |
hydralazine/valproic acid: cohort 2 |
1 |
2009 |
| Drug |
hydralazine/valproic acid: cohort 3 |
1 |
2009 |
| Drug |
hydralazine/valproic acid: cohort 4 |
1 |
2009 |
| Drug |
hydralazine/valproic acid: cohort 5 |
1 |
2009 |
| Radiation |
hyperfractionated |
1 |
2002 |
| Procedure |
hyperthermia treatment |
1 |
2001 |
| Drug |
hyperthermic intraperitoneal chemotherapy |
1 |
2019 |
| Radiation |
hypofractionated chest radiotherapy |
1 |
2009 |
| Procedure |
hypofractionated external beam |
1 |
2007 |
| Radiation |
hypofractionated radiation |
1 |
2016 |
| Radiation |
hypofractionated radiation/chemotherapy |
1 |
2016 |
| Radiation |
hypofractionated radiotherapy (hyport) |
1 |
2009 |
| Drug |
i124-nm404 |
1 |
2007 |
| Biological |
î³î´ t |
1 |
2015 |
| Other |
î³î´ t cells |
1 |
2017 |
| Other |
î³î´ t cells/ a cryosurgery/ire |
1 |
2017 |
| Biological |
î³î´ t/dc-cik cells |
1 |
2015 |
| Drug |
ibi305 |
1 |
2019 |
| Behavioral |
idaho |
1 |
2018 |
| Drug |
idelalisib |
1 |
2017 |
| Biological |
ido peptide vaccination |
1 |
2010 |
| Dietary Supplement |
igen0206 |
1 |
2019 |
| Procedure |
iiia small cell lung cancer (sclc) |
1 |
2018 |
| Device |
illinois bone marrow aspiration neddle |
1 |
2015 |
| Drug |
iloprost |
1 |
2004 |
| Drug |
ilx651 |
1 |
2004 |
| Biological |
ima201 product |
1 |
2017 |
| Drug |
ima202 product |
1 |
2018 |
| Device |
image guided video-assisted thoracic surgery (vats) resection |
1 |
2018 |
| Other |
imaging biomarker analysis |
1 |
2007 |
| Procedure |
imaging biomarkers |
1 |
2013 |
| Behavioral |
imaging studies) |
1 |
2013 |
| Drug |
imatinib |
1 |
2005 |
| Biological |
imc-1121b (ramucirumab) |
1 |
2010 |
| Biological |
imc-a12 (cixutumumab) |
1 |
2009 |
| Drug |
imetelstat |
1 |
2010 |
| Drug |
imetelstat sodium (grn163l) |
1 |
2007 |
| Drug |
imexon |
1 |
2006 |
| Drug |
immu-132 |
1 |
2012 |
| Drug |
immune checkpoint inhibitors |
1 |
2016 |
| Drug |
immune checkpoint inhibitors/docetaxel |
1 |
2016 |
| Biological |
immune enhancers add on to soc |
1 |
2015 |
| Drug |
immuno-therapeutic agent |
1 |
2017 |
| Biological |
immunotherapy |
1 |
2016 |
| Biological |
immunotherapy (standard of care) |
1 |
2017 |
| Drug |
imo-2055 |
1 |
2008 |
| Radiation |
imp-288-indium |
1 |
2010 |
| Radiation |
imp-288-lutetium |
1 |
2010 |
| Device |
implantation of anchored beacon transponder in the lung |
1 |
2011 |
| Procedure |
implanted markers |
1 |
2007 |
| Drug |
imprime pgg |
1 |
2016 |
| Biological |
imprime pggâ® injection |
1 |
2009 |
| Behavioral |
in-person meeting |
1 |
2020 |
| Other |
in-person pc |
1 |
2017 |
| Other |
in minimally invasive surgery<vagus nerve is not preserved |
1 |
2019 |
| Other |
in minimally invasive surgery<vagus nerve preservation |
1 |
2019 |
| Drug |
inbrx-106 - hexavalent ox40 agonist antibody |
1 |
2019 |
| Drug |
inc280 (capmatinib) |
1 |
2015 |
| Biological |
incagn02385 |
1 |
2018 |
| Drug |
incagn02390 |
1 |
2018 |
| Procedure |
incentive spirometry |
1 |
2014 |
| Biological |
incomplete freund’s adjuvant |
1 |
2006 |
| Drug |
individualized neoantigen peptides vaccine |
1 |
2020 |
| Radiation |
individualized stereotactic ablative radiotherapy (isabr) |
1 |
2011 |
| Drug |
indoximod |
1 |
2015 |
| Drug |
induction carboplatin |
1 |
2004 |
| Drug |
induction chemotherapy |
1 |
2013 |
| Drug |
induction paclitaxel |
1 |
2004 |
| Procedure |
indwelling catheter |
1 |
2018 |
| Biological |
infliximab |
1 |
2002 |
| Biological |
infusion of 0.9% saline without ald518 |
1 |
2009 |
| Drug |
inhalation of hyperpolarized xenon gas |
1 |
2014 |
| Drug |
inhaled budesonide 800 âµg twice daily |
1 |
2005 |
| Procedure |
injection of 99m-tc-nm-01 |
1 |
2016 |
| Drug |
ins316 |
1 |
2001 |
| Procedure |
integrated addiction treatment program |
1 |
2015 |
| Other |
integrated palliative care intervention |
1 |
2009 |
| Other |
integrative care |
1 |
2016 |
| Radiation |
intensity-modulated radiation therapy (imrt) |
1 |
2017 |
| Procedure |
intensity modulated radiation therapy |
1 |
2007 |
| Radiation |
intensity modulated radiation therapy (imrt) |
1 |
2019 |
| Radiation |
intensity modulated radiotherapy (imrt) |
1 |
2010 |
| Radiation |
intensity modulated radiotherapy treatment |
1 |
2013 |
| Behavioral |
intensive telephone counseling (8 sessions) with nicotine replacement |
1 |
2017 |
| Behavioral |
interactive voice response system |
1 |
2007 |
| Behavioral |
interactive voice response telephone system |
1 |
2007 |
| Procedure |
intercostal uniportal vats |
1 |
2017 |
| Drug |
interferon |
1 |
2012 |
| Biological |
interferon alpha |
1 |
2003 |
| Drug |
interleukin-2 |
1 |
2007 |
| Drug |
interleukin-2 (il2) |
1 |
2017 |
| Biological |
interleukin-4 pe38kdel cytotoxin |
1 |
2002 |
| Other |
internet access if needed |
1 |
2009 |
| Other |
intervention |
1 |
2018 |
| Drug |
intervention a: irinotecan; oxaliplatin; neulasta |
1 |
2005 |
| Drug |
intervention b: etoposide; carboplatin; neulasta |
1 |
2005 |
| Behavioral |
intervention invitation materials |
1 |
2015 |
| Other |
intracellular fluorescence polarization analysis |
1 |
2007 |
| Drug |
intralesional il-2 |
1 |
2017 |
| Drug |
intravenous (iv) sea-cd40 |
1 |
2015 |
| Drug |
intravenous etoposide |
1 |
2006 |
| Drug |
intravenous etoposide/cisplatin |
1 |
2006 |
| Drug |
intravenous topotecan |
1 |
2006 |
| Drug |
intravenous topotecan/cisplatin |
1 |
2006 |
| Drug |
investigational drug |
1 |
2002 |
| Drug |
ip |
1 |
2006 |
| Drug |
ipatasertib |
1 |
2015 |
| Drug |
ipi 504 |
1 |
2011 |
| Drug |
ipi 504/docetaxel |
1 |
2011 |
| Biological |
ipilimumab 1 mg |
1 |
2013 |
| Biological |
ipilimumab 1 mg/kg |
1 |
2013 |
| Drug |
ipilimumab, 10 mg |
1 |
2010 |
| Drug |
ipilimumab, 3 mg |
1 |
2010 |
| Other |
ire |
1 |
2017 |
| Procedure |
ire surgery |
1 |
2017 |
| Drug |
irinotecan injection [camptosar] |
1 |
2019 |
| Drug |
irinotecan liposome injection |
1 |
2017 |
| Drug |
irinotecan/carboplatin/concurrent radiation |
1 |
2005 |
| Drug |
irinotecan/cisplatin |
1 |
2014 |
| Drug |
irinotecan/cisplatin after chemoradiotherapy |
1 |
2005 |
| Drug |
irinotecan/lobaplatin |
1 |
2018 |
| Drug |
iron sucrose injection |
1 |
2018 |
| Radiation |
irradiation: ha-pci |
1 |
2014 |
| Device |
irreversible electroporation ablation |
1 |
2015 |
| Drug |
irx4204 |
1 |
2016 |
| Drug |
iscar |
1 |
2004 |
| Drug |
iscar quercus |
1 |
2006 |
| Drug |
isis eif4e rx |
1 |
2010 |
| Drug |
isoflurane, sevoflurane |
1 |
2019 |
| Drug |
isoflurane, sevoflurane/desflurane |
1 |
2019 |
| Drug |
isolated perfusion |
1 |
2001 |
| Drug |
isotretinoin |
1 |
1999 |
| Drug |
isovue-200 |
1 |
2016 |
| Drug |
ispinesib |
1 |
2004 |
| Drug |
itraconazole 200 mg |
1 |
2018 |
| Radiation |
itv |
1 |
2012 |
| Drug |
iv acetaminophen |
1 |
2013 |
| Drug |
iv avastin (bevacizumab) |
1 |
2008 |
| Behavioral |
ivr |
1 |
2007 |
| Behavioral |
ivr/triage |
1 |
2007 |
| Drug |
ixabepilone, 32 mg/m^2 |
1 |
2008 |
| Drug |
ixabepilone, 32 mg/m^2 / carboplatin, 5 mg/min/ml |
1 |
2008 |
| Drug |
ixabepilone, 32 mg/m^2 / carboplatin, 6 mg/min/ml |
1 |
2008 |
| Drug |
jin fu kang |
1 |
2005 |
| Drug |
jinfukang |
1 |
2015 |
| Drug |
jnj-61186372 |
1 |
2015 |
| Drug |
kanglaite injection |
1 |
2019 |
| Drug |
kanglaite injection/chemotherapy |
1 |
2019 |
| Drug |
karenitecin |
1 |
2001 |
| Drug |
ketamine |
1 |
2016 |
| Biological |
keyhole limpet hemocyanin |
1 |
2000 |
| Drug |
keytruda injectable product |
1 |
2019 |
| Genetic |
ki-67 protein expression |
1 |
2009 |
| Biological |
kif20a peptides with adjuvant |
1 |
2013 |
| Drug |
kos-1584 |
1 |
2008 |
| Behavioral |
ky leads survivorship care |
1 |
2016 |
| Drug |
l-alanosine |
1 |
2003 |
| Drug |
l-nmma |
1 |
2017 |
| Drug |
l19tnfî± |
1 |
2014 |
| Other |
laboratory assay |
1 |
2005 |
| Drug |
ladiratuzumab vedotin |
1 |
2019 |
| Procedure |
laparoscopic surgery |
1 |
2019 |
| Drug |
laromustine |
1 |
2006 |
| Drug |
larotrectinib |
1 |
2015 |
| Drug |
larotrectinib sulfate |
1 |
2015 |
| Procedure |
laser ablation |
1 |
2018 |
| Other |
lat |
1 |
2016 |
| Radiation |
late ccrt |
1 |
2010 |
| Procedure |
late paravertebral block. |
1 |
2012 |
| Drug |
lazertinib |
1 |
2015 |
| placebo |
lazertinib-matching placebo 240 mg |
1 |
2020 |
| Drug |
lazertinib-matching placebo 240 mg/160 mg |
1 |
2020 |
| Drug |
lazertinib 240 mg |
1 |
2020 |
| Drug |
lazertinib 240 mg/160 mg |
1 |
2020 |
| Drug |
lbh581 |
1 |
2010 |
| Drug |
lcl161 |
1 |
2016 |
| Other |
ldct brochure |
1 |
2017 |
| Drug |
lde225, etoposide |
1 |
2012 |
| Drug |
lde225, etoposide/cisplatin |
1 |
2012 |
| Drug |
ldk378(ceritinib) |
1 |
2017 |
| placebo |
lenvatinib matched placebo |
1 |
2012 |
| Other |
less frequent surveillance strategy |
1 |
2015 |
| Behavioral |
letter |
1 |
2019 |
| Dietary Supplement |
leu |
1 |
2010 |
| Dietary Supplement |
leu vs total aa |
1 |
2010 |
| Drug |
levofloxacin |
1 |
2000 |
| Drug |
life information rehabilitation therapy |
1 |
2017 |
| Behavioral |
lifestyle-integrated exercise |
1 |
2019 |
| Behavioral |
light physical activity |
1 |
2013 |
| Behavioral |
light physical activity 1 |
1 |
2018 |
| Behavioral |
light physical activity 2 |
1 |
2018 |
| Dietary Supplement |
lindera obtusiloba extract |
1 |
2020 |
| Drug |
linifanib |
1 |
2010 |
| Drug |
liposomal bupivacaine |
1 |
2018 |
| Other |
liquid chromatography |
1 |
2007 |
| Drug |
lisinopril |
1 |
2013 |
| Drug |
lmb-100 |
1 |
2019 |
| Drug |
lmwh: dalteparin |
1 |
2014 |
| Procedure |
lobectomy / mediastinal lymph node dissection/systematic lymph node sampling |
1 |
2018 |
| Radiation |
local definitive radiotherapy |
1 |
2017 |
| Radiation |
local radiation therapy |
1 |
2019 |
| Drug |
losartan |
1 |
2010 |
| Genetic |
loss of heterozygosity analysis |
1 |
2003 |
| Procedure |
low-dose computed tomography annual scan x3 |
1 |
2014 |
| Procedure |
low-dose computed tomography baseline scan only |
1 |
2014 |
| Diagnostic Test |
low-dose computed tomography of chest |
1 |
2019 |
| Other |
low-dose ct screening with quantitative assessment |
1 |
2019 |
| Other |
low-dose ct screening with quantitative assessment/management of imaging biomarkers |
1 |
2019 |
| Other |
low-dose ct screening with visual assessment |
1 |
2019 |
| Other |
low-dose ct screening with visual assessment/management of imaging biomarkers |
1 |
2019 |
| Device |
low-dose helical computed tomography |
1 |
2002 |
| Device |
low-frequency rotating magnetic therapy system |
1 |
2016 |
| Radiation |
low-let cobalt-60 gamma ray therapy |
1 |
1999 |
| Radiation |
low-let electron therapy |
1 |
1999 |
| Radiation |
low-let photon therapy |
1 |
1999 |
| Radiation |
low dose computed tomography (ct) |
1 |
2010 |
| Procedure |
low dose computed tomography imaging |
1 |
2014 |
| Drug |
low volume iso-osmolar non-ionic radio contrast medium |
1 |
2015 |
| Drug |
loxo-292 (selpercatinib) |
1 |
2017 |
| Behavioral |
lrha |
1 |
2019 |
| Behavioral |
lrla |
1 |
2019 |
| Diagnostic Test |
lsi alk break apart dna fish test |
1 |
2019 |
| Drug |
ltt462 |
1 |
2016 |
| Biological |
lucanix |
1 |
2010 |
| Biological |
lucanixâ„¢ |
1 |
2008 |
| Behavioral |
lucas decision aid |
1 |
2016 |
| Biological |
lung cancer-specific t cells |
1 |
2017 |
| Other |
lung cancer screening |
1 |
2019 |
| Behavioral |
lung cancer screening decision tool |
1 |
2016 |
| Device |
lung radiofrequency ablation |
1 |
2008 |
| Biological |
lung tumor associated antigen |
1 |
1999 |
| Device |
lungbrella marker implantation |
1 |
2019 |
| Device |
lungbrella marker implantation/vats partial lobe resection |
1 |
2019 |
| Behavioral |
lungcare |
1 |
2019 |
| Drug |
lurtotecan liposome |
1 |
2000 |
| Drug |
lxh254 |
1 |
2016 |
| Drug |
ly01008 |
1 |
2018 |
| Drug |
ly01610( irinotecan hydrochloride liposome injection ) |
1 |
2020 |
| Drug |
ly2181308 |
1 |
2010 |
| Drug |
ly2510924 |
1 |
2011 |
| Drug |
ly2523355 |
1 |
2009 |
| Drug |
ly3295668 erbumine |
1 |
2019 |
| Drug |
ly573636-sodium |
1 |
2006 |
| Drug |
lyc-55716 |
1 |
2018 |
| Procedure |
lymphadenectomy |
1 |
2008 |
| Drug |
m2 d1,8, 21, 28 |
1 |
2012 |
| Drug |
m2 on day 1 |
1 |
2005 |
| Drug |
m2 on days 1and 8, repeated every 21 days over four cycles. |
1 |
2005 |
| Drug |
m2) iv (in the vein) on day 1 |
1 |
2012 |
| Drug |
m2) iv (in the vein) on day 1 to day 5 of a 28-day cycle for 2 cycles |
1 |
2012 |
| Drug |
m200 (volociximab), carboplatin, paclitaxel |
1 |
2008 |
| Drug |
m200 (volociximab), carboplatin, paclitaxel, bevacizumab |
1 |
2008 |
| Drug |
m2es |
1 |
2010 |
| Drug |
mac-321 |
1 |
2003 |
| Drug |
mage-12 peptide vaccine |
1 |
2007 |
| Procedure |
magnetic resonance imaging |
1 |
2017 |
| Drug |
maintenance chemotherapy |
1 |
2014 |
| Drug |
maitake mushroom extract compound |
1 |
2015 |
| Other |
management of imaging biomarkers |
1 |
2019 |
| Procedure |
management of therapy complications |
1 |
2009 |
| Device |
manufacturer (vpap st) |
1 |
2012 |
| Drug |
manuka honey in liquid form |
1 |
2010 |
| Drug |
manuka honey in lozenge form |
1 |
2010 |
| Biological |
mapatumumab |
1 |
2007 |
| placebo |
matched placebo |
1 |
2006 |
| Drug |
matuzumab |
1 |
2005 |
| Drug |
mb02 (bevacizumab biosimilar drug) |
1 |
2017 |
| Other |
measure dcam levels in blood |
1 |
2012 |
| Procedure |
mechanical ventilation |
1 |
2008 |
| Device |
medela thopaz thoracic drainage system |
1 |
2013 |
| Drug |
medi-575 |
1 |
2010 |
| Drug |
medi4736 (anti-pd-l1) |
1 |
2015 |
| Drug |
medi4736 (durvalumab) |
1 |
2015 |
| Drug |
medi4736 (durvalumab) in combination with tremelimumab (anti-ctla4) |
1 |
2015 |
| Drug |
medi5752 |
1 |
2018 |
| Drug |
medi7247 |
1 |
2018 |
| Other |
media intervention |
1 |
2017 |
| Procedure |
mediastinal lymph node dissection |
1 |
2018 |
| Other |
medical history data collection |
1 |
2019 |
| Other |
medical imaging |
1 |
2013 |
| Behavioral |
medical outcomes study social support survey |
1 |
2015 |
| Behavioral |
meditation |
1 |
2015 |
| Behavioral |
meditation/discussion sessions |
1 |
2015 |
| Drug |
megestrol acetate |
1 |
2002 |
| Drug |
megf0444a |
1 |
2011 |
| Dietary Supplement |
melatonin |
1 |
2008 |
| Drug |
memantine hydrochloride |
1 |
2012 |
| Drug |
merestinib |
1 |
2016 |
| Drug |
mesna |
1 |
1999 |
| Diagnostic Test |
mesothelin expression |
1 |
2019 |
| Drug |
met |
1 |
2010 |
| Other |
met analysis on tissue |
1 |
2012 |
| Other |
met analysis on tissue/blood |
1 |
2012 |
| Drug |
met/vegfr2 inhibitor foretinib |
1 |
2010 |
| Drug |
metformin xr |
1 |
2014 |
| Drug |
methotrexate |
1 |
2018 |
| Drug |
methotrexate tablet |
1 |
2017 |
| Biological |
methoxy polyethylene glycol epoetin beta |
1 |
2003 |
| Drug |
methoxyamine |
1 |
2015 |
| Drug |
methylprednisolone 0.5mg•kg-1 |
1 |
2016 |
| Drug |
methylprednisolone 1 mg•kg-1 |
1 |
2016 |
| Drug |
metmab |
1 |
2009 |
| Drug |
metoprolol |
1 |
2010 |
| Biological |
mg1-magea3 |
1 |
2016 |
| Biological |
mga012 |
1 |
2015 |
| Drug |
mgcd265 |
1 |
2015 |
| Drug |
mgn1703 |
1 |
2014 |
| Other |
mick assay |
1 |
2005 |
| Combination Product |
microdevice loaded with 19 chemotherapeutic agents |
1 |
2019 |
| Device |
microwave ablation with acculis accu2i pmta applicator |
1 |
2016 |
| Radiation |
mid-position radiation strategy |
1 |
2012 |
| Drug |
mifepristone |
1 |
2015 |
| Drug |
mil60 |
1 |
2017 |
| Biological |
milsâ„¢ - nsclc |
1 |
2019 |
| Device |
mimig system |
1 |
2014 |
| Behavioral |
mindfulness based pulmonary rehabilitation |
1 |
2012 |
| Behavioral |
mindfulness based stress reduction |
1 |
2011 |
| Behavioral |
mindfulness intervention |
1 |
2012 |
| Behavioral |
minimal treatment |
1 |
2014 |
| Procedure |
minimum dose computed tomography (mndct) scan |
1 |
2005 |
| Device |
miseq sequencer |
1 |
2017 |
| Device |
miso pet scan |
1 |
2015 |
| Drug |
mistletoe |
1 |
2004 |
| Drug |
mistletoe extract |
1 |
2007 |
| Drug |
mithramycin |
1 |
2016 |
| Other |
mitochondria-targeted system therapy |
1 |
2019 |
| Other |
mitochondria-targeted system therapy/with radiofrequency ablation |
1 |
2019 |
| Drug |
mitomycin c |
1 |
1999 |
| Drug |
mitomycin c, vindesine, cisplatin |
1 |
2005 |
| Drug |
mitomycin c, vindesine, cisplatin/radiotherapy |
1 |
2005 |
| Drug |
mk-0646 |
1 |
2008 |
| Drug |
mk-1308 |
1 |
2018 |
| Drug |
mk-3475 (phase i) |
1 |
2015 |
| Drug |
mk-3475 (phase ii) |
1 |
2015 |
| Biological |
mk-4280 |
1 |
2018 |
| Drug |
mkc-1 |
1 |
2006 |
| Drug |
ml intravenous solution |
1 |
2018 |
| Drug |
ml intravenous solution [opdivo] |
1 |
2019 |
| Device |
mlc tracking |
1 |
2015 |
| Drug |
mldg |
1 |
2015 |
| Drug |
mln8237 (alisertib) |
1 |
2010 |
| Drug |
mmc |
1 |
2005 |
| Drug |
mocetinostat |
1 |
2017 |
| Behavioral |
modified assisted relaxation therapy |
1 |
2020 |
| Behavioral |
modified medical research council |
1 |
2015 |
| Other |
modified medical research council dyspnea patient reported outcomes |
1 |
2020 |
| Device |
modulated electro-hyperthermia (meht) |
1 |
2016 |
| Biological |
mogamulizumab |
1 |
2015 |
| Procedure |
molecular profiling |
1 |
2011 |
| Drug |
monalizumab (iph2201 |
1 |
2019 |
| Other |
monitoring by sentinel application |
1 |
2015 |
| Device |
monitoring device |
1 |
2017 |
| Biological |
monoclonal antibody 11d10 anti-idiotype vaccine |
1 |
2000 |
| Biological |
monoclonal antibody 3h1 anti-idiotype vaccine |
1 |
2000 |
| Biological |
monoclonal antibody hu3s193 |
1 |
2004 |
| Drug |
montanide isa-51 |
1 |
2007 |
| Biological |
montanide isa 51 vaccine |
1 |
2016 |
| Drug |
morab-009 |
1 |
2006 |
| Other |
more frequent surveillance strategy |
1 |
2015 |
| Drug |
morphine p.o. |
1 |
2006 |
| Drug |
morphine s.c. |
1 |
2006 |
| Drug |
motesanib diphosphate |
1 |
2004 |
| Diagnostic Test |
mr |
1 |
2018 |
| Other |
mri scan |
1 |
2017 |
| Other |
mri t1 t2 sequences |
1 |
2014 |
| Drug |
mtc-dox for injection |
1 |
2002 |
| Drug |
mtig7192a |
1 |
2018 |
| Behavioral |
mtm |
1 |
2015 |
| Biological |
muc1 peptide-poly-iclc vaccine |
1 |
2017 |
| Other |
multi-faceted intervention to improve continuity of care |
1 |
2011 |
| Radiation |
multi-fraction sabr |
1 |
2013 |
| Dietary Supplement |
multi-herbal agent acapha |
1 |
2007 |
| Genetic |
multifocal lung adenocarcinoma |
1 |
2013 |
| Behavioral |
multimodal |
1 |
2018 |
| Behavioral |
multimodal/exercise-based intervention |
1 |
2018 |
| Radiation |
multiple-fraction stereotactic body radiation therapy (sbrt) |
1 |
2009 |
| Behavioral |
muscle resistance training |
1 |
2013 |
| Biological |
mv mix vaccine |
1 |
2015 |
| Biological |
mva-muc1-il2 |
1 |
2006 |
| Procedure |
mwa |
1 |
2019 |
| Biological |
mycobacterium w. |
1 |
2008 |
| Biological |
n-propionylated polysialic acid |
1 |
2011 |
| Drug |
nab-paclitaxel 100 mg |
1 |
2013 |
| Drug |
nab-paclitaxel 100 mg/m^2 |
1 |
2013 |
| Drug |
nab-paclitaxel iv |
1 |
2014 |
| Drug |
nab-paclitaxel/carboplatin |
1 |
2018 |
| Drug |
nab paclitaxel. |
1 |
2018 |
| Drug |
nadroparin calcium |
1 |
2010 |
| Drug |
naloxegol |
1 |
2017 |
| Drug |
naquotinib |
1 |
2014 |
| Drug |
nasea 0.6mg |
1 |
2012 |
| Biological |
natural killer |
1 |
2017 |
| Biological |
natural killer t cell |
1 |
2017 |
| Biological |
natural killer/natural killer t cell |
1 |
2017 |
| Procedure |
nausea |
1 |
1999 |
| Procedure |
nausea/vomiting therapy |
1 |
1999 |
| Biological |
navitoclax |
1 |
2014 |
| Drug |
nb-paclitaxel |
1 |
2019 |
| Behavioral |
nci website |
1 |
2016 |
| Drug |
nda etoposide - study |
1 |
2017 |
| Drug |
nda etoposide - usual |
1 |
2017 |
| Drug |
near infrared imaging |
1 |
2005 |
| Drug |
nebuliser solution |
1 |
2019 |
| Drug |
nebuliser suspension |
1 |
2019 |
| Device |
needle angle measurement |
1 |
2010 |
| Drug |
nelfinavir mesylate |
1 |
2007 |
| Drug |
neoadjuvant chemotherapy |
1 |
2018 |
| Drug |
neoadjuvant chemotherapy (taxol |
1 |
2009 |
| Drug |
neoadjuvant chemotherapy (taxol/carboplatin) |
1 |
2009 |
| Drug |
neratinib |
1 |
2013 |
| Drug |
neulastaâ® (pegfilgrastim) |
1 |
2005 |
| Drug |
nexavar (sorafenib, bay43-9006) |
1 |
2010 |
| Procedure |
next-generation sequencing |
1 |
2015 |
| Device |
nextseq500 sequencer |
1 |
2015 |
| Drug |
nicotinamide |
1 |
2015 |
| Drug |
nicotine lozenge |
1 |
2006 |
| Drug |
nicotine replacement patch |
1 |
2011 |
| Drug |
nivolumab / ipilimumab |
1 |
2017 |
| Drug |
nivolumab / plinabulin |
1 |
2016 |
| Drug |
nivolumab 10 mg/ml intravenous solution |
1 |
2018 |
| Drug |
nivolumab 10 mg/ml intravenous solution [opdivo] |
1 |
2019 |
| Drug |
nivolumab 360 mg |
1 |
2017 |
| Drug |
nivolumab in combination with ipilimumab |
1 |
2016 |
| Drug |
nivolumab/ipilimumab |
1 |
2018 |
| Combination Product |
nk cell |
1 |
2019 |
| Combination Product |
nk cell/pd-1 antibody |
1 |
2019 |
| Biological |
nk cells |
1 |
2017 |
| Drug |
nk012 |
1 |
2009 |
| Diagnostic Test |
no daily chest xray |
1 |
2018 |
| Radiation |
no intervention |
1 |
2018 |
| Drug |
no local definitive radiotherapy |
1 |
2017 |
| Other |
no lung plug |
1 |
2007 |
| Radiation |
no personalized dose redistribution |
1 |
2015 |
| Radiation |
non-daily stereotactic body radiotherapy |
1 |
2018 |
| Other |
non-investigational platinum-based doublet chemotherapy |
1 |
2015 |
| Other |
none, standard chemotherapy only |
1 |
2014 |
| Drug |
normal saline solution |
1 |
2017 |
| Drug |
nov-002 injection in combination with carboplatin vs. paclitaxel |
1 |
2006 |
| Drug |
nov-002 injection in combination with carboplatin vs. paclitaxel/carboplatin |
1 |
2006 |
| Drug |
novel drug combination |
1 |
2009 |
| Device |
novottf-100m device |
1 |
2016 |
| Device |
novottf-200a |
1 |
2018 |
| Drug |
npi-0052 (marizomib) |
1 |
2008 |
| Drug |
npi-0052 (marizomib) / vorinostat |
1 |
2008 |
| Combination Product |
nrt |
1 |
2017 |
| Drug |
nt-i7 |
1 |
2020 |
| Other |
nursing educational intervention |
1 |
2010 |
| Behavioral |
nutritional counseling |
1 |
2012 |
| Biological |
ny-eso-1 fusion protein cdx-1401 |
1 |
2012 |
| Drug |
obatoclax |
1 |
2008 |
| Drug |
obatoclax mesylate |
1 |
2007 |
| Drug |
obatoclax mesylate 250 ml |
1 |
2006 |
| Drug |
ocz103-os |
1 |
2013 |
| Drug |
od for 12 weeks |
1 |
2007 |
| Drug |
ogx-427 |
1 |
2013 |
| Drug |
olanzapine |
1 |
2018 |
| Drug |
olaparib pill |
1 |
2019 |
| Drug |
olaparib pill 100 mg |
1 |
2018 |
| Drug |
olaparib pill 150 mg |
1 |
2018 |
| Drug |
olaparib pill 200 mg |
1 |
2018 |
| Drug |
olaparib pill 250 mg |
1 |
2018 |
| Drug |
olaparib pill 300 mg |
1 |
2018 |
| Drug |
olaparib pill 50 mg |
1 |
2018 |
| Biological |
olaratumab |
1 |
2009 |
| Drug |
oleclumab (medi9447) |
1 |
2019 |
| Drug |
oltipraz |
1 |
2000 |
| Drug |
omaveloxolone |
1 |
2013 |
| Drug |
ombrabulin (ave8062) |
1 |
2010 |
| Drug |
onartuzumab (metmab) |
1 |
2011 |
| Drug |
onartuzumab [metmab] |
1 |
2014 |
| Radiation |
once daily radiotherapy |
1 |
2007 |
| Biological |
oncolytic measles virus encoding thyroidal sodium iodide symporter |
1 |
2011 |
| Diagnostic Test |
oncomine |
1 |
2019 |
| Dietary Supplement |
oncoxinâ® |
1 |
2018 |
| Procedure |
one-llung ventilation |
1 |
2007 |
| Procedure |
one-lung ventilation |
1 |
2007 |
| Behavioral |
online health management program |
1 |
2015 |
| Procedure |
only pulmonary metastasectomy |
1 |
2017 |
| Dietary Supplement |
ons from the start of radiotherapy |
1 |
2018 |
| Dietary Supplement |
ons from the time of grade 2 radiation esophagitis |
1 |
2018 |
| Procedure |
open sleeve lobectomy |
1 |
2018 |
| Biological |
opt-821 adjuvant |
1 |
2011 |
| Drug |
oral decitabine |
1 |
2016 |
| Drug |
oral hycamtin (topotecan) capsules |
1 |
2008 |
| Drug |
oral hycamtin (topotecan) capsules / iv avastin (bevacizumab) |
1 |
2008 |
| Drug |
oral nsaid |
1 |
2015 |
| Drug |
oral opioids |
1 |
2015 |
| Drug |
oral paracetamol |
1 |
2015 |
| Drug |
oral taxane |
1 |
2005 |
| Drug |
oral vinorelbine |
1 |
2008 |
| Drug |
ortataxel |
1 |
2003 |
| Drug |
ose2101 |
1 |
2016 |
| Drug |
osi-211 (liposomal lurtotecan) |
1 |
2002 |
| Drug |
osi-774 (tarceva) |
1 |
2005 |
| Drug |
osi-774: erlotinib, tarcevatm |
1 |
2007 |
| Drug |
osi-906 |
1 |
2010 |
| Drug |
osimertinib 80mg |
1 |
2018 |
| Drug |
osimertinib 80mg/40mg |
1 |
2018 |
| Drug |
osimertinib mesylate tablets |
1 |
2018 |
| Drug |
oxaliplatin, gemcitabine, bevacizumab |
1 |
2005 |
| Drug |
oxygen mixture |
1 |
2017 |
| Biological |
p10s-padre vaccine |
1 |
2014 |
| Drug |
paclitaxel-carboplatin |
1 |
2008 |
| Drug |
paclitaxel (genexolâ®) |
1 |
2009 |
| Drug |
paclitaxel (taxane) |
1 |
2005 |
| Drug |
paclitaxel (taxol) |
1 |
2008 |
| Drug |
paclitaxel / carboplatin |
1 |
2010 |
| Drug |
paclitaxel 200mg |
1 |
2017 |
| Drug |
paclitaxel 200mg/m2 |
1 |
2017 |
| Drug |
paclitaxel 45 mg |
1 |
2018 |
| Drug |
paclitaxel 45 mg/m^2 |
1 |
2018 |
| Drug |
paclitaxel injection |
1 |
2020 |
| Drug |
paclitaxel liposome |
1 |
2016 |
| Drug |
paclitaxel loaded polymeric micelle (genexol-pmâ®) |
1 |
2009 |
| Drug |
paclitaxel poliglumex, pemetrexed |
1 |
2007 |
| Drug |
paclitaxel, 200 mg |
1 |
2008 |
| Drug |
paclitaxel, 200 mg/m^2 |
1 |
2008 |
| Drug |
paclitaxel, carboplatin |
1 |
2008 |
| Drug |
paclitaxel, carboplatin/bevacizumab,erlotinib |
1 |
2008 |
| Drug |
paclitaxel, cisplatin, carboplatin |
1 |
2013 |
| Drug |
paclitaxel. |
1 |
2018 |
| Drug |
paclitaxel/albumin-bound paclitaxel |
1 |
2019 |
| Drug |
paclitaxel/carboplatin/concurrent radiation |
1 |
2005 |
| Drug |
paclitaxel/carboplatin/gefitinib |
1 |
2010 |
| Drug |
paclitaxel/cisplatin |
1 |
2008 |
| Procedure |
pain therapy |
1 |
1999 |
| Procedure |
painless indwelling catheter |
1 |
2018 |
| Drug |
palifermin |
1 |
2004 |
| Radiation |
palliative radiation therapy |
1 |
2010 |
| Other |
palliative radiotherapy |
1 |
2009 |
| Other |
palliative radiotherapy/chemotherapy |
1 |
2009 |
| Other |
palliative therapy |
1 |
2014 |
| Procedure |
palliative thoracic radiotherapy |
1 |
2005 |
| Drug |
panobinostat (lbh589) |
1 |
2008 |
| Drug |
panobinostat (lbh589), sorafenib |
1 |
2009 |
| Drug |
panobinostat, cisplatin, pemetrexed |
1 |
2011 |
| Procedure |
parametric imaging |
1 |
2016 |
| Procedure |
paravertebral block (pvb) |
1 |
2017 |
| Drug |
part a: azd8186 monotherapy |
1 |
2013 |
| Drug |
part b: azd8186 monotherapy |
1 |
2013 |
| Drug |
part c1: abiraterone acetate combination with azd8186 |
1 |
2013 |
| Drug |
part c2: abiraterone acetate combination with azd8186 |
1 |
2013 |
| Drug |
part d1: azd2014 combination with azd8186 |
1 |
2013 |
| Drug |
part d2 azd2014 combination with azd8186 |
1 |
2013 |
| Drug |
pasireotide lar |
1 |
2012 |
| Drug |
pasireotide lar / everolimus |
1 |
2012 |
| Behavioral |
pathways |
1 |
2019 |
| Behavioral |
patient decision aid |
1 |
2014 |
| Behavioral |
patient navigation program |
1 |
2019 |
| Drug |
patients were randomized to receive either docetaxel 60 mg |
1 |
2005 |
| Drug |
patients were randomized to receive either docetaxel 60 mg/m2 on day 1/vinorelbine 25 mg/m2 on days 1and 8, repeated every 21 days over four cycles. |
1 |
2005 |
| Biological |
patients with a living donor |
1 |
2015 |
| Biological |
patients with a ucb donor |
1 |
2015 |
| Drug |
pazopanib hydrochloride |
1 |
2007 |
| Drug |
pazopanib/pemetrexed |
1 |
2009 |
| Drug |
pbf-509_160 mg |
1 |
2015 |
| Drug |
pbf-509_320 mg |
1 |
2015 |
| Drug |
pbf-509_640 mg |
1 |
2015 |
| Drug |
pbf-509_80 mg |
1 |
2015 |
| Drug |
pc |
1 |
2018 |
| Drug |
pd-0325901 |
1 |
2013 |
| Combination Product |
pd-1 antibody |
1 |
2019 |
| Drug |
pd-1 antibody sintilimab |
1 |
2019 |
| Biological |
pd-1 knockout |
1 |
2018 |
| Other |
pd-1 knockout t cells |
1 |
2016 |
| Drug |
pd-1 mab |
1 |
2018 |
| Other |
pd-l1 positive vs pd-l1 negative nsclc patients |
1 |
2018 |
| Drug |
pd0332991 |
1 |
2011 |
| Biological |
pd1-t cells |
1 |
2019 |
| Biological |
pdc*lung01 |
1 |
2019 |
| Drug |
pdgfr dual kinase inhibitor x-82 |
1 |
2018 |
| Drug |
pdr001)_immuno naã¯ve |
1 |
2015 |
| Drug |
pdr001)_immuno treated |
1 |
2015 |
| Drug |
pe) |
1 |
2009 |
| Drug |
peg-rhg-csf |
1 |
2018 |
| Drug |
pegylated g-csf |
1 |
2013 |
| Drug |
pegylated gcsf (peg-gcsf) |
1 |
2016 |
| Drug |
pegylated irinotecan |
1 |
2014 |
| Drug |
pegzilarginase |
1 |
2017 |
| Biological |
pembrolizumab (keytrudaâ®) |
1 |
2019 |
| Biological |
pembrolizumab 10 mg |
1 |
2013 |
| Biological |
pembrolizumab 10 mg/kg |
1 |
2013 |
| Biological |
pembrolizumab 2 mg |
1 |
2013 |
| Biological |
pembrolizumab 2 mg/kg |
1 |
2013 |
| Drug |
pembrolizumab, paclitaxel |
1 |
2015 |
| Drug |
pembrolizumab/amurubicin |
1 |
2017 |
| Drug |
pembrolizumab/bevacizumab |
1 |
2016 |
| Drug |
pembrolizumab/chemotherapy |
1 |
2018 |
| Drug |
pemetrexed - after protocol amendment |
1 |
2006 |
| Drug |
pemetrexed - before protocol amendment |
1 |
2006 |
| Drug |
pemetrexed (alimta) in combination with gemcitabine (gemzar) |
1 |
2002 |
| Drug |
pemetrexed / carboplatin |
1 |
2017 |
| Drug |
pemetrexed / cisplatin |
1 |
2017 |
| Drug |
pemetrexed 1000 mg |
1 |
2005 |
| Drug |
pemetrexed 1000 mg/m2 |
1 |
2005 |
| Drug |
pemetrexed 500 mg/m2 |
1 |
2005 |
| Drug |
pemetrexed disodium f injection |
1 |
2020 |
| Drug |
pemetrexed phase 1 |
1 |
2007 |
| Drug |
pemetrexed phase 2 |
1 |
2007 |
| Drug |
pemetrexed regimen) |
1 |
2016 |
| Drug |
pemetrexed, cisplatin |
1 |
2008 |
| Drug |
pemetrexed, docetaxel |
1 |
2011 |
| Drug |
pemetrexed, docetaxel/gemcitabine |
1 |
2011 |
| Drug |
pemetrexed, paclitaxel |
1 |
2007 |
| Drug |
pemetrexed/ carboplatin |
1 |
2018 |
| Drug |
pemetrexed/ cisplatin |
1 |
2018 |
| Biological |
pemetrexed/donor-derived nk cell infusion |
1 |
2017 |
| Drug |
pemetrexed/gemcitabine/bevacizumab |
1 |
2007 |
| Drug |
pemetrexed/reolysin (and safety run-in) |
1 |
2012 |
| Drug |
pemetrexedâ® |
1 |
2016 |
| Drug |
pen-221 |
1 |
2016 |
| Drug |
pentoxifylline |
1 |
2013 |
| Drug |
perfluorinated gas |
1 |
2017 |
| Drug |
perfluorinated gas/oxygen mixture |
1 |
2017 |
| Device |
perfusion ct imaging |
1 |
2016 |
| Drug |
perifosine |
1 |
2006 |
| Radiation |
peripherally located lung tumor |
1 |
2009 |
| Radiation |
personalized dose redistribution |
1 |
2015 |
| Behavioral |
personalized exercise program |
1 |
2017 |
| Drug |
pertuzumab / trastuzumab / docetaxel |
1 |
2019 |
| Combination Product |
pet-based, dose-painted, accelerated chemoradiotherapy |
1 |
2018 |
| Procedure |
pet diagnostic imaging |
1 |
2005 |
| Diagnostic Test |
pet/ct scans |
1 |
2018 |
| Diagnostic Test |
pet/mr |
1 |
2018 |
| Drug |
pevonedistat |
1 |
2019 |
| Drug |
pf-06747775 |
1 |
2015 |
| Drug |
pf-06821497 |
1 |
2018 |
| Biological |
pf-06936308 |
1 |
2018 |
| Other |
pharmacogenomic study |
1 |
2015 |
| Procedure |
pharmacokinetic sampling |
1 |
2014 |
| Procedure |
pharmacokinetic sampling - rosuvastatin |
1 |
2014 |
| Biological |
phase i - gm.cd40l.ccl21 vaccinations |
1 |
2011 |
| Biological |
phase ii - gm.cd40l cells vaccinations |
1 |
2011 |
| Biological |
phase ii - gm.cd40l.ccl21 vaccinations |
1 |
2011 |
| Procedure |
photodynamic therapy (pdt) |
1 |
2007 |
| Radiation |
photons |
1 |
2014 |
| Behavioral |
physical activity |
1 |
2016 |
| Behavioral |
physical activity/education |
1 |
2016 |
| Behavioral |
physical activity/positive affect |
1 |
2016 |
| Other |
physical exercise |
1 |
2010 |
| Other |
physical exercise/dyspnoea counseling |
1 |
2010 |
| Other |
physical training |
1 |
2011 |
| Procedure |
physician does not receive the results |
1 |
2011 |
| Procedure |
physician receives qol results |
1 |
2011 |
| Other |
physiologic testing |
1 |
2005 |
| Other |
physiological saline |
1 |
2012 |
| Other |
physiotherapy |
1 |
2014 |
| Drug |
pi-88 |
1 |
2005 |
| Drug |
pi3k-beta inhibitor gsk2636771 |
1 |
2015 |
| Drug |
pi3k inhibitor bkm120 |
1 |
2012 |
| Drug |
picoplatin |
1 |
2005 |
| Drug |
pictilisib |
1 |
2011 |
| Procedure |
pigtail catheter |
1 |
2020 |
| Drug |
pioglitazone |
1 |
2016 |
| placebo |
pioglitazone vs. placebo 30 mg |
1 |
2008 |
| Drug |
pirfenidone |
1 |
2017 |
| placebo |
placebo (0.9 % saline) |
1 |
2009 |
| placebo |
placebo (for bavituximab) |
1 |
2013 |
| placebo |
placebo (for bupivacain |
1 |
2015 |
| Drug |
placebo (for bupivacain/fentanyl i epidural catheter) |
1 |
2015 |
| placebo |
placebo (for oral opioids) |
1 |
2015 |
| placebo |
placebo (for ramucirumab) |
1 |
2010 |
| placebo |
placebo 1 capsule x 3 daily until progression |
1 |
2015 |
| placebo |
placebo acupuncture, questionnaires |
1 |
2005 |
| placebo |
placebo ast2818 80mg |
1 |
2018 |
| Drug |
placebo ast2818 80mg//40 mg |
1 |
2018 |
| Drug |
placebo azd9291 80 mg/ 40 mg |
1 |
2014 |
| Drug |
placebo azd9291 80 mg/40 mg |
1 |
2015 |
| placebo |
placebo capsule |
1 |
2013 |
| placebo |
placebo comparator: standard physiotherapy |
1 |
2013 |
| placebo |
placebo erlotinib |
1 |
2011 |
| placebo |
placebo erlotinib 150 |
1 |
2014 |
| Drug |
placebo erlotinib 150/100mg |
1 |
2014 |
| placebo |
placebo for abt-869 |
1 |
2008 |
| placebo |
placebo for lenvatinib |
1 |
2019 |
| placebo |
placebo for veliparib |
1 |
2014 |
| placebo |
placebo granules |
1 |
2016 |
| placebo |
placebo matching lenvatinib |
1 |
2019 |
| placebo |
placebo of aprepitant |
1 |
2015 |
| placebo |
placebo of desloratadine |
1 |
2015 |
| placebo |
placebo osimertinib 80mg |
1 |
2018 |
| Drug |
placebo osimertinib 80mg/40mg |
1 |
2018 |
| placebo |
placebo pf00299804 |
1 |
2011 |
| placebo |
placebo tablets |
1 |
2008 |
| placebo |
placebo to denosumab |
1 |
2013 |
| placebo |
placebo to match zd6474, vandetanib |
1 |
2008 |
| placebo |
placebo to zoledronic acid |
1 |
2013 |
| Drug |
placebo/chemotherapy |
1 |
2018 |
| placebo |
placebo1 |
1 |
2019 |
| placebo |
placebo2 |
1 |
2019 |
| Drug |
platinum-based agent |
1 |
2007 |
| Drug |
platinum-based chemotherapy alone (up to six cycles) |
1 |
2005 |
| Drug |
platinum-based chemotherapy followed by maintenance therapy with gefitinib |
1 |
2005 |
| Drug |
platinum-based chemotherapy/nivolumab |
1 |
2018 |
| Drug |
platinum-based doublet chemotherapy |
1 |
2009 |
| Drug |
platinum-based drug |
1 |
2017 |
| Drug |
platinum-based two drug chemotherapy (cisplatin |
1 |
2016 |
| Drug |
platinum-based two drug chemotherapy (cisplatin/carboplatin / vinorelbine/cisplatin/carboplatin / pemetrexed regimen) |
1 |
2016 |
| Drug |
platinum / gemcitabine |
1 |
2005 |
| Drug |
platinum chemotherapy (cisplatin |
1 |
2009 |
| Drug |
platinum chemotherapy (cisplatin/carboplatin) |
1 |
2009 |
| Drug |
plb1003 |
1 |
2017 |
| Procedure |
pleurectomy |
1 |
2017 |
| Drug |
plinabulin (dp) |
1 |
2015 |
| Drug |
pm01183 |
1 |
2013 |
| Drug |
pm01183 / paclitaxel //- bevacizumab |
1 |
2013 |
| Other |
poligraphy |
1 |
2016 |
| Biological |
polyiclc |
1 |
2012 |
| Genetic |
polymorphism analysis |
1 |
2012 |
| Drug |
polyphenon e |
1 |
2006 |
| Drug |
polysialic acid |
1 |
2000 |
| Drug |
ponatinib 15 mg |
1 |
2018 |
| Drug |
ponatinib 30 mg |
1 |
2018 |
| Radiation |
port-first |
1 |
2016 |
| Radiation |
port-last |
1 |
2016 |
| Behavioral |
positive affect |
1 |
2016 |
| Procedure |
positron emission tomography (pet) scan |
1 |
2005 |
| Procedure |
positron emission tomography (pet) scan imaging |
1 |
2005 |
| Drug |
post-medication for docetaxel) |
1 |
2007 |
| Diagnostic Test |
post-sabr biopsy |
1 |
2018 |
| Behavioral |
post test of a lung cancer screening decision aid |
1 |
2016 |
| Drug |
postoperative adjuvant chemotherapy |
1 |
2018 |
| Drug |
poziotinib |
1 |
2017 |
| Drug |
pralsetinib |
1 |
2020 |
| Drug |
pralsetinib (blu-667) |
1 |
2017 |
| Drug |
pravastatin sodium |
1 |
2007 |
| Behavioral |
pre |
1 |
2016 |
| Drug |
pre-surgical docetaxel |
1 |
2005 |
| Drug |
pre-surgical docetaxel/cisplatin/adjuvant bevacizumab |
1 |
2005 |
| Drug |
pre-surgical treatment with bevacizumab |
1 |
2005 |
| Drug |
pre-surgical treatment with bevacizumab/chemotherapy |
1 |
2005 |
| Behavioral |
pre/post test of a lung cancer screening decision aid |
1 |
2016 |
| Dietary Supplement |
prealbumin goal-based ons |
1 |
2018 |
| Drug |
premetrexed (alimta) |
1 |
2006 |
| Other |
preoperative chest physiotherapy |
1 |
2016 |
| Procedure |
preoperative ct scan-guided localization |
1 |
2017 |
| Drug |
preoperative docetaxel-cisplatin combination chemotherapy |
1 |
2005 |
| Drug |
preoperative docetaxel monotherapy |
1 |
2005 |
| Other |
preoperative pulmonary rehabilitation |
1 |
2019 |
| Radiation |
preoperative radiation |
1 |
2014 |
| Procedure |
preoperative radiochemotherapy |
1 |
2005 |
| Other |
preoperative rehabilitation program |
1 |
2016 |
| Drug |
prerandomization chemotherapy (pcde |
1 |
2009 |
| Drug |
prerandomization chemotherapy (pcde/pe) |
1 |
2009 |
| Behavioral |
prescribed activity |
1 |
2017 |
| Procedure |
prevention |
1 |
2006 |
| Other |
preventive intervention |
1 |
2016 |
| Drug |
prexasertib |
1 |
2016 |
| Drug |
prinomastat |
1 |
2000 |
| Drug |
pro95780 |
1 |
2007 |
| Behavioral |
proactive telephone counseling from va quitline |
1 |
2018 |
| Drug |
probiotic |
1 |
2011 |
| Drug |
probiotics |
1 |
2015 |
| Other |
procedure |
1 |
2014 |
| Device |
progel pleural air leak sealant |
1 |
2011 |
| Behavioral |
progressive stretching |
1 |
2010 |
| Drug |
prolonged continuous infusion gemcitabine |
1 |
2006 |
| Drug |
prolonged glucocorticosteroid (prednisone) regimen |
1 |
2019 |
| Procedure |
prophylactic cranial irradiation (pci) |
1 |
2018 |
| Radiation |
prophylactic cranial irradiation, 1.5 gy fx |
1 |
2003 |
| Radiation |
prophylactic cranial irradiation, 2.0 gy fx |
1 |
2003 |
| Radiation |
prophylactic cranial irradiation, 2.5 gy fx |
1 |
2003 |
| Radiation |
prophylaxis cranial radiotherapy |
1 |
2015 |
| Procedure |
protein-rich nutrition therapy |
1 |
2017 |
| Genetic |
proteomic profiling |
1 |
2007 |
| Radiation |
proton-beam therapy for small cell lung cancer |
1 |
2020 |
| Device |
proton beam therapy |
1 |
2017 |
| Radiation |
proton beam therapy rt |
1 |
2019 |
| Behavioral |
psychoeducation. |
1 |
2012 |
| Behavioral |
psychosocial care conquer fear support intervention (psychoeducation, attention training, worry management, |
1 |
2018 |
| Behavioral |
psychosocial care conquer fear support intervention (psychoeducation, attention training, worry management,/detached mindfulness components) |
1 |
2018 |
| Drug |
ptk787/ zk 222584 |
1 |
2005 |
| Drug |
ptk787/zk 222584 |
1 |
2003 |
| Device |
pulmonary artery energy seal |
1 |
2013 |
| Procedure |
pulmonary complications management |
1 |
2006 |
| Procedure |
pulmonary complications management/prevention |
1 |
2006 |
| Procedure |
pulmonary metastasectomy |
1 |
2017 |
| Behavioral |
pulmonary rehabilitation program |
1 |
2013 |
| Radiation |
pulsed low dose radiation |
1 |
2017 |
| Drug |
pyrazoloacridine |
1 |
1999 |
| Radiation |
q.d. rt |
1 |
2015 |
| Biological |
qbkpn ssi |
1 |
2014 |
| Behavioral |
qigong |
1 |
2016 |
| Drug |
ql1101 |
1 |
2017 |
| Other |
qlq-c30 global health |
1 |
2020 |
| Other |
qlq-c30 global health/quality of life questionnaire |
1 |
2020 |
| Biological |
qs21 |
1 |
2000 |
| Other |
quality of life questionnaire |
1 |
2020 |
| Other |
quality of life questionnaire, lung cancer-specific (qlq-lc13) |
1 |
2020 |
| Procedure |
quantitative high resolution ct scan |
1 |
2008 |
| Drug |
quinacrine dihydrochloride - escalation dose |
1 |
2013 |
| Drug |
quinacrine dihydrochloride - extension dose |
1 |
2013 |
| Drug |
quisinostat |
1 |
2015 |
| Biological |
racotumomab |
1 |
2010 |
| Drug |
rad001 (everolimus) |
1 |
2006 |
| Radiation |
radiation hippocampal avoidance pci |
1 |
2013 |
| Radiation |
radiation prophylactic cranial irradiation |
1 |
2013 |
| Device |
radiation therapy-3 fractions |
1 |
2018 |
| Device |
radiation therapy-5 fractions |
1 |
2018 |
| Radiation |
radiation therapy (radiotherapy) |
1 |
2005 |
| Radiation |
radiation therapy (rt) |
1 |
2014 |
| Radiation |
radiation treatment (rt) |
1 |
2007 |
| Radiation |
radiation with concurrent chemotherapy |
1 |
2013 |
| Procedure |
radical non-small cell lung cancer (nsclc) surgery |
1 |
2005 |
| Radiation |
radical radiotherapy - definitive local treatment. |
1 |
2019 |
| Radiation |
radical radiotherapy (conventional rt |
1 |
2015 |
| Radiation |
radical radiotherapy (conventional rt/sabr) |
1 |
2015 |
| Procedure |
radical surgery |
1 |
2007 |
| Procedure |
radical surgery for stage ii |
1 |
2018 |
| Procedure |
radical surgery for stage ii/iiia small cell lung cancer (sclc) |
1 |
2018 |
| Radiation |
radiochemotherapy 1 |
1 |
2017 |
| Radiation |
radiochemotherapy 2 |
1 |
2017 |
| Radiation |
radiochemotherapy 3 |
1 |
2017 |
| Radiation |
radiochemotherapy 4 |
1 |
2017 |
| Radiation |
radiochemotherapy 5 |
1 |
2017 |
| Radiation |
radiochemotherapy 6 |
1 |
2017 |
| Radiation |
radiochemotherapy 7 |
1 |
2017 |
| Procedure |
radiofrequency |
1 |
2012 |
| Procedure |
radiography |
1 |
2000 |
| Radiation |
radiosurgery |
1 |
2016 |
| Radiation |
radiotherapy (imrt |
1 |
2014 |
| Radiation |
radiotherapy (imrt/3-d crt) |
1 |
2014 |
| Radiation |
radiotherapy (sabr) |
1 |
2017 |
| Drug |
radiotherapy followed by docetaxel |
1 |
2005 |
| Radiation |
radiotherapy group |
1 |
2018 |
| Drug |
radiotherapy) |
1 |
2008 |
| Other |
radiotherapy/concurrent chemo-therapy |
1 |
2010 |
| Behavioral |
radon |
1 |
2018 |
| Behavioral |
radon only |
1 |
2018 |
| Behavioral |
radon/smoking isolated |
1 |
2018 |
| Behavioral |
radon/smoking synergistic |
1 |
2018 |
| Drug |
rapamycin (drug will be held) |
1 |
2007 |
| Other |
rapid on-site evaluation |
1 |
2013 |
| Procedure |
rats |
1 |
2016 |
| Procedure |
rats lobectomy |
1 |
2017 |
| Drug |
rc48 |
1 |
2020 |
| Procedure |
re biopsy |
1 |
2013 |
| Device |
real-time position transponder beacons |
1 |
2017 |
| Other |
real time registry |
1 |
2012 |
| Other |
real time registry/data feedback only |
1 |
2012 |
| Drug |
rebimastat |
1 |
2000 |
| Device |
reciva breath sampler |
1 |
2015 |
| Biological |
recombinant anti-pd-l1 monoclonal antibody injection |
1 |
2020 |
| Biological |
recombinant anti-pd-l1 monoclonal antibody injection/with carboplatin/etoposide |
1 |
2020 |
| Biological |
recombinant fowlpox gm-csf vaccine adjuvant |
1 |
2004 |
| Biological |
recombinant human egf-rp64k |
1 |
2016 |
| Biological |
recombinant human egf-rp64k/montanide isa 51 vaccine |
1 |
2016 |
| Drug |
recombinant human erythropoietin (rhuepo) |
1 |
2005 |
| Biological |
recombinant human interleukin-15 |
1 |
2012 |
| Biological |
recombinant interferon gamma |
1 |
1999 |
| Biological |
recombinant prame protein |
1 |
2013 |
| Biological |
recombinant prame protein/with the as15 adjuvant system gsk2302032a |
1 |
2013 |
| Biological |
recombinant vaccinia-cea(6d)-tricom vaccine |
1 |
2004 |
| Drug |
regn2810/ipi |
1 |
2018 |
| Drug |
regn5093 |
1 |
2019 |
| Drug |
regorafenib |
1 |
2018 |
| Other |
regular diet |
1 |
2018 |
| Device |
rejuvenair |
1 |
2015 |
| Device |
rejuvenairâ„¢ radial spray cryotherapy |
1 |
2014 |
| Procedure |
relaxation therapy |
1 |
2019 |
| Procedure |
remote ischemic preconditioning |
1 |
2011 |
| Behavioral |
remotely supervised exercise (rem) |
1 |
2018 |
| Drug |
reolysin (and safety run-in) |
1 |
2012 |
| Biological |
reolysinâ® |
1 |
2009 |
| Behavioral |
resistance exercise |
1 |
2017 |
| Behavioral |
resistive training |
1 |
2016 |
| Device |
resmed autoset s9 |
1 |
2014 |
| Genetic |
respiragene test |
1 |
2010 |
| Genetic |
respiragene test/risk score |
1 |
2010 |
| Other |
respiratory distress symptom intervention |
1 |
2017 |
| Biological |
respiratory fluids sampling |
1 |
2016 |
| Device |
respiratory muscle training device |
1 |
2019 |
| Drug |
retifanlimab |
1 |
2019 |
| Genetic |
reverse transcriptase-polymerase chain reaction |
1 |
2006 |
| Device |
rf ablation |
1 |
2018 |
| Radiation |
rfa interventions |
1 |
2019 |
| Drug |
rg1507 |
1 |
2008 |
| Drug |
rh-endostatin |
1 |
2013 |
| Drug |
rhenium (re 188 p2045, bay86-5284) |
1 |
2004 |
| Drug |
rhuph20 |
1 |
2018 |
| Drug |
rifampin |
1 |
2007 |
| Biological |
rilotumumab |
1 |
2014 |
| Drug |
risedronate |
1 |
2019 |
| Genetic |
risk score |
1 |
2010 |
| Drug |
rituximab |
1 |
1999 |
| Drug |
ro4929097 |
1 |
2010 |
| Drug |
ro5083945 |
1 |
2010 |
| Drug |
ro5126766 |
1 |
2018 |
| Drug |
ro5490258 |
1 |
2011 |
| Drug |
ro7051790 |
1 |
2016 |
| Drug |
ro7121661 |
1 |
2018 |
| Drug |
ro7198457 |
1 |
2020 |
| Procedure |
robotic thoracic surgery |
1 |
2015 |
| Drug |
rofecoxib |
1 |
2006 |
| Drug |
rogaratinib |
1 |
2018 |
| Drug |
ropivacaine for serratus plane block (spb) |
1 |
2017 |
| Drug |
ropivacaine hcl 0.2% inj vil 10ml |
1 |
2019 |
| Diagnostic Test |
ros1 ihc |
1 |
2019 |
| Drug |
rosuvastatin |
1 |
2014 |
| Other |
routine blood presure management |
1 |
2019 |
| Procedure |
routine gene testing |
1 |
2015 |
| Drug |
rovalpituzumab tesirine (sc16ld6.5) |
1 |
2013 |
| Drug |
rp2d (pbf-509 |
1 |
2015 |
| Drug |
rp2d (pbf-509/pdr001)_immuno naã¯ve |
1 |
2015 |
| Combination Product |
rrx-001 |
1 |
2018 |
| Combination Product |
rrx-001 / eloop device |
1 |
2018 |
| Combination Product |
rucaparib/nivolumab |
1 |
2019 |
| Drug |
rxdx-105 |
1 |
2018 |
| Drug |
s-3304 |
1 |
2004 |
| Drug |
s-588410 |
1 |
2015 |
| Drug |
s1 |
1 |
2019 |
| Drug |
s1/anlotinib |
1 |
2019 |
| Radiation |
sabr) |
1 |
2015 |
| Drug |
saf-189s |
1 |
2020 |
| Drug |
saline 0.9% |
1 |
2019 |
| Other |
saliva |
1 |
2019 |
| Behavioral |
sami |
1 |
2009 |
| Other |
sampling |
1 |
2017 |
| Drug |
sapanisertib |
1 |
2015 |
| Behavioral |
satisfaction questionnaire - general practitioner |
1 |
2016 |
| Behavioral |
satisfaction questionnaire - general practitioner/home nurse |
1 |
2016 |
| Behavioral |
satisfaction questionnaire - patient |
1 |
2016 |
| Drug |
satraplatin |
1 |
2006 |
| Drug |
satraplatin in combination with paclitaxel |
1 |
2005 |
| Drug |
sb8 |
1 |
2016 |
| Radiation |
sbrt 40.0 gy |
1 |
2008 |
| Radiation |
sbrt 42.5 gy |
1 |
2008 |
| Radiation |
sbrt 45.0 gy |
1 |
2008 |
| Radiation |
sbrt 47.5 gy |
1 |
2008 |
| Radiation |
sbrt 50.0 gy |
1 |
2008 |
| Radiation |
sbrt 52.5 gy |
1 |
2008 |
| Radiation |
sbrt 55.0 gy |
1 |
2008 |
| Radiation |
sbrt 57.5 gy |
1 |
2008 |
| Radiation |
sbrt 60.0 gy |
1 |
2008 |
| Radiation |
sbrt with protons |
1 |
2014 |
| Radiation |
sbrt with protons/photons |
1 |
2014 |
| Radiation |
sbrt/tki |
1 |
2018 |
| Drug |
screening platform |
1 |
2019 |
| Drug |
sct-i10 |
1 |
2019 |
| Behavioral |
sdm |
1 |
2017 |
| Drug |
second-line chemotherapy |
1 |
2011 |
| Drug |
second-line chemotherapy agents |
1 |
2006 |
| Other |
second session |
1 |
2015 |
| Procedure |
segmentectomy/wedge resection |
1 |
2007 |
| Diagnostic Test |
selective targeted sampling |
1 |
2019 |
| Drug |
selenium |
1 |
2001 |
| Behavioral |
self-management intervention |
1 |
2012 |
| Behavioral |
self-system therapy for older adults with advanced lung cancer (sst-lc) |
1 |
2019 |
| Drug |
selumetinib 75 mg |
1 |
2012 |
| Drug |
selumetinib/docetaxel |
1 |
2014 |
| Drug |
semaxanib |
1 |
2000 |
| Drug |
sgi-110 |
1 |
2017 |
| Drug |
sgn-15 |
1 |
2003 |
| Drug |
sgn-15, docetaxel |
1 |
2004 |
| Drug |
sh-1028 |
1 |
2018 |
| Drug |
sh t00268c |
1 |
2005 |
| Device |
sham |
1 |
2018 |
| Other |
sham control |
1 |
2018 |
| Device |
sham low-frequency rotating magnetic therapy system |
1 |
2016 |
| Behavioral |
shared decision making (sdm) |
1 |
2019 |
| Drug |
shark cartilage extract ae-941 |
1 |
2000 |
| Drug |
short glucocorticosteroid (prednisone) regimen |
1 |
2019 |
| Biological |
shr-1316 |
1 |
2020 |
| Radiation |
sib |
1 |
2017 |
| Drug |
sid530, taxotere |
1 |
2009 |
| Drug |
sildenafil |
1 |
2008 |
| Drug |
simultaneous chemoradiotherapy for an luo |
1 |
2019 |
| Radiation |
single-fraction stereotactic body radiation therapy (sbrt) |
1 |
2009 |
| Drug |
single arm |
1 |
2019 |
| Radiation |
single fraction radiation therapy |
1 |
2016 |
| Radiation |
single fraction sabr |
1 |
2013 |
| Drug |
sintilimab maintenance |
1 |
2019 |
| Drug |
sintilimab/with docetaxel |
1 |
2019 |
| Drug |
sintilimab/with docetaxel monotherapy |
1 |
2019 |
| Other |
skin biopsy |
1 |
2013 |
| Other |
sleep testing |
1 |
2016 |
| Drug |
sm-153 |
1 |
2006 |
| Other |
smartcare |
1 |
2019 |
| Behavioral |
smoking isolated |
1 |
2018 |
| Behavioral |
smoking synergistic |
1 |
2018 |
| Drug |
sn2310 injectable emulsion |
1 |
2006 |
| Drug |
sndx-275 |
1 |
2008 |
| Drug |
sns-595 |
1 |
2006 |
| Drug |
so-c101 |
1 |
2019 |
| Drug |
soblidotin |
1 |
2003 |
| Other |
sodium bicarbonate |
1 |
2011 |
| Drug |
sodium bicarbonate solution |
1 |
2015 |
| Drug |
sodium phenylbutyrate |
1 |
2000 |
| Drug |
sodium thiosulfate |
1 |
2019 |
| Drug |
sonidegib |
1 |
2019 |
| Drug |
sorafenib (nexavar) |
1 |
2009 |
| Drug |
sorafenib / docetaxel/carboplatin |
1 |
2008 |
| Drug |
spartalizumab |
1 |
2018 |
| Other |
spect-based treatment plan |
1 |
2012 |
| Diagnostic Test |
spect-ct scan |
1 |
2017 |
| Procedure |
spectroscopy |
1 |
2008 |
| Radiation |
sr-89 |
1 |
2006 |
| Drug |
sr48692 |
1 |
2006 |
| Drug |
ss1 (dsfv) pe38 |
1 |
2010 |
| Drug |
sta-9090 |
1 |
2010 |
| Drug |
sta 4783 |
1 |
2004 |
| Drug |
sta 9090 |
1 |
2009 |
| Other |
staging of non-small cell lung carcinoma |
1 |
2016 |
| Radiation |
standard |
1 |
2017 |
| Radiation |
standard-dose trt |
1 |
2016 |
| Combination Product |
standard chemoradiotherapy |
1 |
2018 |
| Drug |
standard chemotherapy |
1 |
2013 |
| Drug |
standard chemotherapy (pcde |
1 |
2009 |
| Drug |
standard chemotherapy (pcde/pe) |
1 |
2009 |
| Procedure |
standard ebna |
1 |
2011 |
| Behavioral |
standard educational information |
1 |
2014 |
| Behavioral |
standard health educational booklet |
1 |
2015 |
| Drug |
standard maintenance for squamous nsclc |
1 |
2014 |
| Other |
standard of care chemotherapy |
1 |
2015 |
| Drug |
standard of care pd-1 therapy |
1 |
2019 |
| Behavioral |
standard of information |
1 |
2015 |
| Other |
standard palliative care group |
1 |
2009 |
| Drug |
standard platinum-based chemotherapy |
1 |
2007 |
| Radiation |
standard radiation dose therapy |
1 |
2008 |
| Radiation |
standard thoracic radiotherapy |
1 |
2016 |
| Device |
stapling |
1 |
2009 |
| Behavioral |
stepped-care intervention |
1 |
2016 |
| Other |
stepped pc |
1 |
2017 |
| Radiation |
stereotactic ablative body radiation (sabr) |
1 |
2017 |
| Radiation |
stereotactic ablative radiotherapy (sabr) |
1 |
2013 |
| Radiation |
stereotactic body radiation therapy/surgery |
1 |
2014 |
| Radiation |
stereotactic body radiotherapy (sabr) |
1 |
2015 |
| Radiation |
stereotactic body radiotherapy (sbrt) 30 gy 3 fractions (#) |
1 |
2018 |
| Radiation |
stereotactic body radiotherapy (sbrt) 54 gy 3 fractions (#) |
1 |
2018 |
| Radiation |
stereotactic body radiotherapy (sbrt) dosed at the maximum tolerated dose |
1 |
2018 |
| Radiation |
stereotactic body radiotherapy/sbrt |
1 |
2019 |
| Radiation |
stereotactic radiation arm 1 |
1 |
2012 |
| Radiation |
stereotactic radiation arm 2 |
1 |
2012 |
| Radiation |
stereotactic radiation arm 3 |
1 |
2012 |
| Radiation |
stereotactic radiation arm 4 |
1 |
2012 |
| Radiation |
stereotactic radiation therapy (srt) |
1 |
2017 |
| Radiation |
sterotactic body radiotherapy |
1 |
2019 |
| Radiation |
sterotactic body radiotherapy/sbrt |
1 |
2019 |
| Drug |
subcutaneous (sc) sea-cd40 |
1 |
2015 |
| Procedure |
sublobar resection |
1 |
2013 |
| Procedure |
subxiphoid uniportal vats |
1 |
2017 |
| Device |
suction is set to -10 cmh2o |
1 |
2016 |
| Device |
suction is set to -2 cmh2o |
1 |
2016 |
| Dietary Supplement |
sugar pill |
1 |
2007 |
| Dietary Supplement |
sulforaphane |
1 |
2017 |
| Drug |
sulijia |
1 |
2017 |
| Drug |
sulindac |
1 |
2006 |
| Drug |
sunitinib/rapamycin (drug will be held) |
1 |
2007 |
| Behavioral |
support education activity |
1 |
2018 |
| Procedure |
support group therapy |
1 |
2018 |
| Procedure |
surgical resection - definitive local treatment. |
1 |
2019 |
| Procedure |
surgical staging |
1 |
2007 |
| Other |
survivorship care plan |
1 |
2020 |
| Drug |
sutent |
1 |
2009 |
| Behavioral |
symptom assessment |
1 |
2012 |
| Other |
symptom experience report |
1 |
2013 |
| Other |
symptoms report |
1 |
2007 |
| Procedure |
systematic lymph node sampling |
1 |
2018 |
| Diagnostic Test |
systematic sampling |
1 |
2019 |
| Drug |
systemic anti-tumor therapy |
1 |
2016 |
| Drug |
systemic therapy |
1 |
2019 |
| Drug |
systemic therapy/standard of care |
1 |
2019 |
| Procedure |
t790m |
1 |
2015 |
| Procedure |
t790m/ testing |
1 |
2015 |
| Drug |
tacedinaline |
1 |
2000 |
| Drug |
tagrissoâ® 80mg (osimertinib) |
1 |
2019 |
| Behavioral |
tai-chi |
1 |
2018 |
| Drug |
tak-165 |
1 |
2002 |
| Drug |
talabostat (pt-100) tablets |
1 |
2004 |
| Drug |
talazoparib tosylate |
1 |
2019 |
| Other |
talc |
1 |
2009 |
| Drug |
talcum powder |
1 |
2019 |
| Drug |
tanespimycin |
1 |
1999 |
| Drug |
tarceva (erlotinib hcl, osi-774 ) |
1 |
2002 |
| Drug |
tarceva (erlotinib hydrochloride) |
1 |
2009 |
| Other |
targeted blood pressure management |
1 |
2019 |
| Drug |
targeted molecular therapy |
1 |
2016 |
| Drug |
targomirs |
1 |
2015 |
| Drug |
tariquidar |
1 |
2003 |
| Drug |
tas-102 |
1 |
2016 |
| Drug |
tas-114 |
1 |
2016 |
| Drug |
taxol/everolimus |
1 |
2010 |
| Drug |
taxoprexin |
1 |
2005 |
| Drug |
taxotere (docetaxel) |
1 |
2010 |
| Drug |
taxotere/cisplatin |
1 |
2002 |
| Drug |
taxotereâ® |
1 |
2006 |
| Procedure |
tbca, tbna |
1 |
2008 |
| Drug |
tc-210 t cells |
1 |
2019 |
| Biological |
tcr-t cells |
1 |
2018 |
| Biological |
tecemotide |
1 |
2009 |
| Radiation |
technetium-99 |
1 |
2004 |
| Radiation |
technetium 99m ethylenedicysteine-deoxyglucose |
1 |
2009 |
| Drug |
telaglenastat |
1 |
2019 |
| Drug |
telaglenastat hydrochloride |
1 |
2019 |
| Device |
telecoaching |
1 |
2019 |
| Behavioral |
telephone call |
1 |
2020 |
| Drug |
telisotuzumab vedotin |
1 |
2018 |
| Procedure |
temla |
1 |
2017 |
| Drug |
temoporfin |
1 |
2013 |
| Device |
template-guided localization |
1 |
2016 |
| Biological |
tergenpumatucel-l |
1 |
2015 |
| Drug |
tesevatinib |
1 |
2015 |
| Procedure |
testing |
1 |
2015 |
| Procedure |
testing for mutation status |
1 |
2010 |
| Drug |
tetrahydrouridine |
1 |
2016 |
| Drug |
tetrathiomolybdate |
1 |
2013 |
| Drug |
tew-7197 |
1 |
2018 |
| Drug |
tg01 |
1 |
2007 |
| Biological |
tg4010 |
1 |
2016 |
| Biological |
therapeutic autologous lymphocytes |
1 |
2001 |
| Procedure |
therapeutic bronchoscopy |
1 |
2012 |
| Combination Product |
therapeutic lymphadenectomy (temla) |
1 |
2013 |
| Combination Product |
therapeutic lymphadenectomy (temla)/stereotactic body radiation therapy (sbrt) |
1 |
2013 |
| Biological |
therapeutic tumor infiltrating lymphocytes |
1 |
2001 |
| Procedure |
therapeutic videothoracoscopy |
1 |
2009 |
| Behavioral |
therapeutic yoga |
1 |
2017 |
| Behavioral |
therapeutic yoga/resistance exercise |
1 |
2017 |
| Behavioral |
third through sixth sessions |
1 |
2015 |
| Radiation |
thoracic irradiation / pemetrexed |
1 |
2007 |
| Radiation |
thoracic radiation |
1 |
2017 |
| Radiation |
thoracic rt |
1 |
2019 |
| Radiation |
thoracic rt/durvalumab |
1 |
2019 |
| Procedure |
thoracic surgery |
1 |
2019 |
| Procedure |
thoracoscopic surgery |
1 |
2018 |
| Radiation |
three-dimensional conformal radiation therapy |
1 |
2001 |
| Procedure |
three ports video-assisted thoracoscopic surgery |
1 |
2019 |
| Drug |
thymosin |
1 |
2018 |
| Other |
tidal volume |
1 |
2008 |
| Drug |
tinzaparin sodium |
1 |
2017 |
| Drug |
tinzaparin sodium 100 ui |
1 |
2007 |
| Drug |
tinzaparin sodium 100 ui/kg/od for 12 weeks |
1 |
2007 |
| Drug |
tislelizumab carboplatin nab-paxlitaxel |
1 |
2018 |
| Drug |
tislelizumab carboplatin paxlitaxel |
1 |
2018 |
| Drug |
tislelizumab, carboplatin |
1 |
2019 |
| Drug |
tislelizumab, carboplatin /cisplatin, etoposide |
1 |
2019 |
| Drug |
tislelizumab,cisplatin |
1 |
2018 |
| Drug |
tislelizumab,cisplatin/carboplatin ,pemetrexed |
1 |
2018 |
| Other |
tissue oxygen measurement |
1 |
2014 |
| Drug |
tivantinib |
1 |
2010 |
| Behavioral |
tlc monthly |
1 |
2015 |
| Behavioral |
tlc quarterly |
1 |
2015 |
| Drug |
tlk286 |
1 |
2004 |
| Drug |
tlk286, cisplatin |
1 |
2004 |
| Biological |
tn lymphocytes |
1 |
2015 |
| Other |
tobacco cessation counseling |
1 |
2016 |
| Behavioral |
tobacco dependence |
1 |
2017 |
| Behavioral |
tobacco dependence/smoking cessation counseling |
1 |
2017 |
| Dietary Supplement |
tocopherol |
1 |
1999 |
| Dietary Supplement |
tocotrienol 300 mg x 3 daily until progression |
1 |
2015 |
| Other |
toolbox for lung cancer screening |
1 |
2019 |
| Drug |
topical clindamycin 2%, triamcinolone acetonide 0.1% soln |
1 |
2007 |
| Drug |
topical lidocaine |
1 |
2019 |
| Drug |
topotecan capsule |
1 |
2017 |
| Drug |
topotecan/cisplatin |
1 |
2002 |
| Drug |
topotecan/docetaxel combination |
1 |
2003 |
| Biological |
toripalimab |
1 |
2019 |
| Drug |
toripalimab injection (js001 ) combine with chemotherapy |
1 |
2019 |
| Drug |
toripalimab injection(js001 ) |
1 |
2019 |
| placebo |
toripalimab injection(js001 ) carboplatin cisplatin etoposide placebo |
1 |
2019 |
| Dietary Supplement |
total aa vs eaa |
1 |
2010 |
| Dietary Supplement |
total aa vs eaa/leu |
1 |
2010 |
| Procedure |
total mediastinal lymph node dissection |
1 |
2017 |
| Procedure |
total mediastinal lymph node dissection/pulmonary metastasectomy |
1 |
2017 |
| Drug |
tpc -vinorelbine,gemcitabine,docetaxel, |
1 |
2011 |
| Drug |
tpc -vinorelbine,gemcitabine,docetaxel,/pemetrexed |
1 |
2011 |
| Drug |
tpx-0046 |
1 |
2019 |
| Drug |
tq-a3334 |
1 |
2020 |
| Drug |
tq-b3101 |
1 |
2019 |
| Drug |
trail) |
1 |
2007 |
| Drug |
trametinib 0.5 mg |
1 |
2018 |
| Drug |
trametinib 1 mg |
1 |
2018 |
| Drug |
trametinib 1.5 mg |
1 |
2018 |
| Drug |
trametinib 2 mg |
1 |
2018 |
| Device |
transcutaneous vagus nerve stimulation |
1 |
2018 |
| Procedure |
transthoracic ultrasound |
1 |
2010 |
| Drug |
trastuzumab deruxtecan |
1 |
2017 |
| Drug |
trastuzumab deruxtecan (ds-8201a) |
1 |
2018 |
| Drug |
treatment |
1 |
2010 |
| Behavioral |
treatment of cancer quality of life questionnaire c30 |
1 |
2015 |
| Behavioral |
treatment of cancer quality of life questionnaire lc-13 |
1 |
2015 |
| Drug |
tremelimumab (anti-ctla4) |
1 |
2015 |
| Drug |
treosulfan |
1 |
2016 |
| Drug |
treprilumab combination with platinum-containing dual-drug chemotherapy |
1 |
2019 |
| Behavioral |
triage |
1 |
2007 |
| Behavioral |
trimodal prehabilitation management |
1 |
2017 |
| Procedure |
triportal pulmonary resection surgery |
1 |
2016 |
| Diagnostic Test |
truesight oncology 500 |
1 |
2019 |
| Behavioral |
truthful information on chemotherapy risks |
1 |
2015 |
| Drug |
ts-1 |
1 |
2013 |
| Drug |
ts-1/cisplatin |
1 |
2013 |
| Drug |
tsr-022 |
1 |
2017 |
| Drug |
tsr-042 |
1 |
2017 |
| Biological |
tucotuzumab celmoleukin |
1 |
2001 |
| Other |
tumor-infiltrating lymphocyte therapy |
1 |
2017 |
| Procedure |
tumor-infiltrating lymphocytes (til) |
1 |
2017 |
| Genetic |
tumor biopsies |
1 |
2019 |
| Other |
tumor collection |
1 |
2019 |
| Procedure |
tumor specimen for methylation analysis |
1 |
2010 |
| Device |
tumor treating fields therapy |
1 |
2019 |
| Drug |
tvb-2640 |
1 |
2018 |
| Radiation |
twice daily radiotherapy |
1 |
2007 |
| Procedure |
two ports video-assisted thoracoscopic surgery |
1 |
2019 |
| Drug |
tyrosine kinase inhibitor |
1 |
2016 |
| Drug |
u3-1287 |
1 |
2010 |
| Drug |
u3-1402 |
1 |
2017 |
| Drug |
ucpvax |
1 |
2016 |
| Drug |
ufur |
1 |
2008 |
| Drug |
ufur/iressa |
1 |
2008 |
| Drug |
ulixertinib |
1 |
2015 |
| Procedure |
ultrasound-guided transbronchial needle-delivered interstitial photodynamic therapy |
1 |
2018 |
| Procedure |
ultrasound imaging |
1 |
2008 |
| Procedure |
uniport video-assisted thoracoscopic surgery |
1 |
2019 |
| Procedure |
uniportal lobectomy with complete lymphadenectomy |
1 |
2019 |
| Procedure |
uniportal pulmonary resection surgery |
1 |
2016 |
| Procedure |
uniportal sleeve lobectomy |
1 |
2018 |
| Behavioral |
unsigned note to provider about cessation medication prescription |
1 |
2018 |
| Behavioral |
unsupervised exercise (unsup) |
1 |
2018 |
| Drug |
uridine 5’-triphosphate (utp) solution for inhalation |
1 |
2005 |
| Other |
urine collection |
1 |
2019 |
| Other |
urine sample collection |
1 |
2015 |
| Procedure |
urine testing |
1 |
2015 |
| Other |
use of [18f]fdg - pet |
1 |
2016 |
| Other |
use of [18f]fdg - pet/ct for the diagnosis/staging of non-small cell lung carcinoma |
1 |
2016 |
| Behavioral |
usual care (routine chemotherapy cycles |
1 |
2013 |
| Behavioral |
usual care (routine chemotherapy cycles/imaging studies) |
1 |
2013 |
| Other |
usual care by cancer center care team |
1 |
2013 |
| Behavioral |
usual care: telephone counseling (3 sessions) with nicotine replacement |
1 |
2017 |
| Radiation |
usual diagnostic workup |
1 |
2013 |
| Other |
usual post operative care |
1 |
2010 |
| Drug |
utidelone injection |
1 |
2018 |
| Biological |
uv1 synthetic peptide vaccine |
1 |
2013 |
| Biological |
uv1 synthetic peptide vaccine/gm-csf |
1 |
2013 |
| Biological |
vaccine |
1 |
2012 |
| Biological |
vaccine / polyiclc |
1 |
2012 |
| Biological |
vaccine 1650-g |
1 |
2013 |
| Biological |
vaccine comprised of klh conjugates of gd2l, gd3l, globo h, fucosyl gm1, |
1 |
2011 |
| Biological |
vaccine comprised of klh conjugates of gd2l, gd3l, globo h, fucosyl gm1,/n-propionylated polysialic acid/opt-821 adjuvant |
1 |
2011 |
| Biological |
vaccine treatment |
1 |
2008 |
| Biological |
vaccine: vaccine comprised of klh conjugates of gd2l, gd3l, globo h, fucosyl gm1, |
1 |
2011 |
| Biological |
vaccinia-cea vaccine |
1 |
1999 |
| Drug |
vadimezan |
1 |
2010 |
| Drug |
valproate |
1 |
2008 |
| Drug |
valproate/doxorubicin |
1 |
2008 |
| Drug |
valproic acid |
1 |
2004 |
| Drug |
valproic acid: cohort -1 |
1 |
2009 |
| Drug |
valproic acid: cohort 0 |
1 |
2009 |
| Drug |
valproic acid: cohort 1 |
1 |
2009 |
| Drug |
valproic acid: cohort 2 |
1 |
2009 |
| Drug |
valproic acid: cohort 3 |
1 |
2009 |
| Drug |
valproic acid: cohort 4 |
1 |
2009 |
| Drug |
valproic acid: cohort 5 |
1 |
2009 |
| Drug |
vandetanib induction |
1 |
2008 |
| Drug |
vandetanib maintenance |
1 |
2008 |
| Drug |
vandetanib, selumetinib |
1 |
2012 |
| Procedure |
vaporizing humidifier |
1 |
2012 |
| Drug |
vargatefâ® |
1 |
2015 |
| Drug |
varlilumab 3 mg |
1 |
2019 |
| Drug |
varlilumab 3 mg/kg |
1 |
2019 |
| Drug |
vatalanib |
1 |
2008 |
| Procedure |
vats lobectomy |
1 |
2017 |
| Device |
vats partial lobe resection |
1 |
2019 |
| Drug |
vegfr |
1 |
2018 |
| Drug |
vegfr/pdgfr dual kinase inhibitor x-82 |
1 |
2018 |
| Drug |
vegfr2 inhibitor foretinib |
1 |
2010 |
| Procedure |
vein ligation first |
1 |
2018 |
| Drug |
velcade/vorinostat |
1 |
2008 |
| Drug |
velcadeâ„¢ (bortezomib) for injection (formerly ps-341) |
1 |
2003 |
| Drug |
vemurafenib |
1 |
2017 |
| Drug |
venetoclax |
1 |
2015 |
| Other |
venous thromboembolism |
1 |
2016 |
| Biological |
viagenpumatucel-l |
1 |
2015 |
| Procedure |
video-assisted thoracic surgery (vats) wedge resection |
1 |
2013 |
| Procedure |
video-assisted thoracoscopic surgery |
1 |
2015 |
| Procedure |
video-thoracoscopy |
1 |
2015 |
| Procedure |
video assisted thoracoscopic surgery (vats) |
1 |
2018 |
| Procedure |
videothoracoscopy |
1 |
1999 |
| Device |
viewray mr-linear accelerator |
1 |
2019 |
| Drug |
vinblastine |
1 |
2010 |
| Drug |
vincristine (vcr) |
1 |
2015 |
| Drug |
vinorelbine 25 mg |
1 |
2005 |
| Drug |
vinorelbine cisplatin radiotherapy |
1 |
2013 |
| Device |
visicoil gold marker 0.7 x 20 mm |
1 |
2009 |
| Procedure |
visual slit-lamp testing |
1 |
2015 |
| Drug |
vitamin a compound |
1 |
2019 |
| Dietary Supplement |
vitamin e |
1 |
2000 |
| Drug |
vmd-928 300-mg capsules |
1 |
2018 |
| Device |
voc analysis |
1 |
2018 |
| Drug |
volitinib |
1 |
2015 |
| Radiation |
volume modulated arc therapy |
1 |
2014 |
| Procedure |
vomiting therapy |
1 |
1999 |
| Biological |
vsv-ifnî²-nis |
1 |
2018 |
| Biological |
vv1 |
1 |
2020 |
| Drug |
w |
1 |
2012 |
| Other |
walk test |
1 |
2014 |
| Drug |
week |
1 |
2012 |
| Drug |
weekly - concomitant chemoradiation 2gy |
1 |
2012 |
| Drug |
weekly dp chemotherapy concurrent with thoracic radiotherapy |
1 |
2018 |
| Other |
weekly internet based pro questionnaires |
1 |
2018 |
| Other |
weekly questionnaires |
1 |
2018 |
| Procedure |
white light bronchoscopy |
1 |
2020 |
| Procedure |
white light bronchoscopy/autofluorescence bronchoscopy |
1 |
2020 |
| Radiation |
whole-brain radiation therapy |
1 |
2010 |
| Radiation |
whole-brain radiotherapy |
1 |
2016 |
| Procedure |
whole body electromyostimulation exercise |
1 |
2017 |
| Radiation |
whole brain radiation therapy |
1 |
2012 |
| Radiation |
whole brain radiation(wbi) |
1 |
2012 |
| Radiation |
whole brain radiotherapy |
1 |
2015 |
| Radiation |
whole lung imrt |
1 |
2014 |
| Combination Product |
with bevacizumab |
1 |
2020 |
| Biological |
with carboplatin |
1 |
2020 |
| Drug |
with cisplatin |
1 |
2013 |
| Other |
with data |
1 |
2015 |
| Drug |
with docetaxel |
1 |
2019 |
| Drug |
with docetaxel monotherapy |
1 |
2019 |
| Drug |
with egfr-tki |
1 |
2019 |
| Other |
with radiofrequency ablation |
1 |
2019 |
| Drug |
with s-1 capsules |
1 |
2017 |
| Biological |
with the as15 adjuvant system gsk2302032a |
1 |
2013 |
| Drug |
with vinorelbine |
1 |
2018 |
| Behavioral |
workshop |
1 |
2015 |
| Biological |
wt-1 analog peptide vaccine |
1 |
2006 |
| Procedure |
x-ray imaging |
1 |
2012 |
| Drug |
xl184 |
1 |
2008 |
| Drug |
xl647 |
1 |
2006 |
| Biological |
xmab20717 |
1 |
2018 |
| Biological |
xmabâ®22841 |
1 |
2019 |
| Biological |
xmabâ®23104 |
1 |
2018 |
| Drug |
xmt-1001 |
1 |
2007 |
| Biological |
xofigo |
1 |
2014 |
| Drug |
yangyinfang |
1 |
2016 |
| Drug |
yiqifang |
1 |
2016 |
| Drug |
yiqiyangyinfang |
1 |
2016 |
| Procedure |
yoga |
1 |
2019 |
| Biological |
young til |
1 |
2014 |
| Radiation |
yttrium y 90 anti-cea monoclonal antibody ct84.66 |
1 |
2008 |
| Drug |
zactima (zd6474) |
1 |
2007 |
| Drug |
zd1839 (iressa) |
1 |
2006 |
| Drug |
zd4054 |
1 |
2008 |
| Drug |
zd6474 (vandetanib) |
1 |
2006 |
| Drug |
zd6474 (vandetanib) 100mg |
1 |
2007 |
| Drug |
zd6474 (vandetanib) 300mg |
1 |
2007 |
| Drug |
zd6474, vandetanib |
1 |
2008 |
| Dietary Supplement |
zinc oxide |
1 |
2006 |
| Biological |
ziv-aflibercept |
1 |
2009 |
| Drug |
zl-2306(nirapairb) |
1 |
2018 |
| Drug |
zn-c3 |
1 |
2019 |
| Drug |
zoledronic acid 4 mg |
1 |
2005 |
| Drug |
zometa |
1 |
2008 |
| Radiation |
zr-89 labelled durvalumab pet |
1 |
2019 |
| Radiation |
zr-89 labelled durvalumab pet/ct |
1 |
2019 |